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Summary 
 
Epigenetic mechnisms are essential for normal development and alterations of epigenetic 
processe are correlated with many human diseases, e.g., cancer. One of the important epigenetic 
modifications, acetylation of lysine, is mainly recognized by structurally conserved protein 
module bromodomains. Targeting bromodomains by small molecules is an emerging 
therapeutic strategy for cancer treatment. In this thesis, we invetigated the protein-ligand 
interactions for bromodomains that belong to different subfamilies, in the context of the 
application of fragment-based drug discovery appoach. 
 In this thesis, fragment-based high throughput screening was employed to identify diverse 
novel chemotypes binding to BRPF1 bromodomain. A multidisciplinary approach combining 
in silico docking, protein X-ray crystallography and calorimetry was used for further hit 
optimization. Two series of potent and selective BRPF1 bromodomain inhibitors, 2,3-dioxo-
quinoxaline and 2,4-dimethyl-oxazole derivatives were characterized eventually. The selectity 
was measured experimentally by biochemical assay and isothermal titration calorimetry, and 
analyzed by explicit-solvent molecular dynamics simulations. Another virtual screening 
campaign in conjunction with ligand-observed NMR spectroscopy was used to discover highly 
ligand-efficient fragments targeting the CREBBP bromodomain and ligand binding mode was 
validated by X-ray crystallography. By application of a de novo developed virtual sysnthesis 
method, an initial fragment hit was evolved into low nanomolar CREBBP inhibitor with 
excellent selectivity against BRD4(1) bromodomain. In another study, using a combined 
scaffold hopping and ligand docking approach, acetyl indoles were discovered as binders of the 
bromodomains of CREBBP, BAZ2B and BRPF1. A comparative crystal structure analysis 
revealed the importance of the gatekeeper residue in bromodomains with respect to the binding 
of ligands.  
In summary, by means of fragment-based drug design approach, a couple of fragment hits 
and potent inhibitors for brodomains were identified, and they are promising starting points to 
generate therapeutic agents and chemical probes to interrogate bromodomain biology. Similar 
fragment-based drug design approaches can be applied to lead discovery projects for less 
studied bromodomains and other drug targets.  
 
 Zusammenfassung 
 
Epigenetische Mechanismen sind für eine normale Entwicklung wesentlich und Veränderungen 
epigenetischer Prozesse sind mit vielen menschlichen Erkrankungen, z.B. Krebs, korreliert. Eine 
der wichtigen epigenetischen Modifikationen, die Acetylierung von Lysin, wird hauptsächlich von 
strukturell konservierten Proteinmodul-Bromodomänen erkannt. Die gezielte Bekämpfung von 
Bromodomänen durch kleine Moleküle ist eine neue therapeutische Strategie für die 
Krebsbehandlung. In dieser Arbeit untersuchten wir die Protein-Ligand-Interaktionen für 
Bromodomänen, die zu verschiedenen Unterfamilien gehören, im Rahmen der Anwendung von 
Fragmenten-basierten Medikamentenentdeckungen. 
In dieser Arbeit wurde das Fragment-basierte Hochdurchsatzscreening eingesetzt, um diverse 
neuartige Chemotypen zu identifizieren, die an BRPF1-Bromodomäne binden. Ein 
multidisziplinärer Ansatz, der In-Silico-Docking, Protein-Röntgenkristallographie und 
Kalorimetrie kombiniert, wurde für die weitere Optimierung der Treffer verwendet. Zwei Serien 
von potenten und selektiven BRPF1-Bromodomäneninhibitoren, 2,3-Dioxochinoxalin und 2,4-
Dimethyloxazolderivaten wurden schließlich charakterisiert. Die Selektivität wurde experimentell 
mittels biochemischer Analyse und isothermer Titrationskalorimetrie gemessen und durch 
explizite Solvens-Moleküldynamiksimulationen analysiert. Eine weitere virtuelle Screening-
Kampagne in Verbindung mit Liganden-beobachteter NMR-Spektroskopie wurde verwendet, um 
hoch ligandeneffiziente Fragmente zu entdecken, die auf die CREBBP-Bromodomäne abzielen, 
und der Ligandenbindungsmodus wurde durch Röntgenkristallographie validiert. Unter 
Verwendung einer de novo entwickelten virtuellen Methode wurde ein anfänglicher 
Fragmentschlag in einen niedrig nanomolaren CREBBP Inhibitor mit ausgezeichneter Selektivität 
gegen BRD4(1) Bromodomäne entwickelt. In einer weiteren Studie, bei der ein kombinierter 
Scaffold-Hopping und Liganden-Docking-Ansatz verwendet wurde, wurden Acetylindole als 
Binder der Bromodomänen von CREBBP, BAZ2B und BRPF1 entdeckt. Eine vergleichende 
Kristallstrukturanalyse zeigte die Bedeutung des Gatekeeper-Restes in Bromodomänen in Bezug 
auf die Bindung von Liganden. 
Zusammengefasst wurden mittels Fragment-based Drug Design Ansatz einige Fragment-Hits und 
potente Inhibitoren für Brodomänen identifiziert, die vielversprechende Ansatzpunkte für die 
Entwicklung von Therapeutika und chemischen Sonden zur Untersuchung der 
Bromodomänenbiologie darstellen. Ähnliche, auf Fragmenten basierende Ansätze zur 
Wirkstoffentwicklung können auf Forschungsprojekte für weniger erforschte Bromodomänen und 
andere Wirkstoffziele angewendet werden. 
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Chapter 1 
 
Introduction 
 
Epigenetic post-translational modifications are crucial for controlling chromatin state and thus 
influence gene expression. In recent years, bromodomains, protein module that recognize the 
acetylated lysine histone mark, have emerged as promising therapeutic targets for the treatment 
of cancer and other diseases.  
Drug discovey is a constanly changing field. Nowadays fragment-based drug design 
(FBDD) gradually becomes a mainstream in lead discovery taking advantage of the high quality 
interactions of the small-size fragments with therapeutic protein target. In this thesis, we will 
focus on the application of the fragment-based drug discovery approach on a series of 
bromodomains, mainly BRPF1, CREBBP, BAZ2B and BRD4(1).  
In the following, a brief intruduction of bromodomain protein family and a more 
detailed description of BRPF1 bromodomain and its implication in leukemia are given in 
Section 1.1 and 1.2, respectively. In Section 1.3, we introduce the fragment-based drug 
discovery and its application in discovering bromodomain inhibitors, and particularly, the use 
of X-ray protein crystallography in FBDD is described in Section 1.4. 
 
1.1 Bromodomains  
Contemporary epigenetics is defined as heritable gene expression that is not associated with 
any alteration of DNA sequence, but with chemical modification of DNA, i.e., DNA 
methylation, or of the covalent modification of histone bound to it [1]. A histone modification 
is a post-translational modification (PTM) to histone proteins which mainly include 
phosphorylation, acetylation, methylation, ubiquitylation and sumoylation [2]. A number of 
protein families are involved in epigenetic regulation through writing, erasing and reading 
specific post-translational modifications, referred to as writers (histone acetyltransferases 
(HATs), histone methyltransferases), erasers (histone deacetylases (HDACs), histone 
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demethylases) and readers (bromodomains, chromodomains, plant homeodomains, etc.). 
Aberrant regulation of epigenetic proteins are hallmarks of many diseases including cancer [3]. 
Lysine acetylation (Kac) is one of the important and main PTMs. Acetylation of chromatin 
is generally related with the structure and function of chromatin, and transcriptional activation 
[2]. It is also found to be involved in regulating metabolism [4] and protein stability [5]. The 
acetylation of lysine residue on histone is catalyzed by histone acetyltransferases (HATs) and 
removed by histone deacetylases (HDACs). Bromodomains (BRDs) are evolutionarily 
conserved protein-protein interaction modules that specifically recognize acetylation marks on 
histone tails.  
Human proteome analysis reveals in total 61 bromodomains found in 46 diverse proteins, 
which can be clustered into eight sub-families. The bromodomain-containing proteins play an 
essential role in regulating gene transcriptions through different ways. First, they can act as 
scaffold to recruit trans chromation factors to assemble large complex. Second, some 
bromodomain-containing proteins are themselves transcriptional factors or regulators. Last, 
BRD-containing proteins can act as methyltransferases, acetyltransferases and helicases, 
thereby they are engaged in various chromation modifications [6]. Proteins contain 
bromodomains have been implicated in several disease process, including inflammation, 
neugological disease, as well as cancer [6,7].  
Bromodomains contain approximately 110 residues folded into a bundle of four left-
handed α helices (αZ, αA, αB and αC), linked by two variable loop regions known as ZA loop 
and BC loop. The four helices form the hydrophobic acetyl binding site to accommodate the 
side chain of the neutralized acetylated lysine, which is flanked by the two loops. Reported 
crystal strucures of bromodomain in complex with acetylated histone tail have revealed details 
of a conserved binding motif for recognition of kac: a conserved asparagine at the N-terminal 
BC loop is responsible for the recognition of acetyl-lysine via a specific hydrogen bond; 
structurally conserved water molecules locating at the bottom of the binding site are also 
involved in the ineractions with the acetyl-lysine. The hydrophic nature of the binding pocket 
of bromodomains as well as the variation of the residues surrounding the kac pocket make them 
as druggable target for developing therapeutic inhibitors. Notably, some inhibitors targeting the 
bromodomain ans extraterminal (BET) subfamily have been advanced into clinical trials for the 
treatment of acute myeloid leukemia (AML) [8].    
 
1.2 BRPF1 bromodomain  
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The bromodomain and plant homeodomain (PHD) finger containing proteins (BRPF1/2/3) are 
members of subfamily IV bromodomains, other members of this subfamily are BRD7, BRD9, 
ATAD2A and ATAD2B bromodomains. BRPF bromodomains contain multiple epigenetic 
reader domains, including a unique double PHD and zinc finger assembly (PZP), a 
bromodomain and a C-terminal PWWP domain. In BRPF1, it’s bromodomain can specifically 
recognize multiple acetyl lysine marks in histone tails including H2AK5ac, H3K14ac, H4K5ac, 
H4K8ac, and H4K12ac [9]. BRPF1 is a scaffolding subunit of the monocytic leukemic zinc 
finger (MOZ) histone acetyltransferase, in which BRPF1 connects the MOZ catalytic subunit 
to ING5 and hFaf6, thereby enhancing the acetylation acrivity of MOZ.  
The MOZ acetyltransferase is involved in chromosomal translocations process found in a 
subtype of acute myeloid leukemia (AML) with poor prognosis [10]. Such chromosomal 
translocation in AML are believed to cause aberrant expression profile of HOX genes mediated 
by the acetylation activity of MOZ during hematopoiesis, which is found to be critical for 
leukemogenesis [11]. In AML with MOZ-TIF2 translocation pattern, the MOZ-TIF2 forms a 
stable complex with BRPF1 and deregulate the expression of HOX genes. The depletion of 
BRPF1 decreases the MOZ localization to HOX genes and mutant MOZ-TIF2 lacking HAT 
activity was incapable of deregulating HOX expression as well as inducing leukemia [12]. MOZ 
complex is also found to be able to associate with the trithorax group protein MLL (mixed-
lineage leukemia) to coordinately activate HOX gene expression [13]. Apart from the important 
role in leukemic translocations, BRPF1 is essentially involved in maintaining the HOX gene 
expression and hematopoiesis in development [14,15]. Togethor, the emerging body of 
evidence suggests the potential of BRPF1 as a therapeutic target in leukemia. The architecture 
of the MOZ complex and its role in leukemogenesis is depicted in Figure 1.  
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Figurge 1. MOZ complex structure and the mechnism of MOZ-TIF2 fusion in leukemogenesis. BRPF1 
recognizes the acetylation and methylation histone modifications by its bromodomain and PWWP 
domain, respectively. MOZ-fusion/BRPF1 complex promotes histone acetylation resulting in 
upregulation of downstream HOX genes expression, which lead to the development of leukemia. The 
figure is adapted and modified from Ref [12]. 
A few nubmer of chemical probes of BRPF1 bromodomain have been developed by both 
industry and academic groups. In general, these compounds bear a 1,3-dimethyl 
benzimidazolone or a N-methylquinolin-2-one scaffold as acetyl-lysine mimetics to target 
BRPF1. Chemical probes are used to interrogate the target-phenotype relationship and this is 
strengthened by development of the chemically diverse inhibitors, since different chemical 
entities may have distinct physiocochemical properties and off-target profiles [16].To explore 
chemically distinct small molecules to target BRPF1, we performed a fragment-based high 
throughput virtual sceening using over 10000 fragments, which led to the discovery of six 
different novel chemotypes (Chapter 2). In a follow up study, two series of potent and selective 
BRPF1 inhibitors were identified and characterized by hit optimization, which is presented in 
Chapter 3. These newly discovered chemotypes are promising starting points for the 
development of novel BRPF1 chemical probes. 
 
1.3 Fragment-based drug design (FBDD) 
With nearly 20 years development, FBDD is increasingly implemented as an alternative for 
high through screening (HTS) in target-based lead discovey. Dozens of molecuels derived from 
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this approach have beedn advanced to clinical trials [17]. In recent years, FBDD is also widely 
applied in the development of bromodomains inhibitors throughout industry and academia [18].  
A fragment-based drug design project usually starts with the construction of a fragment 
library for screening, fragments binding is then experimentally validated and finally the 
promising hits are grown into larger and more potent inhibitors. The process and methodology 
of FBDD is shown in Figure 2. In the Caflisch group, screening is performed by high throughput 
docking [19] which is usually carried out with the in house developed program called SEED 
[20,21]. The process and methodology of FBDD is shown in Figure 2.  
 
Figurge 2. General process of fragmet-based drug design.   
 
In contrast to the large collection of drug-sized compound library that are used in high 
through screening, FBDD adopts a smaller library of low molecular weight (MW < 250 Da) 
compounds for screening on a target protein of interest. Typically, a fragment library comprises 
thousands of chemically diversed scaffolds which can sample chemical space similar to a  
million of ‘drug-like’ molecules. Thus fragment-based screening can achieve higher hit rates 
than conventional high throughput screening. On the other hand, in many cases, a fragment is 
adequate to form favorable interactions with target protein and mismatches between larger 
molecules and target can be avoided, so that screening hits with desirable ligand efficiency (LE) 
can be obtained from a FBDD campaign.   
 Since the fragments bind to target protein weakly (100 μM – 10 mM affinity range), 
sensitive and efficient binding detection methods are required and in fact, this is the key issue 
in FBDD. In practice, biophysical techniques such as Nuclear Magnetic Resonance 
Spectroscopy (NMR), X-ray crystallography, Surface Plasmon Resonance (SPR), Differential 
Scanning Fluorimetry (DSF) are widely used to detect fragment binding. Other methods like 
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microscale thermophoresis and weak affinity chromatography hold the potential to be useful 
tools in fragment screening [17]. As listed above, there are a variety of methods available for 
fragment-finding, however, the limitaiton is whether the target protein is amenable to the 
screening method, which should be carefully considered. Sometimes, combination of some 
screening method are needed. In chapter 4, we report on the discovery of several ligand-efficient 
fragments targeting BAZ2A bromodomain by using a ligand-observed NMR fragment 
screening strategy [22].  
 A challenging task after finding of the initial hits is how to evolve them into lead 
compounds. By means of some cheminformatics applications, e.g., substructure and similarity 
search around screening hits on commercial available compound database often yield more 
potent analogues. An example of hit optimization of BRPF1 inhibitor is described in Chapter 
3. In chapter 6, we show an application of fragment-based scaffold hopping in the discovery of 
inhibitors targeting BAZ2B and CREBBP bromodomains [23]. 
From the medicinal chemistry view, hit optimisation are accomplished by either linking 
two fragments that occupy adjacent sub-pockets, or merging structural portions of overlapped 
molecules into one fragment, or growing the fragment by adding funtional groups [24]. In a 
recent work,  a virtual synthesis method developed in the Caflisch group to grow a previously 
identified fragment instucted rational medicinal chemistry optimization resulting in the 
identification of very potent and selective CREBBP inhibitos (Chapter 5).  
As mentioned above, in silico screening is an alternative way to screen fragments in a 
high-throuput manner. In the past few years, by using an in-house developed docking tool 
SEED [20,21], our group had performed several fragment-based virtual screening campaigns 
on a few number of bromodomains, including BRPF1 [25], BRD4(1) [26], BAZ2A [27], 
BAZ2B [28] and CREBBP [29]. Some of thees campaigns are described throughout this thesis. 
 
1.4 X-ray crystallography in FBDD 
X-ray crystallography is a well-establised method for structural determination of proteins and 
other biomolecules, which is also widely used in the drug discovery scenarios as it can produce 
atomic resolution structures of protein complexes with various ligands. For FBDD an important 
advantage of X-ray crystallography is the validation of fragment hits which are then structurally 
modified to improve potency by cycles of chemical synthesis and acquisition of activity data 
under the guidance of structural information of binding mode primarily derived from X-ray 
crystallography [30]. Both X-ray crystallography and NMR can map the interactions between 
the protein target and ligands, and ideally these two techniques can complement one another. 
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However, NMR takes longer time for determining the three-dimentional structures and it 
generally cannot deal with large proteins. Along with the recent development of high speed 
detectors for rapid X-ray data collection and in situ co-crystallization screening [31], X-ray 
crystallography can even serve as a primariy screening tool in drug discovery.  
 The protein/ligand complex structures are commonly obtained by two ways: soaking and 
co-crystallization. In the soaking appoach, a single ligand or a cocktail ligands in solution will 
be incubated with a crystallized target protein without any ligand or substrate (apo crystal). Co-
crystallization are performed by mixing ligand and target protein prior to crystallization and the 
complex is crystallized.   
 Owing to the relatively weak affinity of fragments, in soaking or co-crystallization 
expriments, fragments should be prepared at high concentrations, even up to 100 mM. This 
requires fragments have good aqueous solubility in the mother liquor used for ligand soaking 
or co-crystallization. 
 Well-established and robust preformed crystals are suitable for compound soaking as 
batches of crystals can be reproduced. In this approach, importantly, apo crystals should be 
compatible with ligand binding. Because bound ligands may induce protein conformational 
change or disrupt crystal lattice contacts, then soaked crystals may crack or dissolve [32].   
Another limitation of soaking is that lattice contacts in apo crystal may inhibit ligand 
from accessing to the binding site of target protein, resuting in false negatives upon ligand 
binding. This issue could be circumvented by performing co-crystallization of protein in the 
presence of ligands. However, it always requires experimentalists to rescreen crystal growth 
conditions for a specific ligand. In the hit optimization stage of a FBDD project, such problems 
can be encountered. Figure 3 shows an example in which crystal contacts occlude ligand 
binding. The apo BRPF1 crystal and a co-crystal of BRPF1 with a fragment are grown from the 
same condition. An attempt of soaking apo BRPF1 with a derivative of the fragment failed. 
Subsequent crystallization optimization yielded the complex structure of BRPF1 with this 
larger ligand. Structural alignment shows an N-terminal glutamic acid residue from another 
symmetry related protein molecule in the space group of the apo crystal that causes steric 
collision with this ligand, while it does not interfer with the smaller fragment. Thus, different 
packings are sometimes required for the fragment and large derivatives of it.  
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Figure 3. Different space groups (packing arrangement in the crystal) for fragment and derivative with 
large substituents. The structure of BRPF1 in complex with a fragment (PDB ID 5O4T; in cyan ) belongs 
to space group P3221 and contains one protein molecule in the asymmetric unit. One of the symmetry 
related protein molecule is shown in green. The structure of BRPF1 complexed with a larger ligand 
(PDB ID 5MWG; in magenta) belongs to space group P212121 which was overlapped to the structure of 
5O4T. The side chain of a glutamate residue in the neibouring protein molecule prevents binding of the 
derivative in the same space group as the parent fragment.  
 
 In this thesis, x-ray crystallography play a central role in many bromodomain FBDD 
projects. Complex crystal structures of bromodomains with ligands are used to validate the 
predicted binding mode in all of the chapters, to guide hit optimization (Chapters 3, 5 and 6) 
and to validate fragment hits identified in silico (Chapters 2 and 7).  
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ABSTRACT: BRPF1 plays a scaﬀolding role in transcription. We report
on fragment screening by high-throughput docking to the BRPF1
bromodomain which resulted in six chemotypes with very favorable ligand
eﬃciency (0.45−0.50 kcal/mol per non-hydrogen atom). Twenty crystal
structures of BRPF1/ligand complexes show structural conservation in the
acetyllysine binding site, common binding motifs, and unusual interactions
(e.g., the replacement of a conserved water molecule). The structural
information is useful for the design of chemical probes.
■ INTRODUCTION
Genetic analysis on zebraﬁsh has shown that the bromodomain
and PHD ﬁnger (BRPF) containing protein BRPF1 is a
member of the Trithorax group with a central role during
development in vertebrates.1 BRPF1 associates with the histone
acetyltransferase monocytic leukemia zinc ﬁnger protein
(MOZ) and recruits it to distinct sites of chromatin. The
bromodomain of BRPF1 binds to acetylated histone tails.2
In contrast to the bromodomain and extra terminal (BET)
subfamily of bromodomains, e.g., bromodomain-containing
protein 4 (BRD4), very few crystal structures of complexes of
the BRPF1 bromodomain with ligands (holo) are available.
Lubula et al.3 reported the crystal structure of the BRPF1
bromodomain in complex with acetylated histone peptides
H4K12ac and H2AK5ac. Demont et al.4 identiﬁed 1,3-dimethyl
benzimidazolones as potent BRPF1 bromodomain inhibitors
and have disclosed the structures of two of these ligands in the
complex with BRPF1.
Experimental approaches to fragment-based screening have
been used to identify ligands of bromodomains of the BET
subfamily, viz., bromodomain-containing protein 2 (BRD2)5
and BRD4,6 and also for non-BET bromodomains, viz., ATPase
family, AAA domain containing 2 (ATAD2),7 bromodomain
adjacent to zinc-ﬁnger domain 2B (BAZ2B),8 and binding
protein of the cAMP response element-binding protein
(CREBBP).9
Here, we have screened a library of 24133 molecules by
docking into the BRPF1 bromodomain followed by exper-
imental validation of the in silico top ranking hits by X-ray
crystallography. We could solve the crystal structures of BRPF1
(see Experimental Section for details) in the complex with 20
ligands at resolutions between 1.33 and 1.75 Å (Table 1). Six
new chemotypes have been identiﬁed: tricyclazole, phenyl-
pyridine, mercaptopurine, hydroxyisoquinoline, quinoxalin-2-
one, and acetylindole. Common binding motifs and infrequent
interactions emerge from the analysis of the 20 crystal
structures. The acetyl lysine binding site of BRPF1 is conserved
except for a slight displacement of the ZA loop. Only one of the
20 ligands displaces a conserved water molecule that is present
in most crystal structures of bromodomain/ligand complexes.
■ RESULTS AND DISCUSSION
We screened in silico the 24133 molecules devoid of rotatable
bonds and with molecular weight smaller than 550 g/mol
(called fragments in the following) that were present in the
2014 version of the ZINC library.13 The screening was carried
out by high-throughput fragment docking into the structure of
apo BRPF1 (PDB code 4LC2) using the program SEED14 (see
Experimental Section for details). Virtual screening required
about 24 h; the preparation of the library of fragments took less
than 1 h, and the docking of the 24133 fragments required less
than a day on a commodity desktop. An initial set of 13
molecules among the top 30 ranking fragments was selected
according to predicted binding energy (SEED energy) and
availability and tested by experiments of soaking into crystals of
the apo form of the BRPF1 bromodomain. The crystal
structures of the complexes of BRPF1 with ﬁve of these
fragments (1, 2, 3, 5, and 8 in Table 1 and Supporting
Information (SI), Figure S1) were solved. Electron densities
were not observed for the other eight fragments (SI, Figure S2).
The predicted binding mode of fragments 1, 2, and 8 was
conﬁrmed by the crystal structures (SI, Figure S1). Fragment 3
shows a diﬀerent orientation in the crystal with respect to the
docked pose, which is probably due to the lack of reorientation
of the structural water molecules during docking. The oxygen
atom of fragment 5 (1-isoquinolinone) replaces the buried
water molecule that bridges to the side chain of the conserved
Tyr665 (see below) and was present during docking. Thus, the
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hit rate, i.e., ratio of binders versus purchased fragments, is 38%
(or 23% if one considers only the poses correctly predicted by
docking).
An additional set of 15 molecules were tested in a second
round of soaking experiments. This set consists of nine
purchasable analogues (according to the deﬁnition in the ZINC
database with a similarity threshold of 70%) of the ﬁve original
hits, the acetylindole derivative 17 (which binds to another
bromodomain of subfamily IV, the BRD9 bromodomain),15
four molecules similar to 17 (compounds 15, 16, 18, and 19),
and the pan-bromodomain inhibitor bromosporine (20).16 In
total, ﬁve ligands show a value of the equilibrium dissociation
constant (KD) for the BRPF1 bromodomain smaller than 100
μM while bromosporine has a KD of 0.27 μM (Table 1).
Importantly, the seven ligands with KD < 200 μM (compounds
1, 4, 7, 8, 11, 12, and 15) have very favorable ligand eﬃciency
(LE) in the range 0.45−0.50 kcal/mol per non-hydrogen atom.
Of these, fragments 1 and 8 are two of the ﬁve original docking
hits.
For the analysis of the 20 crystal structures of the BRPF1
bromodomain/ligand complexes (Table 1), it is useful to
describe ﬁrst the binding site and common binding motifs. The
acetyl lysine binding site has a parallelepiped-like shape in
which the ligands are sandwiched by van der Waals contacts
with the ZA-loop side chains Val657, Pro658, and Val662 on
one of the two largest sides of the pocket and Ile652, Asn708,
and Phe714 (the so-called gatekeeper) on the opposite side of
the pocket (Figure 1). The bottom of the binding site is
occupied by conserved water molecules and the phenyl ring of
the conserved Phe653 (SI, Figures S6−S8). The structural
overlap of the 20 complexes shows that the backbone and most
side chains in the acetyl lysine binding site are conserved
(Figure 1A). This ﬁnding is congruent with the similar size of
the compounds, which consist of two or three (fused) ring
systems. Furthermore, all crystals belong to the same space
group and there are no crystal contacts in the acetyl lysine
binding site. The structural similarity in the binding site is very
high for the BC loop (residues 707−712) and the N-terminal
segment of the ZA-loop (residues 650−656). The latter
includes the Asn651-Ile652-Phe653 segment that corresponds
to the Trp-Pro-Phe triad in the BET bromodomains. In
contrast, the central segment of the ZA-loop (residues 657−
668) shows structural heterogeneity. The rigid-body displace-
ment of this part of the ZA-loop reduces the aperture of the
binding site with respect to the apo structure (PDB code
4LC2), which was solved in the same space group as our 20
holo structures (Figure 1B). The slightly narrower binding
pocket in the holo structures with respect to the apo
conformation is a consequence of the intrinsic ﬂexibility of
the ZA-loop and the formation of optimal van der Waals
contacts between the ligand and the hydrophobic side chains of
Val657, Pro658, and Val662 on one side of the pocket and
Ile652 and the gatekeeper Phe714 on the other side (Figure
1C). Quantitatively, the largest backbone displacement with
Table 1. Structures, KD Values for BRPF1, and Ligand
Eﬃciencies (LE) of in Silico Hitsa
Table 1. continued
aMolecules 1−16 can be clustered (SI, Figure S3) in six chemotypes
(horizontal lines). The KD values were determined by a competition
binding assay BROMOscan10 in duplicate (SI, Figure S4). For
compound 20, an IC50 value of 0.65 μM was determined by
AlphaScreen11 (SI, Figure S5). Ligand eﬃciency12 is calculated as LE =
(1.37/HA) × pKD, in the units of kcal/mol per non-hydrogen atom.
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respect to the apo structure is observed for the residues 659−
661 whose Cα atoms move by up to 2.5 Å. The side chain of
Glu661 shows the largest variability in the 20 structures (Figure
1A). Interestingly, the size of the ligand inﬂuences the
orientation of the Glu661 side chain particularly for compounds
13, 19, and 20 (bromosporine), whose binding modes induce
the largest displacement of the tip of the Glu661 side chain (SI,
Figure S8). It is important to note that the slightly diﬀerent
tilting of the ligands is related not only to the rigid-body
displacement of residues 657−668 of the ZA loop but also to
the diﬀerent orientations of the phenyl ring of the Phe714
gatekeeper (Figure 1D). The χ2 dihedral angle of Phe714 varies
in a range of about 75°, resulting in diﬀerent orientations of the
phenyl ring.
The two hydrogen bonds with the NH2 group of the
conserved Asn708 and the buried water molecule that bridges
to Tyr665 are present in all structures except for the complex
with fragment 5 (Figure 2). In this complex, the oxygen atom
of fragment 5 is at hydrogen bond distance to the hydroxyl
oxygen of Tyr665 (2.7 Å) while its distance from the side chain
nitrogen atom of Asn708 is 4.0 Å which is too long for a
hydrogen bond. The scatter plot of the two hydrogen bond
distances shows that the one with the structural water is shorter
in 15 of 19 structures (Figure 3). This result is consistent with a
previous study on BRD2 (ref 5) and provides further evidence
that the hydrogen bond with the buried water molecule that
bridges to the conserved Tyr665 is stronger than the one with
Asn708.
The interaction with the carbonyl oxygen of the conserved
Asn708 is heterogeneous. In the complexes with the ligands 9,
10, 12, and 14, there is a water molecule that acts as bridge to
the side chain CO of Asn708 (Figure 4A,B). This water
molecule corresponds to a structural water molecule of the apo
structure (HOH1007 in 4LC2). In contrast, the bridging water
molecule is replaced by an NH group in ligands 3, 4, and 20
(Figure 4C) and the methyl group of compound 11 (Figure
4D). Similar to compound 11, a previously reported 1, 3-
dimethyl benzimidazolone inhibitor (SI, Figure S9) of the
Figure 1. Structural overlap and analysis of the 20 complex structures. (A) Kac binding site of BRPF1. (B) Displacement of the ZA-loop in the 20
holo structures with respect to the apo structure (4LC2, green). (C) Hydrophobic residues lining the Kac binding site in BRPF1. (D) The phenyl
ring of the gatekeeper residue Phe714 shows diﬀerent orientations for diﬀerent ligands.
Figure 2. Only fragment 5 displaces the buried water molecule that
acts as bridge to the conserved Tyr665. (A) Crystal structures overlay
of all ligands but 5. (B) Structural overlap of the complex with
fragment 5 (pink) and the apo structure (green). 2Fo − Fc electron
density map of 5 is shown in mesh contoured at 1 σ.
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BRPF1 bromodomain replaces the water molecule bridging to
the side chain CO of Asn708 (PDB code 4UYE).
The molecules of the largest cluster (8−14) share the
tetrahydroquinoxalin-2-one scaﬀold (Table 1). As mentioned
above, these ligands do not form a direct hydrogen bond with
the carbonyl oxygen of the Asn708 side chain (Figure 4, SI,
Figures S7, S8). In contrast, in the structures of the complexes
of the CREBBP bromodomain inhibitors9 with the tetrahy-
droquinoxalin-2-one scaﬀold, there are two direct hydrogen
bonds to the conserved asparagine (Asn1168 in CREBBP, PDB
codes 4NYW and 4NYX). The structural overlap shows that
the position of the scaﬀold in the complexes with BRPF1 is
slightly shifted with respect to CREBBP (SI, Figures S9, S10).
The two mercaptopurine fragments 3 and 4 show distinct
binding mode as compared with a 2-amine-9H-purine derived
BRD9 inhibitor17 (SI, Figure S11). In both structures of 3 and
4, the NH group at position 7 donates a hydrogen bond to the
Asn708 side chain CO while the carbonyl group at position 6
forms a bifurcated hydrogen bond with the Asn708 side chain
NH and the water molecule that bridges to Tyr665. In the
BRD4 and BRD9 structures, the 2-amine-9H-purine derivative
shows a ﬂipped orientation with the amine group at position 2,
nitrogen atom at 3, and NH group at 9 involved in hydrogen
bonds to the conserved asparagine and water molecule.
Finally, a polar interaction with the backbone carbonyl of
Ile652 is present in the complex with several ligands. This
interaction was ﬁrst observed in molecular dynamics simu-
lations of the spontaneous binding of acetyl lysine.18 In the
complex structures with the quinoxalinone derivatives 8, 9, 10,
and 13, there is a direct hydrogen bond with the carbonyl of
Ile562, while a bridging water molecule is present for
compounds 12, 18, and 19 (SI, Figures S7, S8).
■ CONCLUSIONS
We have identiﬁed six chemotypes of ligands of the BRPF1
bromodomain by high-throughput docking of fragments, which
was carried out in 1 day on a single commodity processor,
followed by soaking experiments and purchase of hit analogues.
Seven in silico hits have ligand eﬃciency in the range 0.45−0.50
kcal/mol per non-hydrogen atom (Table 1). The X-ray crystal
structures of BRPF1 in complex with 19 compounds (and the
complex with bromosporine, a previously disclosed promiscu-
Figure 3. Scatter plot of hydrogen bond distances involving the ligand
acceptor atom closest to the side chain N atom of the conserved
Asn708. Numbers denote the ligand, and symbols the atomic element
of the acceptor. In 15 of 19 structures, hydrogen bonds with the buried
water that bridges to the Tyr665 side chain are shorter than with the
Asn708.
Figure 4. A water molecule acting as hydrogen bond bridge to the side chain carbonyl of Asn708 was observed in the crystal structures of the
complexes with compounds (A) 9 and 10, and (B) 12 and 14. The bridging water molecule is replaced by the NH group of compounds 3, 4 and 20
(C), and the methyl group of fragment 11 and a benzimidazolone derivative (4UYE) (D). The apo structure (4LC2, green) is shown in all panels as
a basis of comparison.
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ous inhibitor) show that the overall structure of the acetyl
lysine binding site is conserved. Interestingly, the water-bridged
hydrogen bond with the conserved tyrosine of the ZA-loop
(Tyr665) is present in all crystal structures except for the
complex with fragment 5 (1-isoquinolinone), whose oxygen
atom replaces the buried water molecule which does not
improve aﬃnity. The phenyl ring of the gatekeeper residue
(Phe714) shows slightly diﬀerent orientations, while the ZA-
loop accommodates diﬀerent ligands by rigid-body displace-
ment and rearrangement of side chains, in particular Glu661.
The fragment-based high-throughput docking campaigns in
our group have resulted in the identiﬁcation of molecules with
very favorable ligand eﬃciency for the bromodomains of
BRD4,19 CREBBP,20 BAZ2B,21 and BRPF1 (this work). These
bromodomains belong to four diﬀerent subfamilies of human
bromodomains (viz., subfamilies II, III, IV, and V). In the case
of the CREBBP bromodomain, optimization of the initial hits
by chemical synthesis of derivatives has generated several
selective low nanomolar inhibitors with ligand eﬃciency similar
to the initial hits.20 Thus, the screening of fragment libraries by
docking is very eﬃcient and shows high success rate and
negligible cost. The favorable ligand eﬃciency of our hits and
their crystal structures in the complex with the BRPF1
bromodomain are important starting points for hit optimization
and the design of chemical probes to investigate the function of
BRPF1. For instance, the bromine-containing fragments 8 and
9 could be grown into more potent and selective ligands by
Suzuki coupling.
■ EXPERIMENTAL SECTION
Fragment Docking. The nearly 12 million molecules of the ZINC
database (version 2014)13 were ﬁltered for zero rotatable bonds and
molecular weight smaller than 550 g/mol by the program DAIM.22
The resulting library of 24133 fragments was docked into the apo
structure of BRPF1 (PDB code 4LC2) by the program SEED,14 which
evaluates the binding energy using a force ﬁeld-based energy function
with a continuum dielectric approximation of desolvation penalties.23
The binding site for docking was deﬁned by the conserved asparagine
in the BC loop (Asn708) and four buried water molecules (numbered
w1 to w4 in SI, Figures S6−S8) which are present in most crystal
structures of bromodomains. The partial charges and van der Waals
parameters of the protein were taken from the CHARMM36 all-atom
force ﬁeld,24 while the fragments were parametrized using the
CHARMM general force ﬁeld (CGenFF).25 It is important to note
that CGenFF is fully consistent with the CHARMM36 force ﬁeld
because they use the same paradigm for the derivation of partial
charges, van der Waals parameters, and parameters for bonding
interactions (covalent bonds, angles, dihedrals, and improper
dihedrals). The value of the dielectric constant for the continuum
calculations was set to 2.0 and 78.5 in the low-dielectric region
(solute) and high-dielectric region (solvent), respectively. The docking
of the 24133 fragments with SEED required nearly 22 h (about 3 s per
fragment) of a single core of an i7-930 processor at 2.8 GHz.
Chemistry. All screened compounds were purchased from
commercial vendors and the purity of all molecules was analyzed by
HPLC-MS and is determined to be at least 95%. Compound 20
(bromosporine) was purchased from Sigma-Aldrich with purity higher
than 98%.
Protein Production. The gene encoding the bromo-domain of
BRPF1 (aa 626−740) was ampliﬁed by PCR from the original plasmid
(Addgene plasmid no. 53620) and subcloned to a modiﬁed pGEX-4T-
1 vector. A tobacco etch virus (TEV) protease recognition site was
introduced between the glutathione S-transferase (GST) fusion
protein and BRPF1 bromodomain. The recombinant plasmid was
transformed into Escherichia coli strain BL21(DE3). The cells were
grown at 37 °C until an OD600 of 0.6 was reached. After induction
(0.2 mM IPTG) and overnight expression at 16 °C, the GST-tagged
protein was puriﬁed by a Glutathione Sepharose 4B column and the
GST tag was removed with TEV protease afterward. The
bromodomain was further puriﬁed using a Superdex 75 column in
the buﬀer of 50 mM HEPES (pH 7.5), 0.15 M NaCl, and 0.5 mM
DTT. Eluted protein was concentrated to 22 mg/mL (NanoDrop
spectrophotometer) in the same buﬀer and frozen in liquid nitrogen.
Crystallization. Sparse-matrix crystallization screens were per-
formed with a Phoenix crystallization robot to identify initial
crystallization conditions. BRPF1 bromodomain was crystallized by
vapor diﬀusion in hanging drops at 4 °C. Crystallization buﬀer is
composed of 0.1 M sodium acetate pH 5.5 (or 0.1 M BIS-TRIS
propane pH 6.5), 0.15−0.2 M sodium nitrate, and 18−22% PEG3350.
Overnight soaking of ligands was performed by transferring the apo
crystals into the crystallization buﬀer in which the compounds were
previously dissolved at 5 mM. Soaked crystals were cryoprotected with
the crystallization buﬀer supplemented with 20% glycerol prior to
freezing in liquid nitrogen. Fragments 5 and 6 were cocrystallized with
BRPF1 in the crystallization buﬀer and cryoprotected the same way as
the soaked crystals.
Data Collection and Structure Solution. Diﬀraction data were
collected at the Swiss Light Source, Paul Scherrer Institute (Villigen,
Switzerland), beamlines PXI and PXIII. Data were processed with
XDS26 and SCALA,27 and structures were solved by molecular
replacement with Phaser28 using PDB 4LC2 as search model. Initial
models were reﬁned iteratively with Phenix29 and manual model
building with COOT.30 Crystal data collection and reﬁnement
statistics are summarized in SI, Tables S1−S5.
BROMOscan and AlphaScreen Assays. BROMOscan technol-
ogy is a competition experiment that uses an immobilized ligand and a
DNA-tagged bromodomain protein.10 Compounds that bind to the
bromodomain of interest will prevent binding of the bromodomain to
the immobilized ligand. The amount of captured bromodomain is
quantiﬁed by qPCR, and the dissociation constants are calculated with
a standard dose−response curve. Further details about the assays can
be found in the SI. AlphaScreen assays11 consist of a donor bead that is
able to transfer singlet oxygen to an acceptor bead that is in the
proximity, and as a result, the acceptor bead emits a luminescent/
ﬂuorescent signal. In the presence of a bromodomain ligand, the
donor/acceptor complex is disrupted, leading to a loss of singlet
oxygen transfer and loss of the ﬂuorescent signal.
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containing protein 2; BRD4, bromodomain containing protein
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Fig S1. Comparison of docked pose obtained by the fragment-docking program SEED (carbon atoms 
in magenta) and binding mode in the crystal structure (carbon atoms in yellow) of fragments 1, 2, 3 
and 8. Heteroatoms are colored as follows: N (blue), O (red), S (yellow), and Br (maroon). The six 
conserved water molecules in the Kac binding pocket are labeled W1 to W6.  
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Fig S2. False positive hits from fragment docking by SEED. These fragments were among the 13 
fragments purchased from 30 top ranked ones, but binding is not observed by X-ray crystallography 
(soaking into BRPF1 apo crystals). 
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Fig S3. Similarity matrix of compounds 1 to 16. The similarity (Tanimoto coefficient) was calculated 
based on the RDKit fingerprint which is implemented in the RDKit1 toolkit. The size and darkness 
(vertical legend on the right) of the circles indicate similarity. The hierarchical complete-link 
algorithm with the R programming language generates six clusters (orange boxes). 
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BromoScan assay2 
BromoScan assays on BRPF1 for the 14 compounds were performed at DiscoveRx. T7 phage strains 
displaying bromodomains were grown in parallel in 24-well blocks in an E. coli host derived from the 
BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a frozen stock 
(multiplicity of infection= 0.4) and incubated with shaking at 32°C until lysis (90-150 minutes). The 
lysates were centrifuged (5,000 x g) and filtered (0.2 μm) to remove cell debris. Streptavidin-coated 
magnetic beads were treated with biotinylated small molecule or acetylated peptide ligands for 30 
minutes at room temperature to generate affinity resins for bromodomain assays. The liganded beads 
were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1 % BSA, 0.05 % 
Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific phage binding. Binding 
reactions were assembled by combining bromodomains, liganded affinity beads, and test compounds 
in 1x binding buffer (17% SeaBlock, 0.33x PBS, 0.04% Tween 20, 0.02% BSA, 0.004% Sodium azide, 7.4 
mM DTT). Test compounds were prepared as 1000X stocks in 100% DMSO and subsequently diluted 
1:10 in monoethylene glycol (MEG) to create stocks at 100X the screening concentration (resulting 
stock solution is 10% DMSO/90% MEG). The compounds were then diluted directly into the assays 
such that the final concentration of DMSO and MEG were 0.1% and 0.9%, respectively. All reactions 
were performed in polystyrene 96-well plates in a final volume of 0.135 ml. 
The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads 
were washed with wash buffer (1x PBS, 0.05% Tween 20). The beads were then re-suspended in elution 
buffer (1x PBS, 0.05% Tween 20, 2 μM nonbiotinylated affinity ligand) and incubated at room 
temperature with shaking for 30 minutes. The bromodomain concentration in the eluates was 
measured by qPCR. Binding constants (Kds) were calculated with a standard dose-response curve 
using the Hill equation: 
Response = Background +
Signal − Background	
1 + (K
	 	/	Dose	 )
 
Curves were fitted using a non-linear least square fit with the Levenberg-Marquardt algorithm. 
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Fig S4. Dose-response curves in duplicates for the 16 compounds tested for binding to the BRPF1 
bromodomain in the competition binding assay at DiscoveRx. 
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Fig S5. IC50 value of compound 20 determined by the AlphaScreen binding assay3 at Reaction Biology. 
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Table S1. X-ray data collection and refinement statistics for complex structures of the BRPF1 
bromodomain and compounds 1, 2, 3 and 4. 
 
 Data Collection 
PDB ID 5EQ1 5EWD 5E3G 5E3D 
ligand 1 2 3 4 
space group P3221 P3221 P3221 P3221 
Cell dimensions     
a, b, c (Å) 60.38, 60.38, 63.20 60.67, 60.67, 63.02 60.86, 60.86, 62.99  60.73, 60.73, 62.43 
α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 
resolution (Å) 40.29 - 1.55 40.36 - 1.58 40.40 - 1.65 40.22 - 1.71 
unique observations*  19761(2835) 18839(2686) 16662(2374) 14799(2108) 
completeness* 99.9 (100.0) 100.0(100.0) 100.0(100.0) 99.7(99.1) 
redundancy* 9.4 (8.9) 9.6(9.6) 9.7(10.0) 9.5(9.6) 
Rmerge* 0.041 (0.338) 0.029(0.359) 0.040(0.442) 0.031(0.405) 
I/σI* 25.9 (6.1) 34.7(5.7) 25.6(4.9) 30.3(5.1) 
 Refinement 
Rwork/Rfree* 0.189(0.229)/0.194(0.292) 0.199(0.233)/0.225(0.252) 0.196(0.208)/0.205(0.268) 0.192(0.241)/0.222(0.319) 
r.m.s deviations of bond 
lengths (Å) 
0.008 0.006 0.007 0.007 
r.m.s deviations of bond 
angles (°) 
0.879 0.666 0.765 0.710 
no. of non-hydrogen atom / 
average B-factor (Å2) 
    
protein 946/37.56 946/40.90 944/45.24 936/48.64 
ligand 13/40.53 12/56.25 12/57.45 12/59.34 
water 80/43.30 103/46.65 64/46.49 75/48.63 
residues in protein chain  628 - 739 627 - 739 628 - 739 628 -739 
Ramanchandran      
Favored  98.25 100.00 99.12 99.12 
allowed 1.75 0.00 0.88 0.88 
disallowed 0.00 0.00 0.00 0.00 
* Highest resolution shell is shown in parentheses. 
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Table S2. X-ray data collection and refinement statistics for complex structures of the BRPF1 
bromodomain and compounds 5, 6, 7 and 8.  
 
 
 
 
 
 
 
 
 Data Collection 
PDB ID 5C87 5EM3 5EWH 5C85 
ligand 5 6 7 8 
space group P3221 P3221 P3221 P3221 
Cell dimensions     
a, b, c (Å) 60.56, 60.56, 63.60 60.14, 60.14, 63.23 60.44, 60.44, 62.68 60.72, 60.72, 61.87 
α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00  90.00, 90.00, 120.00 
resolution (Å) 30.00 - 1.55 40.20 - 1.40 40.18 - 1.63 40.07 - 1.70 
unique observations*  20025(2861) 26409(3814) 16966(2453) 14925(2129) 
completeness* 100.0(100.0) 99.7(99.7) 100.0(100.0) 100.0(100.0) 
redundancy* 9.1(6.0) 9.2(8.8) 9.5(9.9) 9.7(9.5) 
Rmerge* 0.048(0.341) 0.049(0.236) 0.073(0.358) 0.031(0.326) 
I/σI* 26.6(4.8) 25.4(8.4) 16.3(5.3) 37.1(6.5) 
 Refinement 
Rwork/Rfree* 0.181(0.221)/0.198(0.26) 0.173(0.187)/0.196(0.224) 0.190(0.212)/0.223(0.288) 0.207(0.241)/0.225(0.269) 
r.m.s deviations of bond 
lengths (Å) 
0.007 0.010 0.006 0.007 
r.m.s deviations of bond 
angles (°) 
0.920 0.780 0.743 0.931 
no. of non-hydrogen atom 
/ average B-factor (Å2) 
    
protein 947/38.01 974/19.79 955/28.65 929/50.59 
ligand 11/44.55 22/22.39 11/40.01 12/55.99 
water 124/44.19 170/30.45 134/40.01 79/48.55 
residues in protein chain 628 - 739 625 – 739 (extra serine 
residue 625 at the N 
terminal )       
627 - 739 628 -739 
Ramanchandran      
Favored  99.12 99.15 99.14 99.12 
allowed 0.88 0.85 0.86 0.88 
disallowed 0.00 0.00 0.00 0.00 
* Highest resolution shell is shown in parentheses. 
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Table S3. X-ray data collection and refinement statistics for complex structures of the BRPF1 
bromodomain and compounds 9, 10, 11 and 12. 
 
 
 
 
 
 
 
 
 
 Data Collection 
PDB ID 5DYC 5DY7 5EPS 5EPR 
ligand 9 10 11 12 
space group P3221 P3221 P3221 P3221 
Cell dimensions     
a, b, c (Å) 60.81, 60.81, 63.11  60.67, 60.67, 62.38 60.63, 60.63, 62.50 60.92, 60.92, 63.02 
α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 
resolution (Å) 40.44 - 1.65 40.19 - 1.69 40.20 - 1.47 40.45 - 1.65 
unique observations*  16556(2353) 15153(2094) 23061(3316) 16718(2400) 
completeness* 99.5(99.3) 99.2(95.5) 100.0(99.8) 100.0(100.0) 
redundancy* 9.7(10.0) 9.5(9.3) 9.5(9.3) 9.5(9.9) 
Rmerge* 0.039(0.408) 0.060(0.440) 0.042(0.285) 0.035(0.366) 
I/σI* 28.2(5.4) 18.7(4.5) 25.4(6.6) 28.6(5.6) 
 Refinement 
Rwork/Rfree* 0.198(0.237)/0.235(0.289) 0.179(0.243)/0.204(0.306) 0.188(0.202)/0.198(0.250) 0.198(0.264)/0.220(0.285) 
r.m.s deviations of bond 
lengths (Å) 
0.006 0.007 0.007 0.008 
r.m.s deviations of bond 
angles (°) 
0.694 0.773 0.738 0.681 
no. of non-hydrogen 
atom / average B-factor 
    
protein 951/43.43 956/31.17 952/32.75 948/44.14 
ligand 12/53.58 15/39.11 12/47.99 12/59.44 
water 82/46.97 142/37.17 111/39.47 71/45.87 
residues in protein chain 627 - 739 627 - 739 627 - 739 628 -739 
Ramanchandran(%)     
Favored  99.13 99.15 100.00 99.12 
allowed 0.87 0.85 0.00 0.88 
disallowed 0.00 0.00 0.00 0.00 
* Highest resolution shell is shown in parentheses. 
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Table S4. X-ray data collection and refinement statistics for complex structures of the BRPF1 
bromodomain and compounds 13, 14, 15 and 16. 
 
 
 
 
 
 
 
 
 
 
 Data Collection 
PDB ID 5EWC 5DYA 5ETB 5ETD 
ligand 13 14 15 16 
space group P3221 P3221 P3221 P3221 
Cell dimensions     
a, b, c (Å) 60.93, 60.93, 63.05 61.16, 61.16, 62.15 60.37, 60.37, 63.50 60.32, 60.32, 62.92 
α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 
resolution (Å) 40.46 - 1.75 40.31 - 1.65 40.36 - 1.33 40.19 - 1.40 
unique observations*  14043(1999) 16557(2370) 31032(4300) 26520(3791) 
completeness* 100.0(99.9) 99.8(100.0) 99.3(95.6) 99.9(99.5) 
redundancy* 9.7(9.7) 9.5(9.8) 8.7(4.9) 9.2(8.4) 
Rmerge* 0.049(0.406) 0.027(0.417) 0.038(0.158) 0.044(0.334) 
I/σI* 24.1(5.1) 37.1(5.2) 31.1(7.8) 22.9(5.3) 
 Refinement 
Rwork/Rfree* 0.194(0.252)/0.211(0.312) 0.186(0.214)/0.213(0.264) 0.174(0.204)/0.186(0.235) 0.176(0.215)/0.186(0.219) 
r.m.s deviations of bond 
lengths (Å) 
0.008 0.007 0.008 0.008 
r.m.s deviations of bond 
angles (°) 
0.731 0.790 0.791 0.756 
no. of non-hydrogen 
atom / average B-factor 
    
protein 942/46.33 937/39.08 944/21.15 944/25.24 
ligand 17/58.74 16/52.93 13/26.45 12/27.97 
water 91/49.34 115/43.46 179/34.57 138/34.71 
residues in protein chain 628 - 739 628 - 739 628 - 739 628 - 739 
Ramanchandran      
Favored  99.12 99.12 98.23 99.12 
allowed 0.88 0.88 1.77 0.88 
disallowed 0.00 0.00 0.00 0.00 
* Highest resolution shell is shown in parentheses. 
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Table S5. X-ray data collection and refinement statistics for complex structures of the BRPF1 
bromodomain and compounds 18, 19, and 20. 
 
 
 
 
 
 
 
 
 
 Data Collection 
PDB ID 5EV9 5EVA 5C7N 
ligand 18 19 20 
space group P3221 P3221 P3221 
Cell dimensions    
a, b, c (Å) 60.36, 60.36, 63.46  60.36, 60.36, 63.39 60.50, 60.50, 63.11 
α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 
resolution (Å) 40.35 - 1.45 40.33 - 1.45 40.31 - 1.75 
unique observations*  24170(3476) 24128(3476) 13890(1986) 
completeness* 100.0(99.9) 99.9(100.0) 100.0(100.0) 
redundancy* 9.4(9.3) 9.3(9.0) 9.7(9.8) 
Rmerge* 0.032(0.285) 0.041(0.292) 0.044(0.420) 
I/σI* 33.0(6.9) 27.6(7.0) 27.5(5.4) 
 Refinement 
Rwork/Rfree* 0.188(0.242)/0.221(0.257) 0.183(0.222)/0.197(0.235) 0.180(0.229)/0.220(0.289) 
r.m.s deviations of bond 
angles (°) 
0.009 0.008 0.010 
r.m.s deviations of bond 
lengths (Å) 
0.885 0.834 0.987 
no. of non-hydrogen 
atom / average B-factor 
   
protein 939/38.50 938/32.67 955/45.50 
ligand 19/50.15 17/46.97 28/62.80 
water 130/46.12 152/42.00 102/48.89 
residues in protein chain 628 - 739  627 - 739 628 - 739 
Ramanchandran     
Favored  99.12 98.23 97.39 
allowed 0.88 1.77 2.61 
disallowed 0.00 0.00 0.00 
* Highest resolution shell is shown in parentheses. 
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Fig S6. Close view of binding mode of compounds 1, 2, 3, 4, 5 and 6. Conserved water molecules in the 
binding pocket are labeled W1 to W6 (pink spheres). 2Fo-Fc electron density maps contoured at 1 σ 
for ligands are shown by a mesh. Two alternative conformations of fragment 6 are shown in yellow 
and cyan. 
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Fig S7. Same as Figure S7 for compounds 7, 8, 9, 10, 11 and 12. For fragments 7 and 12, 2Fo-Fc electron 
density maps are contoured at 0.8 σ. 
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Fig S8. Same as Figure S7 for compounds 13, 14, 15, 16, 17, 18, 19 and 20. For ligands 19 and 20, 2Fo-Fc 
electron density maps are contoured at 0.8 σ. 
 
 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig S9. Chemical structures of inhibitors for structural comparison. 
(a)N-[1,3-dimethyl-2-oxo-6-(piperidin-1-yl)-2,3-dihydro-1H-benzimidazol-5-yl]-2-methoxybenzamide, 
(b) 6-(5-bromo-2-methoxyphenyl)-9H-purin-2-amine,  
(c)(3R)-N-[3-(3,4-dihydroquinolin-1(2H)-yl)propyl]-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-5-
carboxamide, and (d) (3R)-N-[3-(7-methoxy-3,4-dihydroquinolin-1(2H)-yl)propyl]-3-methyl-2-oxo-
1,2,3,4-tetrahydroquinoxaline-5-carboxamide. 
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Fig S10. Comparison of the binding modes of dihydroquinoline ligands in BRPF1 (top) and CREBBP 
(bottom). The structural alignment (middle) shows that the binding modes are different.  (Top) In 
BRPF1, the bromine substituent of fragment 9, the trifluromethyl of 10, and the carboxylate of 14 occupy 
the same position, while fragment 12 (5EPR) is devoid of substituent and its orientation is slightly shifted. 
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Fig S11. Comparison of the binding modes of mercaptopurine fragments 3 and 4 in BRPF1 (top) with 
the previously reported 2-amine-9H-purine ligands of the BRD9 (4XY8, bottom) and BRD4 (4XY9, 
bottom) bromodomains. The structural alignment (middle) shows that the binding modes are 
different which is consistent with the fact that these ligands share only the purine scaffold. 
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a b s t r a c t
Bromodomain and plant homeodomain (PHD) ﬁnger containing protein 1 (BRPF1) is a member of
subfamily IV of the human bromodomains. Experimental evidence suggests that BRPF1 is involved in
leukemia. In a previous high-throughput docking campaign we identiﬁed several chemotypes targeting
the BRPF1 bromodomain. Here, pharmacophore searches using the binding modes of two of these
chemotypes resulted in two new series of ligands of the BRPF1 bromodomain. The 2,3-dioxo-quinoxaline
21 exhibits a 2-mM afﬁnity for the BRPF1 bromodomain in two different competition binding assays, and
more than 100-fold selectivity for BRPF1 against other members of subfamily IV and representatives of
other subfamilies. Cellular activity is conﬁrmed by a viability assay in a leukemia cell line. Isothermal
titration calorimetry measurements reveal enthalpy-driven binding for compounds 21, 26 (KD¼ 3 mM),
and the 2,4-dimethyl-oxazole derivative 42 (KD¼ 10 mM). Multiple molecular dynamics simulations and
a dozen co-crystal structures at high resolution provide useful information for further optimization of
afﬁnity for the BRPF1 bromodomain.
© 2018 Elsevier Masson SAS. All rights reserved.
1. Introduction
Bromodomains are evolutionarily conserved protein-protein
interaction modules that selectively bind to acetyl-lysine (Kac)
residues. They recognize acetylated histone tails, and are thus
involved in the regulation of gene expression. Human proteome
analysis indicates that there are eight bromodomain subfamilies,
with 61 members found in 42 diverse proteins. Bromodomain-
containing proteins have important role in biological process and
are functionally implicated in disease processes, including cancer,
inﬂammation and viral replication [1]. The bromodomain structure
consists of approximately 110 residues folded into a bundle of four
left-handed a helices (aZ, aA, aB and aC). Two variable loops
termed ZA loop and BC loop, connect the helices and form the Kac
binding site [2]. Despite the structural conservation of bromodo-
mains, sequence and structural heterogeneity in the loop regions
result in different druggability [3].
The most studied bromodomains are the members of the bro-
modomain and extra terminal domain (BET) subfamily. Highly
potent and speciﬁc inhibitors for the BET subfamily have shown
therapeutic potential in a number of diseases, particularly in
oncology [4e6]. Outside the BET subfamily, the recent disclosure of
chemical probes for bromodomains like CREBBP/EP300 [7e11],
BRD7/9 [12e14], BAZ2A/B [15,16], SMARCA2/4 [17], PCAF [18], and
ATAD2 [19] will facilitate the elucidation of the biological function
and target validation of the non-BET bromodomains.
The bromodomain and plant homeodomain (PHD) ﬁnger con-
taining proteins (BRPF1/2/3) are members of subfamily IV. BRPFs
contain multiple epigenetic reader domains, including a unique
double PHD and zinc ﬁnger assembly, a bromodomain and a C-
terminal PWWP domain. As a multivalent chromatin regulator,
BRPF1 recognizes histonemarks via both the bromodomain and the
PWWP domain [20]. The BRPF1 bromodomain preferentially binds
to multiple acetyl-lysine marks in histone tails including H2AK5ac,
H3K14ac, H4K5ac, H4K8ac, and H4K12ac [21]. BRPF1 is a subunit of
monocytic leukemic zinc ﬁnger (MOZ) histone acetyltransferase
(HAT) which acetylates free histones and affects gene transcription.
In the MOZ HAT quaternary complex, BRPF1 enhances the acety-
lation activity of MOZ.
The MOZ HAT is involved in chromosomal translocations pro-
cess found in a subtype of acute myeloid leukemia (AML) with poor
prognosis [22]. The chromosomal translocation in AML leads to the
production of fusion proteins inwhichMOZ is linked to either CREB
binding proteins (CBP) [23], or CBP homolog p300 [24], or the
transcriptional intermediary binding factor 2 (TIF2) [25]. MOZ
fusion proteins cause aberrant expression proﬁle of HOX genes
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mediated by the acetylation activity of MOZ during hematopoiesis,
which is found to be critical for leukemogenesis [26]. Overall, the
emerging body of evidence suggests the potential of BRPF1 as a
therapeutic target in leukemia.
To date, only one chemical probe has been disclosed for the
BRPF1 bromodomain. The 1,3-dimethylbenzimidazolone scaffold
was optimized into a chemical probe for BRPF1 (GSK6853 [27]), and
a dual BRPF1-TRIM24 inhibitor (compound 34 in Ref. [28]) (Fig. 1).
The recently reported compounds NI-42 and NI-57 bear a struc-
turally different scaffold N-methylquinolin-2-one [29,30]. The
compounds NI-42 and NI-57 are pan-BRPF bromodomain in-
hibitors, showing a biased potency on BRPF1, and less than six-fold
selectivity over BRPF2.
As outlined above, current development of BRPF1 chemical
probes still focuses on the 1,3-dimethylbenzimidazolone and N-
methylquinolin-2-one scaffolds. It would be valuable to develop
compounds structurally orthogonal to the reported BRPF1 chemical
probes, especially for inhibitors which are selectivewithin the BRPF
subfamily, to better elucidate the biological function of BRPF1. In
our previous study, several diverse chemotypes targeting BRPF1
were discovered by high-throughput virtual screening and vali-
dated by X-ray crystallography [31]. In the present study, based on
two previously identiﬁed small molecule hits, a hit-to-lead
campaign was carried out using a structure-based virtual
screening strategy. Two series of low micromolar inhibitors were
identiﬁed which exhibit good selectivity within and outside the
subfamily IV bromodomains. Isothermal titration calorimetry was
used to measure thermodynamic parameters of binding and
conﬁrm selectivity. Explicit solvent molecular dynamics simula-
tions [32,33] conﬁrmed the stability of the head group of the ligand
in the Kac binding site and revealed ﬂexibility of the ligand tail
(which is partially exposed to solvent) and part of the ZA loop.
2. Results and discussion
2.1. First pharmacophore search
Taking advantage of the rich structural information from our
fragment hits [31], we set out to explore the readily available
commercial chemical space by a combination of pharmacophore
search followed by substructure search (Fig. 2).
At the beginning of this project, a pharmacophore search [34]
using PDB coordinate 5EPS as template led to the identiﬁcation of
365 molecules that include either a 1-ethyl-2,3-dioxo-4H-qui-
noxaline or a 1-ethyl-3-methyl-2-oxoquinoxaline core group (see
section 4. Experimental). Presumably, a carbonyl group of the
Fig. 1. Representative BRPF1 inhibitors reported previously.
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scaffold acts as the Kac mimetic, which can form a hydrogen bond
to the conserved asparagine (Asn708) in BRPF1. Therefore, this key
hydrogen bond interaction was used to ﬁlter docking poses
generated by Autodock Vina [35]. Seven of the 24 selected com-
pounds exhibited KD values below 50 mM as determined by a
competition binding assay [36] (Table 1 and Table S2). Moreover,
compounds 2, 5 and 8 showed good selectivity on BRPF1 against
TRIM24 (KD> 100 mM) and BRD4(1) (KD> 100 mM) bromodomains.
Overall, this series of compounds shows reasonable cLogP values
(<3) and have lipophilic efﬁciency higher than 2.0.
Crystallographic screening (soaking or co-crystallization, see
Experimental) was performed to validate the pharmacophore
search and pose predicted by docking. Three co-crystals of the
BRPF1 bromodomain with compounds 2, 7 and 8 were solved at
resolutions higher than 1.6Å (Table S1). As expected from the
docking results (Fig. S1), the quinoxaline head group binds in the
Kac pocket with the canonical hydrogen bonding to Asn708 and a
buried water molecule bridging to the side chain of Tyr665 (Fig. 3).
Interestingly, both of the carbonyl groups on the quinoxaline ring of
2 form hydrogen bond interactions with the bridging water mole-
cule (Fig. 3A). In the crystal structure with compound 2, the 3-
position carbonyl group has an additional hydrogen bond interac-
tionwith the SH group of Cys704 which locates at the bottom of the
Kac pocket. Furthermore, the NH group of quinoxaline of 2 is
involved in a hydrogen bond to the backbone carbonyl of Ile652.
Compared to 7 and 8, the additional methyl group at the amide
linker of 2 displaces a conservedwater molecule in the binding site.
The amide-based linkers occupy different positions in the binding
site (Fig. 3D). The tail groups of these compounds pack against the
nonpolar part of the side chain of Glu661.
The binding modes of 2, 7 and 8 show two orientations of the
quinoxaline scaffold: the ethyl group of 2 points towards the side
chain of Tyr707 in the BC loop, whereas the ethyl group of 7 and 8
points towards the side chains of Ile652 and Phe653 in the so-called
NIF shelf (i.e., the Asn651-Ile652-Phe653 triad) in the N-terminal
segment of the ZA loop. The structural overlap of the crystal
structures of BRPF1 in the complex with compounds 2, 7, and 8
shows that a modiﬁed quinoxaline with methyl or ethyl groups at
both positions 1 and 4 could be accommodated in the binding
pocket.
To test this hypothesis, we tried to crystallize BRPF1 with the
fragment 9, i.e., 1,4-dimethylquinoxaline-2,3-dione (Table 2). The
co-crystal structure at resolution of 1.5Å shows clear electron
density for fragment 9 (Fig. 3E). Similarly to the binding mode of
compound 2, both of the carbonyl groups on the quinoxaline ring of
the fragment are involved in hydrogen bonding to the structurally
conserved water molecule that acts as bridge towards the hydroxyl
group of the evolutionary conserved Tyr665. The hydrogen bond
interactions with the side chains of Cys704 and Asn708 are also
present. One of the two methyl groups on the quinoxaline ring
forms van der Waals interactions with the side chain Ile652 and
Phe653 of the NIF shelf.
2.2. Substructure search
Fragment 9 provided a starting point for a substructure search.
Nearly 1400 compounds were retrieved via substructure search in
the ZINC database [37], for which either methyl or ethyl groups are
present at positions 1 and 4 on the quinoxaline core, and varied tail
groups at positions 6 and 7. To in silico screen these candidate
compounds, ﬂexible docking was performed with Autodock Vina
[35] and docking poses were ﬁltered using the structure of the
complex with compound 9 as reference. Next, binding poses were
reﬁned by energy minimization with CHARMM [38] using a similar
protocol as in a recent work [39], and ranked with a knowledge-
based scoring function DSX [40]. The top 1596 poses (of a total of
3967 poses) were inspected visually, and 32 compounds with
favorable lipophilic contacts and hydrogen bonds were purchased
for binding afﬁnity measurements by BROMOscan and AlphaScreen
[41]. Like before, a crystallographic screening was performed by
both soaking and co-crystallization methods. Of the 32 molecules
screened, compounds 13, 16, 21, 26 and 36 showed binding to the
Kac pocket by co-crystallization and could be unambiguously built
into the electron density map.
Crystal structures of BRPF1 with 13, 16, 21, 26 and 36 were
solved at resolutions higher than 1.8Å (Table S1). As expected, the
quinoxaline head groups bind to the Kac pocket in a similar way as
for the parent scaffold 9 (Fig. 4). The docking approach successfully
predicted the crystallographic poses, as for 13, 16, 21 and 26, the
docked poses show root-mean-square deviation (RMSD) less than
1.6Å with respect to the binding mode in the crystal structure
(Fig. S1). In all cases, the carbonyl group at position 3 can simul-
taneously form hydrogen bond interactions with Asn708, Cys704
and water bridging to the conserved Tyr665. As for the other
carbonyl, it acts as hydrogen bond acceptor for the NH2 of Asn708.
The tail groups show interesting binding features in the crystal
structures. The phenyl ring of 13 and 21 and aromatic ring of 16 and
26 form an edge-to-face p-p stacking interactionwith the so-called
gatekeeper residue which is Phe714 in BRPF1. The isobutyl group of
13 and 21 and the saturated ring of the tetralin in compounds 16
and 26 occupy a hydrophobic groove located between the side
chains of Ile 713 and Phe714. The substituents at the position 6 of
Fig. 2. Flowchart of the discovery of quinoxaline-2,3-dione derivatives.
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the quinoxaline point towards the NIF shelf. Furthermore, the
morpholine group in 21 and 26 contacts a backbone carbonyl of
Gly650 via a water mediated hydrogen bond.
The crystal structures can be employed to interpret the
structure-activity relationship for this series of compounds. The
substituent at position 6 seems crucial in increasing binding po-
tency, as evidenced by some pairwise comparisons (Table 2). For
example, by introduction of a morpholine group, potency of 21 is
signiﬁcantly increased as compared to 13 which has a pyrrolidine
group, as observed in both the BROMOscan (KD of 18 mMand 1.8 mM
for compounds 13 and 21, respectively) and AlphaScreen assay (IC50
of 11 mMand 1.9 mM). Similarly, improved potency was observed for
24 (IC50 of 3.6 mM in AlphaScreen) as compared to 10
(IC50¼10.5 mM). However, compounds bearing 6-position mor-
pholine or piperidine groups showed similar afﬁnity. For instance,
16 (piperidine group at position 6) shows an IC50 of 1.7 mM in
AlphaScreen and 26 (piperidine) has an IC50 of 3.4 mM. As seen from
the crystal structure of BRPF1/16, the position 2 carbonyl of 16
provided an additional hydrogen bonding interaction with the
bridging water molecule, which may compensate for the loss of the
interaction with Gly650, as compared to 26. Overall, for this com-
pound series with the sulfonamide linker, it seems bulkier group at
position 6 may bring higher potency. For future lead optimization,
it might be beneﬁcial to directly contact Gly650 by introduction of a
modiﬁed 6-position substituent.
Due to a single crystal structure with compound 36
(IC50¼16 mM) and the discrepancy between BROMOscan and
AlphaScreen assay results (e.g., compound 32 has a KD> 50 mM and
IC50¼ 4.4 mM, respectively), it is difﬁcult to discuss the structure-
activity relationship for the compounds 28-36 which have an
amide linker. We propose that for this category of compounds, the
amide and the linked group may stack against the ﬂexible side
chain of Glu661, as exempliﬁed by the crystal structure of BRPF1/36
(Fig. 4E). Interestingly, it seems that heterogeneous 6-position
groups can be employed for this series, for instance, a dieth-
ylamino group in 28 (IC50¼ 0.77 mM) and a methyl-piperidine
substituent in 32 (IC50¼ 4.4 mM) both result in potent compounds.
Isothermal titration calorimetry was used to characterize the
Table 1
Validation of pharmacophore search results. 2D structures and binding afﬁnity of 1-ethyl-2,3-dioxo-4H-quinoxaline and 1-ethyl-3-methyl-2-oxoquinoxaline derivatives.
Cpd 2D structure BROMOscan KD (mM)a cLogPb [LiPEc] PDB Code
BRPF1 TRIM24 BRD4(1)
1 16 ND ND 2.46 [2.34]
2 17 >100 >100 1.96 [2.81] 5O5A
3 36 ND ND 2.56 [1.88]
4 45 ND ND 2.11 [2.24]
5 19 >100 >100 2.71 [2.01]
6 18 ND ND 1.80 [2.94]
7 >50 ND ND e 5O5F
8 20 >100 >100 1.29 [3.41] 5O55
a BROMOscan is a competition binding assay. The KD values were measured in duplicates.
b Calculated with ChemAxon (www.chemaxon.com).
c Lipophilic efﬁciency is calculated as LiPE¼ pIC50 - cLogP. ND indicates data not determined.
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Fig. 3. Co-crystal structures of the BRPF1 bromodomain in complex with compounds 2 (A), 7 (B), 8 (C), and 9 (E). The conserved water molecules and other water molecules
involved in ligand binding are shown as pink and red spheres, respectively, while hydrogen bonds are shown by dashed lines using a threshold on hydrogen bond donor and
acceptor of 3.5Å. The 2Fo e Fc electron density maps are shown in blue mesh at a contour level of 1.0 sigma. For compounds 8 and 9, the electron density maps are shown at 0.8
sigma. (D) Superimposition of binding poses of compounds 2 (yellow), 7 (cyan) and 8 (green). (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the Web version of this article.)
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binding thermodynamics of compound 21 (Fig. 5C). A KD value of
2.7 mM was obtained, which is in good agreement with the BRO-
MOscan (KD of 1.8 mM) and AlphaScreen (IC50 of 1.9 mM) assay re-
sults. The ITC data indicated that binding of 21 to the BRPF1
bromodomain is mainly enthalpic, with an enthalpy change
of 8.5 kcalmol1 and a small entropy penalty of 0.9 kcalmol1.
Furthermore, ITC measurements of the binding of compound 26
showed similar thermodynamic characteristics, with a KD of 2.5 mM,
DH of 8.6 kcalmol1, and eTDS of 0.9 kcalmol1 (Fig. S2). These
measurements suggest optimal hydrogen bonding and van der
Waals interactions between the BRPF1 bromodomain and this se-
ries of compounds. Overlap to the apo structure shows only minor
conformational changes in BRPF1 upon binding of 21 and its ana-
logues (Fig. 4F).
Taken together, the substructure search using fragment 9 and
information on its binding mode has led to the discovery of a series
of compounds with low micromolar afﬁnity and favorable lipo-
philic efﬁciency. In total 11 compounds have IC50 below 10 mM, 10
compounds exhibit LiPE higher than 3.0, and even LiPE higher than
4.0 for compounds 19, 22, and 23.
2.3. Selectivity
We next analyzed the selectivity proﬁle of compound 21 by the
AlphaScreen assay (Fig. 5D). The assay results showed that 21 has
negligible activity on subfamily IV members BRPF2, BRPF3, and
ATAD2 bromodomains, and marginal activity (IC50¼ 204 mM) on
BRD9 bromodomain. Moreover, 21 was inactive on promiscuous
BRD4(1) (subfamily II) and CREBBP (subfamily III) bromodomains.
In addition, binding of 21 to the BRPF2 bromodomainwas too weak
to record the thermodynamic signature in an ITC measurement
(Fig. 5C, red curves). To elucidate the structural basis of the selec-
tivity of 21, the crystal structure of BRPF1/21 was aligned with apo
BRPF2 and BRD4(1) bromodomain structures (Fig. 5A and B,
respectively). The favorable van der Waals contacts between the
sulfonamide linker of 21 and Pro658 in BRPF1 are absent in BRPF2,
as the side chain of the corresponding residue in BRPF2 (Ser592)
points outwards the binding site. The structural overlap with
BRD4(1) suggests that steric collisions may occur between the
morpholine ring of 21 and Trp81 (W of the WPF shelf) in BRD4(1).
Furthermore, the binding pocket of BRD4(1) is narrower than that
of BRPF1, especially for the ZA loop segment surrounding Leu92,
which may also cause steric clashes with 21. Sequence alignment of
BRPF1 bromodomain with other bromodomains tested in the
selectivity panel provided additional information (Fig. S3). First, the
gatekeeper in the BRPF subfamily members is a phenylalanine,
while it is a smaller hydrophobic residue (valine or isoleucine) or a
tyrosine in other bromodomains, for which the T-shaped p-p
stacking with 21 cannot be formed. Secondly, Pro658 in BRPF1
corresponds to polar residues in other bromodomains (except
TRIM24), and as such the lipophilic contacts with 21 are not
possible.
2.4. Molecular dynamics simulations
To further investigate the binding mode and selectivity of
compound 21, three independent molecular dynamics runs were
performed for its complex with the BRPF1 bromodomain and three
with the BRPF2 bromodomain. The binding mode of 21 in BRPF1 is
stable in the Kac pocket during the 500 ns simulation time (Fig. 6A).
Conversely, 21 was not stable in BRPF2 and in one of the three MD
runs it escaped from the binding pocket within the ﬁrst 100 ns and
there was no re-binding. The crucial hydrogen bond interaction
between the NH group of Asn708 and the 3-position carbonyl
group of 21 was present in 90% of the simulation time for BRPF1
while it broke in the ﬁrst 100 ns in two of the three runs with the
BRPF2 complex.
Besides reporting on the main intermolecular interactions, the
molecular dynamics trajectories shed light on the orientation and
intrinsic ﬂexibility of the tail group. The dihedral angle distribution
of the sulfonamide linker shows that 21 is mainly in a conformation
with the isobutyl phenyl group projecting towards the BC loop, and
sporadically this group ﬂipped to contact the ZA loop residues (red
histograms in Fig. 6B). The simulation of 21 free in solution, i.e., in
the unbound state (blue histogram in Fig. 6B), showed that the
most populated orientation of the sulfonamide linker is the same as
in the complex with BRPF1. As for the X-ray structure, the dihedral
angle of the sulfonamide is within the main state observed in the
MD simulations of the free (and bound) state. Thus, compound 21 is
not strained in its bound conformation observed along the MD
simulations and in the X-ray structure. Concerning the relative
ﬂexibility of the BRPF1 binding site, the ZA loop region showed the
largest ﬂexibility during the simulations (Fig. S4), particularly for
the segment Leu659-Ser660-Glu661 (Fig. S5). The plasticity of the
ZA loop is consistent with previous simulation studies [42,43]. A
bulkier substituent and/or a functional group that stacks against
the ﬂexible Glu661 side chain might reduce the ﬂexibility of the ZA
loop but it is not possible to predict if the resulting entropic penalty
would be fully balanced by an enthalpic gain, i.e., additional
favorable interactions.
2.5. Cellular assays
For measuring the cellular efﬁcacy of this series of compounds,
we selected compound 26, which has higher solubility than 21 in
the preliminary assay (data not shown). Cell viability was evaluated
on acute myeloid leukemia cell lines THP-1 and HL-60. Compound
26 showed growth inhibition in THP-1 cells in a dose-response
manner with an EC50 of 32 mM, while it displayed no obvious
toxicity to normal ﬁbroblast cell line BJ (Fig. 7). In contrast to the
THP-1 cell with MLL translocation, 26 showed little effect on non-
MLL-rearranged acute leukemia cell line HL-60 in the cell
viability assay (data not shown). These observations are in linewith
a previous study [29] which reported that AML cell lines exhibiting
MLL translocation are sensitive to inhibition of BRPF1. However,
further optimization of potency is required for further in-
vestigations of themechanism of action of this series of compounds
in leukemia cells.
2.6. Second pharmacophore search; discovery of 2,4-dimethyl-
oxazole derivatives
From another pharmacophore search [34] based on PDB struc-
ture 5EVA (N-methylpyrazole-based compound 19 of Ref. [37]), we
identiﬁed compounds 42 and 43 (Table 3). We note that these two
compounds bear a 2,4-dimethyl-oxazole head, which is different
from the 3,5-dimethyl-isoxazole widely used as scaffold in BET
bromodomain inhibitor [44e47]. Compound 42 exhibited a KD of
3.5 mM in BROMOscan assay and IC50 of 30.6 mM in AlphaScreen
assay for the BRPF1 bromodomain and no measurable binding to
the TRIM24 and BRD4(1) bromodomains. Compound 43 showed
substantially weaker afﬁnity than 42.
To validate the pharmacophore model, co-crystal structures of
BRPF1 with 42 and 43 were obtained. BRPF1/42 was solved in two
different space groups (Fig. 8 and Table S1). In both cases the 2,4-
dimethyl-oxazole head is positioned at the bottom of the Kac site,
with the nitrogen atom on it forming hydrogen bonds with Asn708
and the bridging water molecule. The thiazole group stack against
Pro658. The tail group 3,5-dimethyl-piperidine show different
orientations in two crystal forms; it either points to the ZA channel
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Table 2
2D structures and assay results of the 2,3-dioxo-quinoxaline derivatives.
Cpd R1 R2 BROMOscan AlphaScreen
BRPF1 %Ctrla TRIM24 %Ctrla BRPF1 KD (mM) BRPF1 IC50 (mM) cLogPb [LiPEc] PDB Code
9 H H ND ND ND >400 e 5O4T
10 43 @100 mM 72 @100 mM ND 10.5 3.48 [1.50]
11 17 @100 mM 84 @100 mM ND ND e
12 3.1 @100 mM 86 @100 mM ND 8.7 3.35 [1.71]
13 0 @100 mM 94 @100 mM 18 (n¼ 2) 11.0 3.05 [1.91] 5OV8
14 3.9 @75 mM 100 @75 mM 11 (n¼ 2) ND 1.49 [3.47]
15 9.9 @100 mM 97 @100 mM ND >10 e
16 12 @100 mM 75 @100 mM ND 1.7 3.26 [2.51] 5MWG
17 41 @100 mM 74 @100 mM ND 3.4 2.48 [2.98]
18 22 @100 mM 82 @100 mM ND ND e
19 ND ND ND 4.4 1.13 [4.22]
20 4.1 @50 mM 90 @50 mM 33 (n¼ 2) ND 1.18 [3.30]
21 8.4 @100 mM 79 @100 mM 1.8 (n¼ 2) 1.9 (n¼ 4) 2.43 [3.29] 5MWH
22 11 @100 mM 84 @100 mM ND 2.0 (n¼ 2) 1.41 [4.29]
(continued on next page)
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Table 2 (continued )
Cpd R1 R2 BROMOscan AlphaScreen
BRPF1 %Ctrla TRIM24 %Ctrla BRPF1 KD (mM) BRPF1 IC50 (mM) cLogPb [LiPEc] PDB Code
23 ND ND ND 5.4 1.18 [4.08]
24 ND ND ND 3.6 2.85 [2.59]
25 ND ND ND 10.1 1.69 [3.30]
26 ND ND ND 3.4 2.19 [3.27] 5O4S
27 23 @100 mM 77 @100 mM ND 23.6 3.47 [1.16]
28 1.6 @25 mM 96 @25 mM 9.7 (n¼ 2) 0.77 2.12 [3.99]
29 ND ND ND >200 e
30 13 @100 mM 86 @100 mM >20 (n¼ 2) 27.0 1.81 [2.76]
31 49 @50 mM 100 @50 mM ND ND e
32 0 @50 mM 91 @50 mM >50 (n¼ 2) 4.4 2.90 [2.46]
33 46 @25 mM 97 @25 mM >25 (n¼ 2) ND e
34 ND ND ND 22.3 3.08 [1.57]
35 91 @25 mM 97 @25 mM ND ND e
36 55 @20 mM 100 @20 mM 7.1 (n¼ 2) 16 1.23 [3.56] 5MWZ
37 H 68 @100 mM 94 @100 mM ND ND e
38 H 81 @50 mM 82 @50 mM ND ND e
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or the NIF shelf (Fig. 8A and B). Interestingly, the oxygen atom of the
oxazole head, and three nitrogen atoms (viz., the NH group of the
amide linker, the thiazole nitrogen, and tertiary amino in the tail
group) are involved in a water-mediated hydrogen bonding
network with the backbone carbonyl groups of Asn651 and Ile652.
In the BRPF1/43 crystal structure (Fig. 8C), the head group of 43
binds in a similar way as 42, whereas thewater-mediated hydrogen
bond with the carbonyl group of Asn651 is lost. Compound 43 has a
pyridine ring corresponding to the thiazole of 42, and a different
tail group which occupies the ZA channel. Concerning intra-ligand
interactions, an intramolecular hydrogen bond between the oxa-
zole oxygen and the NH group of the amide linker seems to
contribute to the stability of the bound conformation of compounds
42 (Fig. 8A and B) and 43 (Fig. 8C).
A substructure search using 2,4-dimethyl-N-(thiazol-2-yl)oxa-
zole-5-carboxamide yielded a single molecule in the ZINC database.
Thus, we decided to perform a similarity search which yielded 15
analogues of compound 42 with a Tanimoto coefﬁcient larger than
0.3. These 15 compounds were evaluated using the AlphaScreen
assay (Table S4). They all showedweaker potency than 42, probably
due to their head groups which are different from the oxazole of 42.
In the biochemical assays (BROMOscan and AlphaScreen), com-
pound 42 presented good selectivity over TRIM24 and BRD4(1)
bromodomains (Table 3). To further analyze potency and selectivity,
we measured the interaction of 42 with the bromodomains of
BRPF1 and BRPF2 by means of ITC. Compound 42 showed a KD of
10.9 mM on BRPF1 (which is consistent with the afﬁnity of 3 mM and
30 mM measured by AlphaScreen and BROMOscan, respectively,
Table 3) while binding signal was not detected for BRPF2 (Fig. 8F).
Similar to 21 and 26, compound 42 appears to be another ‘enthalpic
efﬁcient’ BRPF1 inhibitor, with DH of 7.9 kcalmol1 and eTDS of
1.2 kcal mol1. Crystal structure alignment of the BRPF1/42 com-
plex with apo BRPF2 clearly shows that the Pro658 is essential for
the selectivity over BRPF2 (Fig. 8D), as discussed above for the 2,3-
dioxo-quinoxaline derivatives. The structural overlap with the
BRD4(1) structure reveals potential clashes of compound 42 with
the side chains of Trp81 (in the WPF shelf) and Leu92 (Fig. 8E).
These bulky side chains are oriented towards the center of the
binding site in BRD4(1) while the corresponding residues in BRPF1,
Asn651 and Glu661, respectively, point outside.
3. Conclusions
Our previous high-throughput fragment docking campaign [31]
paved the way for the present structure-based hit-optimization
study. Pharmacophore and substructure searches combined with
orthogonal binding assays and X-ray crystallography have led to the
identiﬁcation of a series of 1,4-dimethyl-2,3-dioxo-quinoxaline
derivatives, which are structurally different from previously re-
ported BRPF1 bromodomain inhibitors. Some of these compounds
showed low micromolar inhibitory activity towards the BRPF1
bromodomain, as conﬁrmed by both biochemical and biophysical
assays. Among them, 21 is a 2-mM ligand of the BRPF1 bromodo-
main with >100-fold selectivity over other bromodomains. Co-
crystal structures of BRPF1 with this series of compounds
revealed interesting binding features, e.g., a water-bridged
hydrogen bond to the carbonyl of Gly650 in the ZA loop. More-
over, the X-ray structures provided structural insights into the
origin of selectivity and helped to explain the structure-activity
relationship. Molecular dynamics simulations were used to inves-
tigate the binding pose of 21 to BRPF1 and its ﬂexibility. The anti-
proliferative activity on acute myeloid leukemia cell lines was
conﬁrmed by cell viability assay with 26.
From another pharmacophore search, we discovered compound
42 which bears a 2,4-dimethyl-oxazole scaffold. The selective in-
hibition of 42 on BRPF1 over other bromodomains was demon-
strated by both biochemical assay and isothermal titration
calorimetry. Crystallographic study showed extensive hydrogen
bond interactions formed in the Kac pocket of BRPF1 upon binding
of 42. The chemotypes discovered in the present study exhibit
favorable physicochemical properties, for instance, three of the 1,4-
dimethyl-2,3-dioxo-quinoxaline derivatives have lipophilic efﬁ-
ciency higher than 4.0. Moreover, the compounds 21, 26, and 42
show enthalpy-driven binding in isothermal titration calorimetry
measurements, which makes them suitable candidates for opti-
mization [48].
Taken together, a total of 74 small molecules identiﬁed in silico
were evaluated by biochemical and/or biophysical assays. Of these
74 small molecules, 57 compounds originated from the pharma-
cophore searches that made use of the crystal structure of the
BRPF1 bromodomain in the complex with 1-methyl-2-oxo-4H-
Table 2 (continued )
Cpd R1 R2 BROMOscan AlphaScreen
BRPF1 %Ctrla TRIM24 %Ctrla BRPF1 KD (mM) BRPF1 IC50 (mM) cLogPb [LiPEc] PDB Code
39 H 86 @75 mM 81 @75 mM ND ND e
40 H ND ND ND >200 e
41 H ND ND ND >200 e
a The single-dose value is the percentage of remaining binding of the competitor molecule with respect to DMSO solution at the compound concentration shown in mM; thus
lower values indicate stronger binding of the compounds.
b Calculated with ChemAxon.
c Lipophilic efﬁciency is calculated as LiPE¼ pIC50-cLogP. The AlphaScreen IC50 values are used for the pIC50, except for compounds 14 and 20 for which the BROMOscan KD
value was employed as the AlphaScreen was not performed. ND indicates data not determined. Compound 36 has N-ethyl substitutions instead of N-methyl.
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Fig. 4. Co-crystal structures of BRPF1 bound to 13 (A), 16 (B), 21 (C), 26 (D), and 36 (E). The conserved water molecules and other water molecules involved in ligand binding are
shown as pink and red spheres, respectively, while hydrogen bonds are shown by dashed lines. The 2Fo e Fc electron density maps are shown in blue mesh at a contour level of 1.0
sigma. (F) Overlap of the complex structures of BRPF1/13 (pink), BRPF1/16 (slate), BRPF1/21 (green), BRPF1/26 (yellow), and apo BRPF1 4LC2 (cyan). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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Fig. 5. Selectivity proﬁle of compound 21. (A) Structural comparison of BRPF1/21 (white) with apo BRPF2 PDB code 3RCW (salmon). Dashed lines emphasize van der Waals contacts
with the side chain of Pro658 in BRPF1 which corresponds to Ser592 in BRPF2 (see text). (B) Structural comparison of BRPF1/21 (white) with apo BRD4(1) structure 2OSS (pink). (C)
Thermodynamic characterization of interactions of 21with BRPF1 (black) and BRPF2 (red) by ITC. Thermographs, ﬁt of integrated data and ﬁt residuals are shown in the top, middle
and bottom panel, respectively. (D) Compound 21 was tested by means of AlphaScreen on bromodomains of BRPF1, BRPF2, BRPF3, ATAD2, BRD9, BRD4(1) and CREBBP. Error bars
indicate SEM. Binding is not observed for the off-targets even at a 200 mM concentration of compound 21. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the Web version of this article.)
Fig. 6. MD simulations of 21 in the complex with BRPF1 or BRPF2. (A) Time series of RMSD of compound 21 from the initial structure (blue) and distance between Nd atom of
Asn708 and 3-position oxygen atom of 21 (red). Three independent MD runs were started with randomly assigned velocities for the complex with BRPF1 (left) and BRPF2 (right). (B)
Histograms of the dihedral angle distribution of the sulfonamide linker of compound 21 in BRPF1 (red) or water (blue). Insets show the conformations of 21 in BRPF1. The vertical
line indicate the sulfonamide dihedral angle of 64 in the crystallographic pose (PDB code 5MWH). (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the Web version of this article.)
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quinoxaline (PDB code 5EPS) and 17 compounds from the search
using an N-methyl-pyrazole derivative (compound 19 of Ref. [31];
PDB code 5EVA), respectively. The pharmacophore and substruc-
ture searches were restricted to the purchasable compounds. Since
the chemical diversity of the purchasable derivatives is limited it
was not possible to reach low nanomolar potency which usually
requires optimization by chemical synthesis of derivatives
[11,49,50]. The main goal of this work was the identiﬁcation of
novel and selective BRPF1 ligands with structural information on
their binding mode. Towards this goal, we have solved 12 holo
structures of the BRPF1 bromodomain, nine complexes of BRPF1
with 1,4-dimethyl-2,3-dioxo-quinoxaline derivatives and three
complexes with 2,4-dimethyl-oxazole derivatives. We propose the
newly identiﬁed chemotypes and their structural information as
attractive starting points for further development by medicinal
chemistry.
4. Experimental
4.1. In silico screening
Two BRPF1 complex structures 5EPS and 5EVA were used for
pharmacophore search with ZINCPharmer [34]. The coordinate set
5EPS contains a fragment 3,4-dihydro-1-methylquinoxalin-2(1H)-
one, of which the carbonyl group on the quinoxaline ring was
deﬁned as hydrogen bond acceptor, the hydrophobic methyl group
and the aromatic benzene are also included in the pharmaco-
phores. In 5EVA, BRPF1 is complexed with a compound that bears a
1-methyl-pyrazole head. Similar to the aforementioned fragment,
the methyl group on the pyrazole ring was used as hydrophobic
group and the nitrogen atom served as hydrogen bond donor. The
carboxamide and the aromatic diﬂuorophenyl group were also
used as pharmacophores.
Pharmacophore search based on the structure 5EPS revealed a
series of compounds that possess either a 2,3-dioxo-4H-quinoxa-
line or a 3-methyl-2-oxoquinoxaline head. In total 365 such ana-
logues were assembled and docked into the 5EPS structure with
Autodock Vina after manual removal of the ligand. The conserved
six water molecules were kept in the Kac binding site and the
Glu661 was set to be ﬂexible during docking. A ﬁlter of hydrogen
bonding to the conserved Asn708 was applied and 24 compounds
with a binding afﬁnity< 6.5 kcalmol1 were selected from 1753
docking poses for further experimental binding validation.
Substructure search based on fragment 9was performed against
the ZINC database using an RDKit-based python script. The
retrieved 1391 compounds were docked into the 5EPS structure
with Autodock Vina using same docking settings as described
above. Filters of hydrogen bonding to the Asn708, binding afﬁnity
more favorable than 6.5 kcalmol1, and a RMSD calculation
within 1Å using the fragment as reference were applied, resulting
in 3967 binding poses from 1174 compounds. These molecules
were parameterized with CGenFF [51] which is fully consistent
with the CHARMM36 force ﬁeld. Next the binding poses were
reﬁned by energy minimizationwith CHARMM [38]. The optimized
binding poses were rescored with a knowledge-based scoring
function DSX [40]. In total 1596 poses from 754 compounds sur-
vived when a cutoff of DSX score at 110 was applied. The binding
poses were visually inspected and 32 compounds were selected
based on chemical structure diversity and availability.
Compounds 42 and 43 were identiﬁed by the pharmacophore
searchwith structure 5EVA. The search for compounds similar to 42
was performed against ZINC database using a python script based
on RDKit [52]. Totally 16 analogues with Tanimoto coefﬁcient
greater than 0.3 were selected for binding assay validation.
4.2. Chemistry
All compounds were purchased from Enamine Ltd. and Chem-
div. Their chemical structure was conﬁrmed by HPLC-MS and
proton NMR analysis (Supporting Information).
Fig. 7. Cell viability assay of 26 in leukemia cell line THP-1 and normal human
ﬁbroblast cell line BJ. The cells were treated with 26 for 72 h. Data points are triplicates
and error bars represent SEM.
Table 3
Derivatives of 2,4-dimethyl-oxazole identiﬁed in the second pharmacophore search.
Cpd 2D structure BROMOscan KD (mM) AlphaScreen IC50 (mM) ITC
KD (mM) cLogPa LEc PDB code
BRPF1 TRIM24 BRD4(1) BRFP1 BRD4(1) BRPF1 [LiPEb]
42 3.5 (n¼ 2) >50 >50 30.6 (n¼ 2) >200 10.9 2.13 [2.83] 0.29 5OWA
6EKQ
43 >75 (n¼ 2) ND ND ND ND ND e e 5O5H
a Calculated with ChemAxon.
b Lipophilic efﬁciency is calculated as LiPE¼ pIC50-cLogP, according to the ITC data.
c Ligand efﬁciency is calculated as LE ¼ (1.4/HA) pKD, according to the ITC data. ND indicates data not aquired.
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4.3. BROMOscan assay
The BROMOscan assay was performed at DiscoveRx. T7 phage
strains were used to display bromodomains in an E. coli host
derived from the BL21 strain. Streptavidin-coated magnetic beads
were treated with biotinylated small molecule or acetylated pep-
tide ligands for 30min at room temperature to generate afﬁnity
resins for bromodomain assays. Binding reactions were assembled
by combining bromodomains, liganded afﬁnity beads, and test
compounds in 1x binding buffer (17% SeaBlock, 0.33 PBS, 0.04%
Tween 20, 0.02% BSA, 0.004% Sodium azide, 7.4mM DTT). Test
compounds were prepared as 1000 stocks in DMSO and subse-
quently diluted 1:10 in monoethylene glycol (MEG) to create stocks
at 100 the screening concentration (resulting stock solution is
10% DMSO/90% MEG). The compounds were then diluted directly
into the assays such that the ﬁnal concentration of DMSO and MEG
were 0.1% and 0.9%, respectively. All reactions were performed in
polystyrene 96-well plates in a ﬁnal volume of 0.135ml.
Fig. 8. Co-crystal structures of BRPF1 bound to 42 (A, B) and 43 (C). BRPF1/42 was crystallized in P21 (A) and C2 (B) space groups.The conserved water molecules and other water
molecules involved in ligand binding are shown as pink and red spheres, respectively, while hydrogen bonds are shown by dashed lines. The 2Fo e Fc electron density maps are
shown in blue mesh at a contour level of 1.0 sigma. (D) Structural comparison of BRPF1/42 (white) with apo BRPF2 structure 3RCW (salmon). (E) Structural comparison of BRPF1/42
(white) with apo BRD4(1) structure 2OSS (pink). (F) Thermodynamic characterization of interaction of 42with BRPF1 (black) and BRPF2 (red) by ITC. Thermographs, ﬁt of integrated
data and ﬁt residuals are shown in the top, middle and bottom panel, respectively. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
Web version of this article.)
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The assay plates were incubated at room temperature with
shaking for 1 h and the afﬁnity beads were washed with wash
buffer (1 PBS, 0.05% Tween 20). The beads were then resus-
pended in elution buffer (1 PBS, 0.05% Tween 20, 2 mM non-
biotinylated afﬁnity ligand) and incubated at room temperature
with shaking for 30min. The bromodomain concentration in the
eluates was measured by qPCR. Binding constants (KD) were
calculated with a standard dose-response curve using the Hill
equation. Curves were ﬁtted using a non-linear least square ﬁt with
the Levenberg-Marquardt algorithm. Assay results are shown in
Table S3 in Supporting Information.
4.4. AlphaScreen assay
The AlphaScreen assay was carried out at Reaction Biology. Re-
combinant His-tagged bromodomains, test compounds and bio-
tinylated H4(1-21)K5/8/12/16Ac peptide were delivered to a 384-
well OptiPlate and incubated at room temperature for 30min
with gentle shaking. Streptavidine donor beads and nickel chelate
acceptor beads were added to plates followed by incubation in dark
for 60min with gentle shaking. Recombinant bromodomains,
compounds, donor and acceptor beads were prepared as 4 stock
solution in the buffer of 50mM HEPES-HCl, pH 7.5, 100mM NaCl,
1mg/ml BSA, 0.05% CHAPS and 0.5% DMSO. Alpha signal (Ex/
Em¼ 680/520-620 nm) was measured with an EnSpire plate
reader. Dose-response curve was ﬁt with GraphPad Prism 6 using a
nonlinear regression analysis model.
4.5. Protein production
BRPF1 bromodomain was puriﬁed as an N-terminal GST fusion
protein in E.coli as described previously. Puriﬁed protein was
changed into ITC buffer (50mM HEPES, pH 7.5 and 150mM NaCl)
using gel ﬁltration chromatography for the use of ITC measure-
ments. The vector harboring N-terminal 6-His tagged BRPF2 bro-
modomain was purchased from Addgene (#25342). BRPF2 plasmid
was transformed to BL21-CodonPlus competent cells. Protein
expression was induced by adding 0.2mM IPTG to the TB medium
when OD600 reached 0.6e0.8, followed by overnight culturing at
18 C. Harvested cells were disrupted using a French Press instru-
ment in the buffer of 50mM HEPES, pH 7.5, 300mM NaCl, 10mM
Imidazole, and 5% Glycerol. Lysate was loaded to a nickel afﬁnity
column and contaminants were washed away using a buffer of
50mM HEPES, pH 7.5, 300mM NaCl, 25mM Imidazole and 5%
Glycerol. Target protein was puriﬁed using an elution buffer
(50mM HEPES, pH 7.5, 300mM NaCl, 250mM Imidazole and 5%
Glycerol). The 6-His tag was removed by TEV protease afterwards.
Finally, protein was puriﬁed using gel ﬁltration chromatography in
the ITC buffer. Protein concentration (A280) was determined using
a NanoDrop spectrophotometer.
4.6. Isothermal titration calorimetry (ITC)
ITC experiments were carried out on a Microcal iTC200 instru-
ment (GE Healthcare) at 25 with a reference power of 10 mCal/s,
while stirring at a speed of 1000 rpm. Compounds were dissolved
in DMSO and were diluted into the ITC buffer at appropriate con-
centrations and equivalent amount of DMSO was added to protein
sample. Bromodomains at a concentration of 350e400 mM were
injected into cell containing 20e40 mM compounds (reverse titra-
tion). An initial control injection of 0.4 mL was applied and 150 s
spacing time between injections was set during titrations. Raw data
were integrated and baseline corrected using NITPIC [53] and were
analyzed with SEDPHAT [54] using a single-site binding model.
Thermographs were plotted with GUSSI [55]. Thermodynamic
parameters were calculated according to DG¼DH e TDS, where
DG, DH, and TDS are changes in free energy, enthalpy, and entropy
of binding, respectively.
4.7. Crystallization of BRPF1/ligand complexes
BRPF1 bromodomain was co-crystallized with inhibitors by
vapor diffusion in hanging drops at 277 K. Co-crystals of BRPF1with
compound 2, 7, 8, 9,16, 21, 26 and 43were grown bymixing protein
sample at 22mg/ml concentration with an equal volume of reser-
voir buffer of 0.1M Bis-tris propane, pH 6.5, 0.2M Sodium nitrate,
20% PEG3350. For soaking trials, apo BRPF1 crystals were obtained
under the same condition. Co-crystals of BRPF1 with 13 and 36
were obtained using well solution of 0.1M Bis-Tris propane pH7.4,
5% Ethylene glycol, 0.15M Sodiumnitrate and 25% PEG3350. BRPF1/
42 complex can be crystallized either against reservoir buffer of
0.2MMgCl2 and 20% PEG3350 or a buffer of 0.1M Bis-Tris propane,
pH 9.0, 10% Ethylene glycol, 0.15M Sodium nitrate and 25%
PEG3350.
4.8. Structure determination and reﬁnement
Crystals obtained from co-crystallization or soaking were
screened for diffraction and data sets were collected at the Swiss
Light Source, Paul Scherrer Institute (Villigen, Switzerland),
beamlines X06DA and X06SA. Data reduction was performed with
XDS [56] and scaled with Aimless [57]. Structures were solved by
molecular replacement with Molrep [58] in CCP4 suite [59] using
apo BRPF1 structure 4LC2 as a search model. Structures were
reﬁned with PHENIX [60] and were manually built with COOT [61]
for several rounds. Topology ﬁles of compounds were obtained
from the PRODRG server [62].
4.9. Molecular dynamics simulations
Molecular dynamics simulations were carried out with GRO-
MACS [63] on Cray XC40 compute nodes at Swiss National Super-
computing Center (6900 Lugano, Switzerland). The co-crystal
structure of BRPF1 in complex with 21 was used as starting coor-
dinate set with conserved water molecules kept in the binding site.
As in previous protein structure-based virtual screening campaigns
[64,65] the CHARMM36 force ﬁeld [66] was used for the parame-
ters of BRPF1, the CGenFF [51] for those of compound 21, and water
was represented by the TIP3P model. All of the simulations were
run in a cubic water box with minimum distance between protein
andwater box edge of 12Å using periodic boundary conditions. The
systems were neutralized by adding Naþ and Cl counter ions and
energy minimization was carried out for 10,000 steps. A 100-ps
NVT run followed by a 100-ps NPT run were performed to equili-
brate the system. The electrostatic interactions were calculated
with the particle mesh Ewald algorithm and all bonds were con-
strained using the LINCS algorithm. Production simulations were
carried out with a time step of 2 fs at constant temperature (300 K)
and pressure (1 atm). Snapshots were saved every 10 ps and
analyzed with built-in GROMACS tools.
4.10. Cell viability assay
AML cell lines THP-1 and HL-60, and normal skin ﬁbroblast BJ
were purchased from Shanghai Institute for Biological Science. Cells
were maintained in RPMI-1640 medium (THP-1) and DMEM me-
dium (HL-60 and BJ) containing 10% (v/v) fetal bovine serum (FBS),
at 37 C in a humidiﬁed atmosphere of 5% CO2. The growth inhib-
itory activity of tested compounds were measured using Cell
Counting Kit-8 according to manufacturer's instruction (Dojindo
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Molecular Technologies). Cells were seeded in 96 well plates in
100 mL media per well. Compounds and vehicle (DMSO) were
added at varying concentrations and cell cultures were incubated
37 C for 72 h. Optical density at a wavelength of 450 nm was
measured using a plate reader (Epoch, BioTek). Dose-response
curves were generated and EC50 values were calculated using
non-linear regression analysis with GraphPad Prism 6. All mea-
surements were performed at least three times.
Accession code
The coordinate ﬁles of BRPF1 in complex with 2 (5O5A), 7
(5O5F), 8 (5O55), 9 (5O4T), 13 (5OV8), 16 (5MWG), 21 (5MWH), 26
(5O4S), 36 (5MWZ), 42 (5OWA and 6EKQ), and 43 (5O5H) have
been deposited to the Protein Data Bank. Authors will release the
coordinates and experimental data upon article publication.
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Table S1. X-ray data collection and refinement statistics for the structures of the BRPF1 bromodomain in complex 
with small molecules identified by virtual screening. 
 
 
PDB ID 5O5A 5O5F 5O55 5O4T 
Compound 2 7 8 9 
Data Collection     
space group P3221 P3221 P3221 P3221 
Cell dimensions  a, b, c (Å) 60.69, 60.69, 63.04 60.76, 60.76, 63.52 60.86, 60.86, 62.99  60.64, 60.64, 63.47 
Cell dimensions α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00 
resolution (Å) 40.37 - 1.60 40.52 - 1.30 31.57 - 1.45 40.46 - 1.50 
unique observations*  18144(900) 33637 (1591) 24259 (3462) 21891(1029) 
completeness* 99.9 (100.0) 99.08 (96.04) 99.8 (99.0) 99.4(97.4) 
redundancy* 10.6 (10.0) 7.3 (4.6) 9.4 (8.1) 13.2(12.9) 
Rmerge* 0.043 (0.633) 0.022 (0.437) 0.031 (0.468) 0.090(0.642) 
CC(1/2) 0.999 (0.879) 1.000 (0.802) 1.000 (0.999) 0.997(0.812) 
I/σI* 25.5 (3.7) 37.3 (3.1) 31.2 (4.5) 16.9(3.0) 
Refinement     
Rwork/Rfree* 0.189(0.229)/0.194(0.292) 0.199(0.233)/0.225(0.252) 0.196(0.208)/0.205(0.268) 0.182(0.247)/0.212(0.271) 
r.m.s deviations bond  (Å) 0.008 0.006 0.007 0.005 
r.m.s deviations  angles (°) 0.879 0.666 0.765 0.723 
B-factors(P/L/O) (Å2) ** 37.5/41.9/45.5 20.7/27.0/34.1 30.6/32.0/41.7 28.9/35.3/39.5 
Ramanchandran  Favored  98.25 100.00 99.12 99.10 
Ramanchandran Allowed 1.75 0.00 0.88 0.90 
Ramanchandran Disallowed 0.00 0.00 0.00 0.00 
     
     
PDB ID 5OV8 5MWG 5MWH 5O4S 
Compound 13 16 21 26 
Data Collection     
space group P21 P21 P21 P21 
Cell dimensions  a, b, c (Å) 48.19, 56.54, 48.60    48.60, 61.14, 48.60 60.69, 60.69, 63.04 48.61, 62.69, 48.82 
Cell dimensions  α, β, γ (°) 90.00, 102.41, 90.00 90.00, 101.63, 90.00 90.00, 90.00, 120.00 90.00, 101.81, 90.00 
resolution (Å) 47.46 - 1.80 37.56 – 1.50 38.19 - 1.65 38.00 - 1.75 
unique observations*  23018(1295) 42415(1960) 34911(1685) 29072(1578) 
completeness* 97.1(93.1) 95.0(89.2) 99.5 (96.7) 99.9(99.4) 
redundancy* 3.9(3.9) 6.8(3.5) 13.3(9.1) 13.2(12.9) 
Rmerge* 0.040(0.220) 0.209(0.253) 0.135(0.816) 0.151(0.730) 
CC(1/2) 0.998(0.946) 0.990(0.914) 0.998(0.864) 0.985(0.961) 
I/σI* 18.7(4.3) 12.5(5.2) 21.6 (2.1) 22.6(4.1) 
Refinement     
Rwork/Rfree* 0.196(0.230)/0.243(0.315) 0.224(0.256)/0.243(0.320) 0.186(0.295)/0.221(0.305) 0.178(0.254)/0.220(0.297) 
r.m.s deviations bond  (Å) 0.006 0.006 0.006 0.006 
r.m.s deviations  angles (°) 0.804 0.887 0.773 0.722 
B-factors(P/L/O) (Å2) ** 26.9/29.7/36.7 24.9/28.0/35.0 37.7/40.2/45.8 35.8/38.0/42.8 
Ramanchandran  Favored  99.08 99.54 98.62 100.00 
Ramanchandran  Allowed 0.92 0.46 1.38 0.00 
Ramanchandran  Disallowed 0.00 0.00 0.00 0.00 
     
     
PDB ID 5MWZ 5OWA 6EKQ 5O5H 
Ligand 36 42 42 43 
Data Collection     
space group P3221 P21 C2 P3221 
Cell dimensions  a, b, c (Å) 60.86, 60.86, 62.99  34.89, 92.30, 81.22 71.21, 57.78, 70.45 61.03, 61.03, 63.79 
Cell dimensions  α, β, γ (°) 90.00, 90.00, 120.00 90.00, 101.22, 90.00 90.00, 108.66, 90.00 90.00, 90.00, 120.00 
resolution (Å) 40.46 - 1.25 39.93 - 1.95 43.89 – 1.65 40.70 – 1.85 
unique observations* 37830(1871) 34898(5200) 32602(1588) 12134(740) 
completeness* 99.9(99.9) 94.9(96.5) 99.7(100.0) 100.0(100.0) 
redundancy* 18.4(16.8) 3.3(3.4) 4.6(4.2) 18.6(19.2) 
Rmerge* 0.056(0.452) 0.083(0.469) 0.046(0.345) 0.041(0.640) 
CC(1/2) 0.999(0.957) 0.991(0.762) 0.999(0.879) 1.000(0.955) 
I/σI* 31.4(7.9) 12.0(2.6) 18.0(3.4) 43.9(5.4) 
Refinement     
Rwork/Rfree* 0.163(0.165)/0.180(0.186) 0.219(0.309)/0.267(0.393) 0.156(0.188)/0.181(0.226) 0.190(0.409)/0.234(0.460) 
r.m.s deviations bond  (Å) 0.004 0.007 0.009 0.008 
r.m.s deviations  angles (°) 0.768 1.205 1.003 1.098 
B-factors(P/L/O) (Å2) ** 15.4/22.5/29.4 40.4/44.7/42.4 20.2/18.9/35.3 35.6/51.7/43.4 
Ramanchandran  Favored 99.11 98.86 100.00 100 
Ramanchandran  Allowed 0.89 0.92 0.00 0 
Ramanchandran  Disallowed 0.00 0.23 0.00 0 
* Statistics for the highest resolution shell is shown in parentheses. 
* * P/L/O indicate protein, ligand in the active site and solvent molecules, respectively.  
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Table S2. 2D structures of the 1-ethyl-2,3-dioxo-4H-quinoxaline and 1-ethyl-3-methyl-2-oxoquinoxaline 
derivatives that did not show binding at the highest concentration tested. 
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Table S3. BromoScan assay results for selected compounds on BRPF1, TRIM24 and BRD4(1) bromodomains. The 
assays were performed in duplicate.  
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Fig. S1. Superimposition of the pose predicted by docking (cyan) and the corresponding binding mode in the crystal 
structures (magenta).   
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Fig. S2. Thermodynamic characterization of the BRPF1-26 interaction by ITC. The Fig. shows thermographs (top), 
fit of integrated data (middle), and fit residuals (bottom). 
 
 
Table S4. Analogues of compound 42 and their binding affinity measured by AlphaScreen. 
 
 
2D Structure Tanimoto 
coefficient 
with 42 
AlphaScreen 
(IC50, uM) 
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Fig. S3. Structure-based sequence alignment of the BRPF1 bromodomain with bromodomains of BRPF2 (BRD1), 
BRPF3, ATAD2, BRD9, BRD4(1), CREBBP (CBP) and TRIM24 (TIF1A). The sequence alignment was obtained 
with ESPript.[1] 
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Fig. S4. Time series of RMSD from the X-ray structure along the three MD simulations of the BRPF1/21 complex. 
RMSD time series for all Cα atoms (blue) and Cα atoms in the ZA loop segment 648-668(red) are shown.  
 
 
 
 
 
Fig. S5. Comparison of the B-factors calculated from the fluctuations of the atoms along the MD simulations of 
the BRPF1/21 complex (red) and B-factors in X-ray crystals. The experimental B-factors are those of the crystal 
structure of the BRPF1/21 complex (blue) and apo BRPF1 (PDB code 4LC2) (black). The ZA loop region (residues 
648-668) and BC loop region (residues 708-712) are highlighted (grey vertical stripes). The function gmx rmsf in 
GROMACS was used to extract B-factors from the MD simulations.[2]  B-factors were averaged over all non-
hydrogen atoms for each residue. 
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a b s t r a c t
Overexpression of the CREB-binding protein (CBP), a bromodomain-containing transcription coactivator
involved in a variety of cellular processes, has been observed in several types of cancer with a correlation
to aggressiveness. We have screened a library of nearly 1500 fragments by high-throughput docking into
the CBP bromodomain followed by binding energy evaluation using a force field with electrostatic solva-
tion. Twenty of the 39 fragments selected by virtual screening are positive in one or more ligand-
observed nuclear magnetic resonance (NMR) experiments. Four crystal structures of the CBP bromod-
omain in complex with in silico screening hits validate the pose predicted by docking. Thus, the success
ratio of the high-throughput docking procedure is 50% or 10% if one considers the validation by ligand-
observed NMR spectroscopy or X-ray crystallography, respectively. Compounds 1 and 3 show favorable
ligand efficiency in two different in vitro binding assays. The structure of the CBP bromodomain in the
complex with the brominated pyrrole 1 suggests fragment growing by Suzuki coupling.
 2017 Elsevier Ltd. All rights reserved.
Bromodomains are protein-protein interaction modules that
bind acetylated lysine (Kac)1 or other acyl modifications of the
lysine side chain.2 The bromodomain fold consists of a left-handed
four-helix bundle (helices Z, A, B, and C) with the interhelical loops
ZA and BC flanking the rim of the acetyllysine-binding pocket.3,4
The potential involvement of bromodomains in several types of
cancer and inflammatory diseases5 sparked interest in developing
small molecules inhibiting their Kac-binding activity.6
The bromodomain of the lysine acetyltransferase CBP (the bind-
ing protein of the cyclic-AMP response element binding protein)
has been the object of intense investigations due to the role of
CBP in several cellular processes and implication in cancer.7
Small-molecule ligands of the CBP bromodomain have been dis-
covered by others using in vitro screening techniques8–12 and in
our research group by in silico screening (high-throughput dock-
ing).13 The latter have been optimized by medicinal chemistry into
potent and selective CBP bromodomain inhibitors.14
Here we report on the identification of ligand-efficient CBP bro-
modomain inhibitors via the computational screening of nearly
1500 small molecules. As a point of departure with respect to
our previous virtual screening campaigns on CBP, here we take
advantage of ligand-based NMR spectroscopy to validate the dock-
ing results. We call the sequential in silico to in vitro strategy Vir-
tual Screen to NMR (VS2NMR).
In an effort to identify ligand-efficient small molecule inhibitors
of the CBP bromodomain, we performed a rigid-ligand docking
screen taking advantage of the software SEED.16,17 A library of
1413 small molecules was docked into the acetyllysine binding site
of the CBP bromodomain (Figs. 1 and S1) and the binding energy of
the resulting poses was calculated using a force field-based energy
function with approximation of desolvation effects in the contin-
uum-dielectric representation.16,17 The docked poses of the frag-
http://dx.doi.org/10.1016/j.bmcl.2017.04.001
0960-894X/ 2017 Elsevier Ltd. All rights reserved.
Abbreviations: Alpha, amplified luminescent proximity homogeneous assay;
ATAD2, ATAD2 ATPase family, AAA domain containing 2; BAZ2A, bromodomain
adjacent to zinc finger domain protein 2A; BAZ2B, bromodomain adjacent to zinc
finger domain protein 2B; BRPF1, bromodomain and PHD finger (BRPF) containing
protein 1; CBP, CREB-binding protein; CREB, cyclic-AMP response element binding
protein; CSPs, chemical shift perturbations; DMSO, dimethyl sulfoxide; DSF,
differential scanning fluorimetry; EP300, adenoviral E1A binding protein; HAC,
heavy atom count; Kac, N-e-acetyllysine; LE, ligand efficiency; NMR, nuclear
magnetic resonance; qPCR, quantitative PCR polymerase chain reaction; STD,
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⇑ Corresponding authors.
E-mail addresses: d.spiliotopoulos@bioc.uzh.ch (D. Spiliotopoulos), caflisch@-
bioc.uzh.ch (A. Caflisch).
Bioorganic & Medicinal Chemistry Letters 27 (2017) 2472–2478
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/locate /bmcl
ments were filtered to enforce a hydrogen bond with the conserved
water molecule w1 (Fig. S1) that bridges to the side chain hydroxyl
of the conserved Tyr1125 (see Supplementary information). The
remaining poses were ranked according to the median rank of a
consensus scoring aimed to prioritize molecules with favorable
electrostatic contribution to the binding energy (including desol-
vation penalties) and van derWaals interactions. Of the 60 selected
fragments, 39 were ultimately chosen to be validated via NMR
techniques (Table S1) based on results from experimental quality
control.18
To experimentally validate these fragments as ligands of the
CBP bromodomain, we took advantage of ligand-based NMR spec-
troscopy. The in silico hits were divided into four mixtures of 9–10
molecules each with minimal 1H NMR spectral overlap. Fragments
which displayed a clear evidence for binding in at least one of three
ligand-observed NMR spectroscopy experiments, viz., 1H, STD, and
R2-filtered,19,20 were selected for further validation. To ensure
specificity for the primary binding site we included competition
experiments with SGC-CBP30, a nanomolar ligand of the CBP bro-
modomain8 (Fig. S2). Overall, specific interactions with the CBP
bromodomain were observed for 20 of the 39 small molecules,
which corresponds to a success ratio (defined as the quotient of
true positives divided by the number of compounds tested by
NMR) of 50% for the in silico screening (Fig. 1). The most pro-
nounced effects were observed for compounds 1–4 (Table 1),
showing STD effects as well as chemical shift perturbation (CSPs)
and enhanced R2 relaxation in presence of CBP (Table 2).
To further validate the 20 compounds that showed binding in
the ligand-observed NMR experiments, competition binding assays
were performed first with the AlphaScreen technology using a
tetra-acetylated peptide segment from the histone H4. At 0.5 mM
compound concentration, 50% or higher inhibition of the CBP bro-
modomain was observed for five of the 20 actives in the NMR
experiments (Table 2). Two of these compounds were not investi-
gated further because of lack of novelty of their head group. These
are the 3-acetylindole 2, which is similar to a fragment recently
disclosed as a 29-mM inhibitor of the BRPF1 bromodomain,21 and
the acetylbenzene derivative 4, which shares the same head group
as our previously disclosed CBP inhibitors.13,14 Furthermore, the
pyrazole derivative 5 was discarded because of its poor affinity,
also confirmed by the lack of shift in the DSF assay (Table 1). The
remaining two compounds (1 and 3) displayed micromolar affinity
in dose-response measurements using two different biochemical
assays (Table 1 and Fig. S3). The IC50 values measured by the
AlphaScreen approach22 are about one order of magnitude less
favorable than the KD values obtained by a competition binding
assay based on DNA-tagged CBP bromodomain and PCR quantifica-
tion.15 Such discrepancies have already been reported in previous
studies of bromodomain ligands.23–25 They are likely to originate
from different experimental conditions, protocols, and/or the use
of different competitor molecules (the AlphaScreen assay was per-
formed using a tetra-acetylated 21-mer H4 peptide whereas a pro-
prietary undisclosed ligand was used for the assay based on DNA-
tagged bromodomain). Importantly, the ligand efficiency of com-
pounds 1 and 3 is very favorable irrespective of the assay (Table 1).
In our previous fragment-based high-throughput docking cam-
paigns for the bromodomains of BRD4 (N-terminal),26 CBP,13
BRPF1,21 BAZ2A (PDB codes 5MGJ, 5MGK, 5MGL, 5MGM),
BAZ2B,27,28 and ATAD2 (PDB codes 5EPB, 5F3A, 5F36) the poses
predicted by docking were validated by protein crystallography.
Similarly, in the present VS2NMR campaign, we decided to validate
the binding poses predicted by docking by means of X-ray crystal-
lography. Towards this goal, we solved the crystal structures of the
complexes of the CBP bromodomain with ligands 1 to 4 at resolu-
tion of 1.65 Å or higher (Figs. 2 and S4, Table S2).
Compound 1 forms four hydrogen bonds with the CBP bromod-
omain (Fig. 2A). There are two direct hydrogen bonds involving the
pyrrole NH and carbonyl oxygen acting as donor and acceptor,
respectively, for the side chain of the conserved Asn1168. Further-
more, two water-mediated hydrogen bonds are formed between
the carbonyl oxygen of compound 1 and the side chain hydroxyl
of the conserved Tyr1125 (through the structural water w1) and
between the NH of the carboxamide and the backbone carbonyl
of Pro1110. The bromine substituent of 1 points towards the side
chains of Leu1120 and Ile1122 in the ZA-loop, which provides sta-
bilization by hydrophobic contacts. The pose predicted by docking
is consistent with the binding mode in the crystal structure except
for the relative orientation of the pyrrole and the N-methylamide,
which is due to the conformer used for docking and the rigid-
ligand docking protocol.
As for compound 1, a minor discrepancy between docked pose
and binding mode in the crystal structure is observed for com-
pound 3 (Fig. 2C) which is again a consequence of the different
conformer used in the rigid-docking protocol. Importantly, the
position of the double-ring system and the two hydrogen bonds
of the carbonyl oxygen (with the side chain of Asn1168 and the
water w1) are predicted correctly by docking. Interestingly, a sec-
ond molecule 3 is present outside of the Kac binding site, with sta-
bilization due to stacking between the indole of Trp1151 and the
phenyl of Tyr1102 of a neighboring CBP bromodomain, and a
hydrogen bond with the side chain of Gln1113 of the same neigh-
boring protein (Fig. 3). Thus, the second binding mode is stabilized
by crystal packing.
The pose predicted by docking for the 3-acetylindole 2 and
acetylbenzene derivative 4 are essentially identical to the binding
mode in the crystal structures (Fig. 2B,D). The methoxy oxygen of
the acetylbenzene derivative 4 is involved in a water-bridged
hydrogen bond with the backbone oxygen of Pro1110 (Fig. 2D) or
the side chain oxygen of Asn1168 (Fig. S5) in the two protein
chains of the asymmetric unit. As expected, the binding pose of 4
superimposes with an acetylbenzene-based sub-micromolar inhi-
bitor reported recently (PDB code 4TQN, Fig. S6).13 In both struc-
Fig. 1. Flowchart of the VS2NMR workflow and subsequent experimental validation
by means of competition binding assays and X-ray crystallography. VS2NMR
consisted of (1) virtual screening by high-throughput fragment docking using the
program SEED16,17 and (2) ligand-based NMR spectroscopy. This efficient screening
strategy was finally validated by (3) two different in vitro binding assays15,22 and X-
ray crystallography. The success ratio of the in silico screening is 50% according to
ligand-observed NMR spectroscopy and 10% according to X-ray crystallography.
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tures, the acetyl oxygen of the ligand acts as acceptor in a direct
hydrogen bond with the side chain NH2 of the conserved
Asn1168 and a water-bridged hydrogen bond to the side chain of
Tyr1125. As reported previously,21,29,30 the distance between the
acetyl oxygen and the bridging water (2.7 Å for both compounds
2 and 4) is shorter than the distance to the nitrogen atom of the
Asn1168 side chain (3.0 Å). A shorter distance to the bridging w1
oxygen than the Asn1168 side chain nitrogen is also observed for
the carbonyl oxygen of compounds 1 and 3 (Fig. S7).
An essential element of our fragment-docking procedure is the
efficient evaluation of the binding energy which is the sum of the
van der Waals interaction and electrostatic energy in the contin-
uum dielectric approximation (see original papers on the SEED
software).16,17 The electrostatic contribution to the binding energy
is the sum of the screened interaction between the (partial)
charges in the protein and the ligand, and the desolvation penalty
of the receptor and fragment upon binding. It is useful to analyze
the individual contributions to the binding energy. Here, we focus
the analysis on the top two poses (according to total binding
energy as calculated by SEED) as the third ranking pose was signif-
icantly less favorable for the four fragment hits 1–4. The total SEED
energy favors the pose that is close to the binding mode observed
in the crystal structure (Fig. 4). On the other hand, the van der
Waals contribution does not consistently favor the binding mode
observed in the crystal structure. The van der Waals energy is
always favorable because it consists of only the fragment/protein
contribution, while the loss of solute/solvent van der Waals energy
upon binding is neglected. In contrast, the electrostatic contribu-
tion to the binding energy (DGelec), which includes desolvation
effects, always favors the pose close to the binding mode observed
in the crystal structure over the second best pose. More precisely,
for compound 3 the desolvation penalty is less unfavorable for the
top pose than the second best pose while for compounds 1, 2, and 4
it is rather the intermolecular electrostatic contribution that favors
the top pose. This analysis provides evidence that a simple scoring
function, e.g., based on only van der Waals energy, would not have
sufficient predictive ability. It also highlights the importance of the
evaluation of the electrostatic energy with solvation for identifying
the correct binding mode among the multiple poses generated by
docking.
In conclusion, we efficiently identified inhibitors of the CBP bro-
modomain by means of a VS2NMR campaign using high-through-
put fragment docking (by the program SEED)16,17 followed by
ligand-observed NMR spectroscopy. First, the initial 1413 frag-
ments were reduced to 39 candidate ligands by in silico screening,
which required only two hours of a commodity computer. Twenty
of these molecules showed specific, competitive binding in ligand-
observed NMR experiments. In contrast to the present study in
which NMR measurements were performed on a small set of mole-
cules preselected by high-throughput docking, in previous reports
by others NMR spectroscopy has been employed as primary
screening with the following protocols: 2D HSQC or HMQC
NMR,31–36 ligand-observed NMR,37,38 protein observed fluorine
NMR,39,40 and target immobilized NMR screening.41 Importantly,
with the present VS2NMR campaign, 50% of the small molecules
predicted by docking as candidate ligands of the CBP bromodomain
were confirmed by ligand-observed NMR spectroscopy, a higher
success ratio than that of primary NMR screens on bromodomains,
which range from 0.3%33 to 13.5%.40 Although it is not possible to
directly compare different screening protocols and targets, the pre-
sent study provides evidence that the VS2NMR strategy is time and
resource efficient. As a matter of fact, the primary screening of
nearly 1500 compounds by NMR, including data analysis, would
have required about three weeks, while the present VS2NMR cam-
paign took about two days.
We have recently carried out a VS2NMR campaign for the
BAZ2A bromodomain starting from the same 1413-fragment
library as in the present study and with the same validation by
ligand-based NMR as secondary screening (D. Spiliotopoulos
et al., manuscript in preparation). The success ratio for CBP (20
Table 1
In silico identified ligands of the CBP bromodomain.
2D structure HACa PDB code DSF (C)b AlphaScreen BROMOscan
CBP EP300 %c IC50 (mM)d LEe KD (mM)f LEe
1 10 5MQE 7.3 7.0 0.1 40 0.60 4 0.74
2 13 5MQK 2.9 2.6 31 n.d.g n.d. n.d. n.d.
3 14 5MPZ 2.3 1.4 34 455 0.33 85 0.40
4 12 5MQG 2.4 2.6 37 n.d. n.d. n.d. n.d.
5 16 – 0.1 1.3 48 n.d. n.d. n.d. n.d.
a HAC: heavy atom count.
b Differential scanning fluorimetry (DSF) measurements were carried out at a bromodomain concentration of 2 lM and a ligand concentration of 1 mM. For each ligand/
bromodomain pair, the shift in the melting temperature is the median value of at least nine measurements. Standard error of the mean values were smaller than 0.3 C in all
cases.
c Binding of the CBP bromodomain to a labelled acetylated peptide in the presence of 0.5 mM of the ligand with respect to DMSO solution, with lower percentage values
indicating stronger inhibition.
d IC50 values were determined by curve fitting of 10-point dose responses.
e Ligand efficiency (LE) values are reported in kcal/mol per heavy atom.
f KD values, as determined by curve fitting of 12-point dose responses in duplicates in a competition-binding experiment based on DNA-tagged CBP bromodomain and
quantitative PCR.15
g n.d.: not determined.
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Table 2
Ligand-based NMR spectroscopy validation of the molecules predicted in silico as CBP bromodomain ligands.
2D structure HACa NMR screeningb AlphaScreen %c
1H STD CPMG
1 10 + + + 0.1
2 13 – + + 31
3 14 + + + 34
4 11 + + + 37
5 16 – – + 48
6 12 – – + 56
7 11 + – + 56
8 14 + + + 74
9 15 + + + 79
10 12 + + + 85
11 12 – + + 92
12 13 + – + 92
13 15 – + + 92
14 15 + + + 93
15 15 + – + 94
16 14 – – + 96
17 17 + – + 98
18 15 – – + 100
19 11 + + + 100
20 17 – – + 102
a HAC: heavy atom count.
b NMR spectroscopy techniques included 1H, saturation transfer difference (STD) NMR and Carr-Purcell-Meiboom-Gill (CPMG).
c Binding of the CBP bromodomain to an acetylated peptide in the presence of 0.5 mM of the ligand with respect to DMSO solution, with lower values indicating stronger
inhibition. The compounds are sorted according to percentage binding.
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actives according to NMR out of 39 candidate ligands) is higher
than for the BAZ2A bromodomain (7 actives out of 20 candidate
ligands) which is a more difficult target as it has a shallower Kac
biding site.
The high ligand efficiency of the in silico identified fragments
calls for hit expansion. In a cellular milieu, the methylester of com-
pound 3 is likely to be converted into a carboxyl group. The result-
ing negative charge on the carboxyl group would hinder binding to
the Kac pocket because of the electrostatic desolvation penalty. On
the other hand, the binding mode of the brominated pyrrole 1 is
compatible with fragment growing by Suzuki coupling.
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Fig. 2. Structural validation of the fragment-based in silico screening campaign for CBP. (A–D) The binding mode in the crystal structures (carbon atoms of ligands in cyan) are
compared to the binding pose predicted by docking with SEED16,17 (carbon atoms in yellow) for compounds (A) 1, (B) 2, (C) 3, and (D) 4 (PDB codes: 5MQE, 5MQK, 5MPZ, and
5MQG, respectively). Conserved water molecules and water molecules present in the crystal structure but not used for docking are shown as red and cyan spheres,
respectively. Compounds 1 and 3 have a different relative orientation of the substituents, which could not be predicted by SEED since the compounds were docked as rigid
molecules.
Fig. 3. Two molecules of compound 3 bind to the CBP bromodomain in the crystal structure. (A) The two compound 3 molecules present in the crystallographic unit of the
CBP/3 complex (gray cartoons) are shown as sticks and transparent spheres. A description of the pose of the molecule bound to the Kac-binding site (carbon atoms in cyan or
gray) can be found in the text. The second molecule (magenta) stacks between the side chains of Trp1151 and Tyr1102 of a neighboring CBP bromodomain. The N- and C-
termini of the bromodomains are shown with a blue and red sphere, respectively. (B) Zoom on the additional compound 3molecule and the protein residues surrounding it.
The polar interaction between the carbonyl oxygen of the ligand and the side chain of the Gln1113 of the neighboring CBP bromodomain is shown with dashed lines. The two
bromodomains are shown with dark and light gray, respectively.
2476 D. Spiliotopoulos et al. / Bioorganic & Medicinal Chemistry Letters 27 (2017) 2472–2478
Accession codes
Structure were deposited to the PDB with accession numbers
5MQE (CBP/1), 5MQK (CBP/2), 5MPZ (CBP/3), and 5MQG (CBP/4).
Conflict of interest
The authors declare no competing interest.
Acknowledgements
We thank the Structural Genomics Consortium at University of
Oxford for providing the plasmid of the CBP bromodomain. EP300
was a gift from Nicola Burgess-Brown (Addgene plasmid # 39018).
The AlphaScreen and BROMOscan measurements were performed
at Reaction Biology Corporation and DiscoverX, respectively. This
work was supported in part by the Swiss National Science Founda-
tion (grant to A.C.) and Max Planck Society and the German
Research Foundation (DFG, RA1944/2-1) (C.R., J. A. and E.W.). D.S.
is a recipient of the SystemsX.ch translational postdoc fellowship
and gratefully acknowledges support from the Holcim Foundation.
A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmcl.2017.04.
001.
References
1. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and
ligand of a histone acetyltransferase bromodomain. Nature. 1999;399
(6735):491–496.
2. Flynn EM, Huang OW, Poy F, et al. A subset of human bromodomains recognizes
butyryllysine and crotonyllysine histone peptide modifications. Structure.
2015;23(10):1801–1814.
3. Zhang G, Smith SG, Zhou MM. Discovery of chemical inhibitors of human
bromodomains. Chem Rev. 2015;115(21):11625–11668.
4. Filippakopoulos P, Knapp S. Targeting bromodomains: Epigenetic readers of
lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337–356.
5. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets.
Expert Rev Mol Med. 2011;13:e29.
6. Ferri E, Petosa C, McKenna CE. Bromodomains: structure, function and
pharmacology of inhibition. Biochem Pharmacol. 2016;106:1–18.
7. Iyer NG, Ozdag H, Caldas C. P300/CBP and cancer. Oncogene. 2004;23
(24):4225–4231.
8. Hay DA, Fedorov O, Martin S, et al. Discovery and optimization of small-
molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc. 2014;136
(26):9308–9319.
Fig. 4. Insights into the energetic terms calculated using SEED for the two top poses of compounds 1 (A–C), 2 (D–F), 3 (G–I), and 4 (J–L). The CBP bromodomain is shown as a
cartoon and sticks with white carbon atoms, whereas the ligands are shown as sticks. The color coding is consistent in all panels (cyan, green, and magenta for binding mode
in the crystal structure, top pose and 2nd best pose according to total SEED energy, respectively). (C, F, I, L) The contributions to the binding energy are the intermolecular van
der Waals energy, the intermolecular electrostatics energy calculated in the solvent using a continuum dielectric representation, the electrostatic desolvation energy of the
receptor and ligand upon binding. These terms sum up to the total energy. The electrostatic contribution to the binding free energy in the solvent (DGelec) is the sum of
intermolecular electrostatic energy and desolvation penalties.
D. Spiliotopoulos et al. / Bioorganic & Medicinal Chemistry Letters 27 (2017) 2472–2478 2477
9. Rooney TP, Filippakopoulos P, Fedorov O, et al. A series of potent CREBBP
bromodomain ligands reveals an induced-fit pocket stabilized by a cation-pi
interaction. Angew Chem Int Ed. 2014;53(24):6126–6130.
10. Picaud S, Fedorov O, Thanasopoulou A, et al. Generation of a selective small
molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Cancer
Res. 2015;75(23):5106–5119.
11. Taylor AM, Cote A, Hewitt MC, et al. Fragment-based discovery of a selective
and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor (CPI-
637). ACS Med Chem Lett. 2016;7(5):531–536.
12. Crawford TD, Romero FA, Lai KW, et al. Discovery of a potent and selective
in vivo probe (GNE-272) for the bromodomains of CBP/EP300. J Med Chem.
2016;59(23):10549–10563.
13. Xu M, Unzue A, Dong J, Spiliotopoulos D, Nevado C, Caflisch A. Discovery of
CREBBP bromodomain inhibitors by high-throughput docking and hit
optimization guided by molecular dynamics. J Med Chem. 2016;59
(4):1340–1349.
14. Unzue A, Xu M, Dong J, et al. Fragment-based design of selective nanomolar
ligands of the CREBBP bromodomain. J Med Chem. 2016;59(4):1350–1356.
15. Quinn E, Wodicka L, Ciceri P, et al. BROMOscan – a high throughput,
quantitative ligand binding platform identifies best-in-class bromodomain
inhibitors from a screen of mature compounds targeting other protein classes.
Cancer Res. 2013;73:4238.
16. Majeux N, Scarsi M, Apostolakis J, Ehrhardt C, Caflisch A. Exhaustive docking of
molecular fragments with electrostatic solvation. Proteins. 1999;37:88–105.
17. Majeux N, Scarsi M, Caflisch A. Efficient electrostatic solvation model for
protein-fragment docking. Proteins. 2001;42(2):256–268.
18. Aretz J, Wamhoff EC, Hanske J, Heymann D, Rademacher C. Computational and
experimental prediction of human C-type lectin receptor druggability. Front
Immunol. 2014;5:323.
19. Mayer M, Meyer B. Characterization of ligand binding by saturation transfer
difference NMR spectroscopy. Angew Chem Int Ed. 1999;38(12):1784–1788.
20. Hajduk PJ, Olejniczak ET, Fesik SW. One-dimensional relaxation- and diffusion-
edited NMR methods for screening compounds that bind to macromolecules. J
Am Chem Soc. 1997;119(50):12257–12261.
21. Zhu J, Caflisch A. Twenty crystal structures of bromodomain and PHD finger
containing protein 1 (BRPF1)/ligand complexes reveal conserved binding
motifs and rare interactions. J Med Chem. 2016;59(11):5555–5561.
22. Philpott M, Yang J, Tumber T, et al. Bromodomain-peptide displacement assays
for interactome mapping and inhibitor discovery. Mol BioSyst. 2011;7
(10):2899–2908.
23. Theodoulou NH, Bamborough P, Bannister AJ, et al. Discovery of I-BRD9, a
selective cell active chemical probe for bromodomain containing protein 9
inhibition. J Med Chem. 2016;59(4):1425–1439.
24. Crawford TD, Tsui V, Flynn EM, et al. Diving into the water: inducible binding
conformations for BRD4, TAF1(2), BRD9, and CECR2 bromodomains. J Med
Chem. 2016;59(11):5391–5402.
25. Tanaka M, Roberts JM, Seo HS, et al. Design and characterization of bivalent BET
inhibitors. Nat Chem Biol. 2016;12(12):1089–1096.
26. Zhao H, Gartenmann L, Dong J, Spiliotopoulos D, Caflisch A. Discovery of BRD4
bromodomain inhibitors by fragment-based high-throughput docking. Bioorg
Med Chem Lett. 2014;24(11):2493–2496.
27. Lolli G, Caflisch A. High-throughput fragment docking into the BAZ2B
bromodomain: efficient in silico screening for X-ray crystallography. ACS
Chem Biol. 2016;11(3):800–807.
28. Marchand JR, Lolli G, Caflisch A. Derivatives of 3-amino-2-methylpyridine as
BAZ2B bromodomain ligands: in silico discovery and in crystallo validation. J
Med Chem. 2016;59(21):9919–9927.
29. Chung C-W, Dean AW, Woolven JM, Bamborough P. Fragment-based discovery
of bromodomain inhibitors part 1: inhibitor binding modes and implications
for lead discovery. J Med Chem. 2011;55(2):576–586.
30. Marchand JR, Caflisch A. Binding mode of acetylated histones to
bromodomains: variations on a common motif. ChemMedChem. 2015;10
(8):1327–1333.
31. Zeng L, Li J, Muller M, et al. Selective small molecules blocking HIV-1 Tat and
coactivator PCAF association. J Am Chem Soc. 2005;127(8):2376–2377.
32. Sachchidanand, Resnick-Silverman L, Yan S, et al. Target structure-based
discovery of small molecules that block human p53 and CREB binding protein
association. Chem Biol. 2006;13(1):81–90.
33. Borah JC, Mujtaba S, Karakikes I, et al. A small molecule binding to the
coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem
Biol. 2011;18(4):531–541.
34. Harner MJ, Frank AO, Fesik SW. Fragment-based drug discovery using NMR
spectroscopy. J Biomol NMR. 2013;56(2):65–75.
35. Chaikuad A, Petros AM, Fedorov O, Xu J, Knapp S. Structure-based approaches
towards identification of fragments for the low-druggability ATAD2
bromodomain. Med Chem Commun. 2014;5(12):1843–1848.
36. Ghosh S, Taylor A, Chin M, et al. Regulatory T cell modulation by CBP/EP300
bromodomain inhibition. J Biol Chem. 2016;13014–13027.
37. Demont EH, Bamborough P, Chung CW, et al. 1,3-Dimethyl benzimidazolones
are potent, selective inhibitors of the BRPF1 bromodomain. ACS Med Chem Lett.
2014;5(11):1190–1195.
38. Wang N, Li F, Bao H, Li J, Wu J, Ruan K. NMR Fragment screening hit induces
plasticity of BRD7/9 bromodomains. ChemBioChem. 2016;17(15):1456–1463.
39. Mishra NK, Urick AK, Ember SW, Schonbrunn E, Pomerantz WC. Fluorinated
aromatic amino acids are sensitive 19F NMR probes for bromodomain-ligand
interactions. ACS Chem Biol. 2014;9(12):2755–2760.
40. Urick AK, Hawk LM, Cassel MK, et al. Dual screening of BPTF and Brd4 using
protein-observed fluorine NMR uncovers new bromodomain probe molecules.
ACS Chem Biol. 2015;10(10):2246–2256.
41. Chaikuad A, Lang S, Brennan PE, et al. Structure-based identification of
inhibitory fragments targeting the p300/CBP-associated factor bromodomain.
J Med Chem. 2016;59(4):1648–1653.
2478 D. Spiliotopoulos et al. / Bioorganic & Medicinal Chemistry Letters 27 (2017) 2472–2478
S1 
 
 
Supporting Information    
 
Virtual Screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain 
 
Dimitrios Spiliotopoulos,*,a Jian Zhu,a Eike-Christian Wamhoff,b,c Nicholas Deerain,a Jean-Rémy 
Marchand,a Jonas Aretz,b,c Christoph Rademacher,b,c and Amedeo Caflisch*,a 
 
Author Affiliations:  
aDepartment of Biochemistry University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, 
Switzerland  
bDepartment of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 
1, 14424 Potsdam, Germany 
cInstitute of Chemistry and Biochemistry, Department of Biology, Chemistry, and Pharmacy, Freie 
Universität Berlin, Takustraße 3, 14195 Berlin, Germany 
 
Corresponding Authors:  
*E-mail: A.C.,  caflisch@bioc.uzh.ch. Phone: +41 44 635 55 21.  D.S., d.spiliotopoulos@bioc.uzh.ch.  
Phone:  +41 44 635 55 92.  
 
  
S2 
 
EXPERIMENTAL SECTION  
Fragment Docking and Scoring. The initial library consisted of 1413 fragments available in the 
laboratory of one of the authors (C.R.).  These molecules were selected from a large panel of commercial 
suppliers and academic collaborations according mainly to diversity. From this library, a total of 2133 
tautomers were generated using the calculator plugins of Marvin 15.8.17, 2015, Chemaxon.  
The in-house developed program SEED1, 2 was used for docking. The target structure was the 
CBP bromodomain complexed to acetylated lysine (PDB code: 3P1C), and the binding site was defined 
as the side chain of the conserved Asn1168 and the six water molecules that are found in most crystal 
structures of this bromodomain (Figure S1).  
The partial charges and van der Waals parameters for the protein and the fragments were taken 
from the CHARMM36 all-atom force field3, 4 and the CHARMM general force field (CGenFF),5 
respectively. Importantly, the same paradigm was used to derive the partial charges and van der Waals 
parameters for the CHARMM36 force field and CGenFF, making the force fields completely consistent. 
SEED uses a force field-based energy function with a continuum dielectric approximation of desolvation 
penalties based on the generalized Born paradigm to evaluate the binding energy.6 The continuum 
calculations were performed setting the dielectric constant to 2.0 and 78.5 for the solute (low-dielectric 
region) and solvent (high-dielectric region), respectively. The docking of the 2133 tautomers with SEED 
required approximately 2 h (about 3 s per fragment) of a single core of an Intel Xeon E5410 processor 
at 2.33 GHz.  
The docked poses were first evaluated for the presence of an acceptor atom involved in a 
hydrogen bond with the conserved water molecule w1 (Figure S1). Moreover, poses with buried polar 
groups of fragment and/or protein not involved in hydrogen bonds were filtered out using an in-house 
developed software (Hydrogen bond penalty lower than 1).7, 8 The final ranking was based on the median 
value of a consensus scoring function that included the ranks of (1) the difference between (1a) the 
electrostatic contribution to the protein/ligand interaction energy in the solvent and (1b) the solvation 
energy of the ligand, (2) the predicted binding energy (SEED total energy), and (3) the van der Waals 
efficiency, i.e., the intermolecular van der Waals contribution divided by the number of non-hydrogen 
atoms. These three terms are meant to prioritize compounds that (1) establish favorable polar 
interactions with the targeted protein considering the opposing free energy of hydration, (2) have 
favorable total energy calculated by SEED, including van der Waals and polar interactions, and (3) are 
fully buried in the binding site. Compounds were sorted using the median of the three rankings. The 
median (and not the mean value) was used as it is less sensitive to outliers.9, 10 Note that SEED treats the 
docked compounds as rigid molecules, meaning that all the terms (including 1a and 1b) are computed 
for the small molecule in the conformation under investigation. A total of 60 small molecules were 
selected using the in silico approach. Of these 60 compounds, 21 were subsequently filtered out due to 
experimental issues (e.g., poor solubility, binding promiscuity and/or chemical reactivity).  
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Protein Expression and Purification. Proteins were expressed and purified as described in 11.  
 
NMR Spectroscopy. All NMR experiments were performed on a PremiumCompact 600 MHz 
spectrometer at 25°C equipped with a OneNMR probe (Agilent). Data were processed using 
MestReNova software suite (Mestrelab Research S. L.). A DPFGSE pulse sequence was utilized for 
solvent suppression.12  
During STD NMR experiments a saturation time tsat of 4.0 s utilizing a train of 50 ms Gauss 
pulses for used with an on- and off-resonance frequency of 0.0 ppm (νsat) and 80.0 ppm (νref).13 For each 
spectrum, 256 scans were recorded in 5 mm sample tubes at sample volumes of 500 to 550 µL. No 
prescan relaxation delay d1 was included and the acquisition time tacq was set to 2.0 s. A T1,rho filter of 
35 ms duration was utilized for receptor resonances suppression. A Carr−Purcell−Meiboom−Gill 
(CPMG) pulse sequence was used to perform R2-filtered NMR experiments with a prescan relaxation 
delay d1 of 2.0 s and an acquisition time tacq of 2.0 s.14 The frequency of 180° pulses (νCPMG) was set to 
100 Hz and the total relaxation time T was set to 0.4 s. The induction of chemical shift perturbations in 
presence of CBP was analyzed using regular 1H NMR experiments. The relaxation delay d1 was set to 
2.0 s and the acquisition time tacq was set to 2.0 s. Spectra were recorded at 128 scans.  
From the 39 selected compounds, four fragment mixtures with minimal 1H NMR spectral 
overlap were predicted using a genetic algorithm. Briefly, this approach was implementing by first 
generating a list of chemical shifts for each fragment. Assignment of the NMR resonances was based 
on previously acquired 1H NMR spectra of the individual fragments. The lists were then randomly 
combined to yield a population of 50 individual virtual fragment mixtures. Assuming a tolerance of 0.3 
ppm for the spectra overlap, a fitness score was calculated. Based on this score, a set of fit fragment 
mixtures is selected and its composition is randomly varied by mutation (mutation rate = 0.01) or 
crossover (crossover rate = 0.8) to generate the next generation of fragment mixtures. This procedure 
was repeated for 1000 generations until convergence to yield fragment mixtures with optimized spectral 
overlap. The termination criterion was the existence of at least one resonance not displaying spectral 
overlap for each fragment.  
Optimized sample mixtures were prepared at 200 µM of each fragment in 50 mM H3PO4 with 
100% D2O, 2% DMSO-d6, 150 mM NaCl at pH 7.4. 100 µM TSP-d4 served as an internal reference. 
The stability of the fragment mixtures over 16 h at room temperature was monitored via 1H NMR. 
CPMG and STD-based fragment screening was conducted first in absence of CBP, followed by the 
addition of 20 µM CBP. Finally, competitive binding experiments were conducted in presence of 20 µM 
SGC-CBP30.15 Hits from virtual screening were considered as validated in case either an STD effect, 
an increased R2 relaxation rate or a 1H chemical shift perturbation occurred in presence of CBP, and the 
nanomolar inhibitor SGC-CBP30 showed competitive binding. The analysis was based on a visual and 
qualitative assessment of the recorded spectra. Fragments displaying an STD effect in absence of protein 
were considered artifacts and were excluded from further analysis.  
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AlphaScreen and BROMOscan assays. AlphaScreen is a bead-based proximity assay technology that 
has been applied to identify small molecules able to displace histone peptides from bromodomains.16 
Briefly, donor and acceptor beads are coupled to the interaction partners and, as the bromodomain ligand 
inhibits this interaction, the detected signal is reduced. A histone H4 tetra-acetylated peptide (H41-
21Kac5Kac8Kac12Kac16) was used for the measurements with the CBP bromodomain ligands in the 
presence of 0.1% DMSO.  
BROMOscan is a competition-based technology using a ligand immobilized to a solid support 
and DNA-tagged bromodomains. The ligand is incubated with the bromodomains in the presence and 
absence of the putative inhibitors and the bromodomains are eluted and quantified by qPCR. The amount 
of bromodomain captured will be reduced if small molecules inhibiting the bromodomain binding to the 
immobilized ligand are present, which results in a reduction of the detected qPCR signal.17 Dissociation 
constants (KD) were calculated in the presence of 0.09% DMSO fitting a 12-point dilution with starting 
concentration of 0.5 mM and dilution factor of 3.0.  
AlphaScreen and BROMOscan assays were carried out at Reaction Biology Corporation and 
DiscoverX Corporation, respectively.  
 
Thermal Shift Measurements. Thermal shift measurements were performed using a 2 µM and 1 mM 
concentration for the bromodomains and ligands, respectively, with 0.3% (v/v) DMSO.  
 
Crystallization, Data Collection and Structure Solution. CBP bromodomain was crystallized by 
vapor diffusion in sitting drops at 4°C. Apo crystals for compound soaking were grown from 0.1 M Bis-
Tris pH 5.5, 0.2 M potassium thiocynate, 5% ethylene glycol and 23% PEG3350. Overnight soaking of 
compounds 1 and 4 were performed by transferring the apo crystals into the crystallization buffer in 
which compounds were previously dissolved at 5-10 mM. Compound 2 was co-crystallized with CBP 
bromodomain using the crystallization buffer of 0.15 M KSCN, 10% ethylene glycol and 20% PEG3350. 
Co-crystal structure of compound 3 bound to CBP bromodomain was determined from crystals grown 
from 0.1 M Bis-Tris pH 6.5, 0.2 M MgCl2, 5% ethylene glycol and 23% PEG3350. Crystals were 
cryoprotected by crystallization buffer supplemented with 20% ethylene glycol prior to freezing in liquid 
nitrogen. Diffraction data from a single crystal was acquired at the X06SA beamline at the Swiss Light 
Source, Paul Scherrer Institut, Villigen, Switzerland. Data was processed with XDS18 and scaled with 
SCALA19 or AIMLESS,20 structures were solved by molecular replacement with Phaser21 or MOLREP22 
using PDB 3DWY as search model. Clear difference electron densities for compounds in the Kac 
binding pocket can be unambiguously modelled. Rounds of manual model building were carried out 
with COOT23 and refinement was performed with Phenix.24 Crystal data collection and refinement 
statistics are summarized in Table S2. 
  
S5 
 
Table S1.  2D structures and contributions to the binding energy (in kcal/mol) for the 39 molecules predicted 
as candidate ligands of the CBP bromodomain by the docking program SEEDa. 
 2D structure 
 intermolecular  electrostatic desolvation  total 
elect. 
Total 
energy  vdW elect.  protein fragment  
1 
 
 –16.9 –11.0  5.1 6.0  0.1 –16.8 
2 
 
 –17.9 –7.7  6.7 3.4  2.4 –15.5 
3 
 
 –14.5 –9.4  6.1 2.6  –0.7 –15.2 
4 
 
 –18.0 –10.3  7.2 3.3  0.2 –17.8 
5 
 
 –18.2 –15.2  8.2 8.7  1.7 –16.5 
6 
 
 –20.1 –9.7  6.9 6.0  3.2 –16.9 
7 
 
 –16.1 –7.7  6.9 3.0  2.2 –13.9 
8 
 
 –14.8 –10.9  6.4 4.4  –0.1 –14.9 
9 
 
 –19.1 –10.2  8.0 2.9  0.7 –18.4 
10 
 
 –22.6 –7.5  5.6 4.8  2.9 –19.7 
11 
 
 –16.8 –9.4  6.5 2.8  –0.1 –16.9 
12 
 
 –22.2 –5.9  7.8 2.2  4.1 –18.1 
13 
 
 –18.6 –5.0  7.5 2.7  5.2 –13.4 
14 
 
 –20.7 –12.2  8.3 6.6  2.7 –18.0 
15 
 
 –17.8 –21.9  11.2 15.1  4.4 –13.4 
16 
 
 –17.1 –11.5  5.6 5.2  –0.7 –17.8 
17 
 
 –19.2 –12.4  8.9 9.1  5.6 –13.6 
18 
 
 –15.3 –3.0  6.5 4.0  7.5 –7.8 
19 
 
 –17.5 –8.1  5.3 2.6  –0.2 –17.7 
20 
 
 –19.5 –10.1  9.0 4.4  3.3 –16.2 
21 
 
 –20.7 –9.4  6.2 5.3  2.1 –18.6 
22 
 
 –20.8 –8.3  6.1 1.6  –0.5 –21.4 
23 
 
 –17.8 –11.1  6.7 8.2  3.8 –14.0 
24 
 
 –16.3 –12.1  5.6 5.0  –1.5 –17.8 
25 
 
 –18.1 –12.5  6.5 6.2  0.2 –17.9 
26 
 
 –18.4 –12.4  6.4 6.3  0.3 –18.0 
27 
 
 –17.9 –8.7  5.8 7.5  4.6 –13.3 
28 
 
 –18.4 –6.2  6.0 5.9  5.7 –12.7 
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29 
 
 –16.2 –12.8  5.2 8.9  1.3 –14.9 
30 
 
 –17.7 –6.3  5.2 2.9  1.8 –15.9 
31 
 
 –16.3 –8.0  6.0 2.8  0.8 –15.5 
32 
 
 –15.5 –7.4  5.4 2.8  0.8 –14.7 
33 
 
 –18.3 –7.0  5.7 2.8  1.5 –16.8 
34 
 
 –16.5 –9.7  6.0 3.4  –0.3 –16.8 
35 
 
 –17.3 –16.2  8.9 7.4  0.1 –17.2 
36 
 
 –17.7 –7.3  7.4 2.4  2.5 –15.2 
37 
 
 –11.9 –14.4  5.6 5.6  –3.2 –15.1 
38 
 
 –11.0 –9.0  4.9 3.5  –0.6 –11.6 
39 
 
 –15.9 –14.3  9.1 6.3  1.1 –14.8 
aThe SEED total energy (total energy) is the sum of the intermolecular van der Waals energy (vdW) and the total 
electrostatic energy.  The total electrostatic is the sum of intermolecular electrostatic energy and desolvation 
penalties for protein and fragment.   
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Table S2. X-ray data collection and refinement statistics for complex structures of the CBP bromodomain 
and compounds 1, 2, 3 and 4.  
Data Collection 
PDB ID 5MQE 5MQK 5MPZ 5MQG 
ligand  1 2 3 4 
space group H3 H3 P212121 H3 
Cell dimensions 
a, b, c (Å) 122.37, 122.37, 39.35 122.36,122.36, 40.37 44.06, 44.06, 60.21 121.44, 121.44, 40.27 
α, β, γ (°) 90.00, 90.00, 120.00  90.00, 90.00, 120.00 90.00, 90.00, 90.00 90.00, 90.00, 120.00 
resolution (Å) 37.38 - 1.65 37.72 - 1.53 44.06 - 1.40 37.61 - 1.35 
unique 
observationsa 
26769(1347) 33860(4964) 23766(1057) 48059(6756) 
completenessa  99.7(99.5) 99.6(99.9) 98.9(90.1) 98.8(95.4) 
redundancya  5.1(4.5) 5.1(4.9) 5.8(3.3) 4.9(4.2) 
Rmergea  0.038(0.425) 0.041(0.485) 0.044(0.336) 0.030(0.335) 
I/σIa  20.2(3.0) 16.5(3.3) 21.2(4.0) 20.7(3.6) 
Refinement 
Rwork/Rfreea  
0.184(0.260) 
/0.223(0.322) 
0.183(0.278)/ 
0.210(0.275) 
0.157(0.206)/ 
0.176(0.273) 
0.171(0.244) 
/0.191(0.252) 
r.m.s. deviations 
of bond lengths 
(Å) 
0.007 0.007 0.005 0.006 
r.m.s. deviations 
of bond angles (°) 
0.909 0.915 0.957 0.891 
Average B-factor (Å2) 
protein 36.13 37.04 17.66 28.87 
ligand 24.69 30.31 24.05 27.71 
water 40.83 41.61 31.76 37.04 
Ramachandran 
favored (%) 98.57 99.06 100 99.50 
allowed (%) 1.43 0.94 0 0.50 
disallowed (%) 0 0 0 0 
aHighest resolution shell is shown in parentheses.  
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Figure S1. CBP bromodomain structure used for docking (PDB code: 3P1C). The six water molecules kept for 
the docking procedures are shown as spheres, with w1 colored in gold (color code for the water molecules as in 
Figure 1B of 25). The size of each sphere is proportional to the frequency of the corresponding water molecule 
(legend on top, right)  in 44 inspected crystal structures of bromodomains bound to an acetyllysine (one structure 
each for PCAF, BRD2(2), BRD3(2), BRD4(2), BRDT(1), BRDT(2), and BAZ2A; two structures for TAF1(2); 
three structures each for CBP, BAZ2B, and TRIM24; four structures each for BRD2(1), ATAD2, and BRPF1; 
seven structures each for BRD4(1) and BRD9).  The side chain of the residues discussed in the main text and the 
acetyllysine are shown as sticks (carbon atoms in gray and yellow, respectively).   
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Figure S2. Ligand-observed NMR screening experiments for compound 1. Peaks of the compound undergo 1H 
chemical shift perturbation (left), an increase in the R2 relaxation (middle) and STD effects (right) in the presence 
of the CBP bromodomain. Binding occurs in the acetyllysine binding site as titration of the nanomolar inhibitor 
SGC-CBP30 reverses all three observables. 
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Figure S3. Competition binding assays for compounds 1 and 3. (A) Dose-response curves in duplicates for the 
compounds 1 (top) and 3 (bottom) tested for binding to the CBP bromodomain in the BROMOscan competition 
binding assay. (B) Dose response curves for binding of hit fragments 1 (black squares) and 3 (open circles) to the 
CBP bromodomain as measured by the AlphaScreen assay using a biotinylated H4 peptide as competitive ligand 
at Reaction Biology Corporation.  (C) SGC-CBP30 is used as a positive control; it consists of 36 heavy atoms and 
has a ligand efficiency of 0.31 kcal mol–1 HAC–1.  
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Figure S4. Close view of binding mode of compounds 1–4.  Conserved water molecules in the binding pocket are 
shown as transparent spheres color coded as in Figure 3. Fo – Fc omit map for each compounds is shown in mesh 
contoured at 3 σ.  
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Figure S5. Comparison of the binding mode in the chain A of the crystal structure of the CBP/4 complex (carbon 
atoms in deep teal, PDB code: 5MQG) with the binding pose predicted by docking with SEED 1, 2 (carbon atoms 
in yellow). The oxygen atom of the methoxy group forms a water-mediated hydrogen bond with the side chain of 
the conserved asparagine. Conserved water molecules (red spheres) and crystallographic water molecules not used 
for docking (deep teal spheres) are shown. Hydrogen bonds are shown as deep teal dashed lines.  
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Figure S6. Comparison of the binding poses of compound 4 and the previously reported compound 40. (A) 
Chemical structure of compounds 4 and 40. (B) Comparison of the CBP/4 complex (cyan) to the CBP/40 complex 
(magenta, PDB code: 4TQN). Compound 4 recapitulates many polar interactions of the larger compound 40 (color-
coded dashed lines), including a water-bridged hydrogen bond with the backbone oxygen of Pro1110. The smaller 
compound 4, though, does not establishes any interaction with the side chain of Arg1173. (C) Comparison of the 
binding pose of compound 4 in the two chains of the asymmetric unit (cyan and green) and compound 40 (magenta).  
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Figure S7. Analysis of the H-bonds of the group that mimics the acetyl of Kac. (A) 2D structures of compounds 
40 (10 in 26, PDB code: 4TQN), 41 (1b in 27, PDB code: 4TS8), 42 (PDB code: 5EIC), 43 (PDB code: 5ENG), and 
44 (PDB code: 5EP7). The carbonyl group involved in the H-bond is in red. (B) Scatter plot of the distances 
involving the side chain nitrogen of Asn1168, with numbers indicating the ligand. In all cases the hydrogen bond 
distance with the conserved water w1 that bridges to the Tyr1125 side chain is shorter than the distance to the 
Asn1168.  
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ABSTRACT: Expanding the chemical space and simulta-
neously ensuring synthetic accessibility is of upmost
importance, not only for the discovery of eﬀective binders for
novel protein classes but, more importantly, for the develop-
ment of compounds against hard-to-drug proteins. Here, we
present AutoCouple, a de novo approach to computational
ligand design focused on the diversity-oriented generation of chemical entities via virtual couplings. In a benchmark application,
chemically diverse compounds with low-nanomolar potency for the CBP bromodomain and high selectivity against the BRD4(1)
bromodomain were achieved by the synthesis of about 50 derivatives of the original fragment. The binding mode was conﬁrmed
by X-ray crystallography, target engagement in cells was demonstrated, and antiproliferative activity was showcased in three
cancer cell lines. These results reveal AutoCouple as a useful in silico coupling method to expand the chemical space in hit
optimization campaigns resulting in potent, selective, and cell permeable bromodomain ligands.
■ INTRODUCTION
The druglike chemical space is estimated at 1060 organic
molecules, but only 100 million have been synthesized to date,
and an even smaller fraction thereof is commercially available.1,2
Libraries of purchasable molecules are biased toward certain
classes of targets, in particular G-protein-coupled receptors and
kinases.3,4 Repositories of pharmaceutical companies consist of
106 to 107 compounds which barely scratch the surface of
chemical space. Success in high-throughput screening ulti-
mately relies on the screening library:5−7 the exploration of
chemical space that is not biased toward already investigated
targets is decisive not only for the discovery of eﬀective binders
for novel protein classes but, more importantly, for the
development of compounds against protein targets that are
hard-to-drug.8−11 Classical de novo strategies can potentially
populate new areas of chemical space,12−16 and thus, programs
have been developed to disconnect molecules following
retrosynthesis rules17,18 producing fragments that can be used
later on to construct new libraries.19 Nevertheless, signiﬁcant
challenges when reaching the synthesis stage might prevent
those new molecular entities from being prepared and,
ultimately, becoming useful chemical probes.13 In addition,
time pressure in drug-discovery campaigns demands new tools
to improve the identiﬁcation of hits and streamline their
optimization into lead compounds.20 Computational tools for
de novo generation of molecular entities via virtual couplings
have been reported.21−24 The method proposed here, called
AutoCouple, distinguishes itself by starting from a set of
available building blocks that are assembled via virtual organic
reactions in such a way that, at the coupling step, the reaction
partners are parsed automatically and are coupled only if no
undesired group is contained (e.g., groups that would require
additional protection steps or lead to cross reactivity products
are discarded). As such, AutoCouple generates libraries of
compounds that are, ideally, synthesizable in one step.
Bromodomains are protein modules that bind acetylated
lysine (KAc) residues in histone tails and other proteins.
Among the 61 known human bromodomains,25 the BET
family, in particular BRD4(1) (the ﬁrst bromodomain of the
protein called BRD4), has been widely targeted because of its
involvement in cancer, type 2 diabetes, and cardiovascular
diseases.26−30 Several small molecule ligands of BET
bromodomains are currently in clinical trials, which highlights
the potential of regulating post-transcriptional modiﬁcations of
histone tails in the current landscape of drug discovery.31−34 In
contrast, selective and potent bromodomain ligands, aiming to
unravel the biological implications of bromodomains outside
the BET family, have only recently started to be devel-
oped.35−54 In particular, the bromodomain of CBP (the
epigenetic reader of the cyclic AMP response element binding
protein) is an interesting target due to its key role in several
diseases including cancer and neurological disorders.55 Despite
recent eﬀorts toward developing novel and selective CBP
bromodomain inhibitors, the chemotypes that are able to act as
KAc mimic are still rather limited and, except for GNE-781,
demand exquisite absolute stereocontrol, thus complicating
their synthetic accessibility (Figure 1A).56−67
Our groups have recently reported the fragment-based
design68,69 of acetyl benzene derivatives as selective nanomolar
Received: August 29, 2017
Published: February 7, 2018
Research Article
Cite This: ACS Cent. Sci. 2018, 4, 180−188
© 2018 American Chemical Society 180 DOI: 10.1021/acscentsci.7b00401
ACS Cent. Sci. 2018, 4, 180−188
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
D
ow
nl
oa
de
d 
vi
a 
62
.2
.8
0.
24
6 
on
 Ju
ne
 1
6,
 2
01
8 
at
 1
4:
30
:2
5 
(U
TC
). 
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
. 
CBP bromodomain ligands.70,71 Compound 1 (Figure 1B),
bearing a benzoic acid moiety, proved to be a synthetically
accessible molecule with an equilibrium dissociation constant
(Kd) of 770 nM for the CBP bromodomain and good selectivity
over BRD4(1) (selectivity >65-fold according to the ratio of Kd
values). The overlap of the crystal structures of the complex of
compound 1 with the CBP bromodomain and the structure of
BRD4(1) (Figure 1C) shows that the selectivity is due to the
steric clash between the benzoate group and the Trp81 side
chain of the so-called WPF triad of BRD4(1). Further
development of this compound was not pursued given its
lack of target engagement in cells, likely due to the negative
eﬀect of the carboxylate on the compound’s permeability, a
commonly encountered problem in medicinal chemistry
optimization campaigns.72−74 We thus set out to identify new
chemotypes enabling interactions at the outer part of the
binding site of the CBP bromodomain (Arg1173 and/or the so-
called ZA loop) that could potentially translate into ligands
with improved potency, selectivity, and cell permeability
compared to hit 1.
To this end, we sought to establish an eﬃcient method for
growing fragments into potent and selective ligands taking
chemical accessibility into account at the outset of the
computation.75,76 This early on synthesis oriented approach
Figure 1. (A) List of current nM inhibitors of the CBP bromodomain.44,56−58,60 Dissociation constant (Kd) determined by isothermal titration
calorimetry (ITC). Half-maximal inhibitory concentration (IC50) determined by time-resolved ﬂuorescence resonance energy transfer (TR-FRET).
Selectivity for CBP over BRD4(1) bromodomains (S1) determined by the ratio of Kd or IC50 values. (B) Crystal structure of the CBP bromodomain
(cyan) in complex with compound 1 (green) (PDB code: 4TQN).70,71 The acetyl benzene moiety acts as a KAc mimic interacting directly and
through a water molecule with the side chains of the conserved residues Asn1168 and Tyr1125, respectively. The carboxylate function of the tail
group forms a salt bridge with the guanidinium of Arg1173. The amide linker is involved in two water-bridged hydrogen bonds with the CBP
bromodomain. (C) Overlay of the complex of compound 1 (green) with the CBP bromodomain (cyan) and the structure of BRD4(1) (4PCI)
shows that the selectivity is due to bumping of the benzoate into the Trp81 side chain (red) of the so-called WPF triad of BRD4(1).
Figure 2. Schematic representation of AutoCouple. A headgroup (here the KAc mimic is shown in orange) is virtually coupled to commercially
available building blocks. The resulting library is ﬁltered out to remove any protein-reactive functionalities and subsequently docked while
maintaining key interactions of the headgroup inside the target’s binding site. The compounds are ranked according to binding energy calculated by a
force ﬁeld with continuum electrostatic solvation.
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would confer on our method the possibility to overcome the
limitations of previously released software tools which typically
suggest hard-to-synthesize molecules, hampering follow-up
medicinal chemistry eﬀorts. Here, we present the realization
of this concept with AutoCouple, a novel approach to de novo
computational ligand design that focuses on the diversity-
oriented generation of chemical entities via virtual chemical
couplings. AutoCouple is the ﬁrst fragment-growing software
tool that generates synthetically accessible molecules with a
force ﬁeld based prediction of their binding energy without any
ﬁtting parameter. Its operative and pragmatic value has been
demonstrated by the discovery of novel chemical blueprints
which translated into nM potent and cell-permeable inhibitors
of the CBP bromodomain with high selectivity over BRD4(1).
Further, the preliminary biological evaluation of cell permeable
ligands points toward the potential use of these compounds to
unravel the role of CBP in several types of solid tumors and
hematological malignancies.77
■ RESULTS AND DISCUSSION
Implementation of AutoCouple and Application to
CBP Bromodomain. First, a suite of Python scripts78,79 was
assembled (see section 1 in the Supporting Information) to
generate a virtual library from commercially available reagents
by a set of coupling reactions suited for medicinal chemistry
(Figure 2). Three reactions were established based on the
following criteria:5,80 (a) the robustness of the intended
chemical coupling, (b) the applicability to a wide variety of
reactants, (c) the proven relevance/use in drug-discovery
campaigns. The acetyl benzene moiety within 1 was retained as
Scheme 1. AutoCouple Results for the CBP Bromodomain Using (A) Amide Condensation, (B) Buchwald−Hartwig Amination,
and (C) Suzuki Cross-Coupling Reactions from Aniline (2), Bromobenzene (3), and Aryl Boronic Ester (4) as “Headgroups”,
Respectivelya
aKd values (μM) were determined by a competition binding assay in duplicates (BROMOscan).
88 IC50 values for compound 16 are indicated in
purple and were determined by ampliﬁed luminescent proximity homogeneous assay (Alpha) screen technology (Reaction Biology). Ligand
eﬃciency (LE) values refer to the CBP bromodomain. Selectivity for CBP over BRD4(1) bromodomains (S1) determined by the ratio of Kd or IC50
values. (D) Chimerization of compounds 5−7. The growing vectors (green arrows) of the diﬀerent coupling strategies show the similarity between
the amide and the C−C coupled products compared to the amine linker in orienting the tail group.
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the KAc mimic (from now on referred to as “headgroup”), and
we thus decided to explore the chemical space of the “tail
group” adjacent to the KAc mimic.
First, commercially available building block libraries were
generated, followed by coupling in silico to the KAc mimic in
compound 1. Aniline 2, bromobenzene 3, and aryl boronic
ester 4 were selected as “headgroups” for amide condensation,
Buchwald−Hartwig amination, and Suzuki cross-coupling,
respectively (Schemes 1A, 1B, and 1C respectively). For the
tail, a library of ∼270,000 commercially available compounds
was sorted according to chemical functionalities. A series of
ﬁlters were applied to limit the ﬁnal molecular complexity and
to discard molecular patterns known to react non-speciﬁcally
with most proteins81,82 as well as heavy metals containing
molecules. Moreover, to avoid redundancies, any building
blocks with the same CAS number were merged. Considering
that chemical couplings imply an increase in the molecular
complexity (except for cleavage reactions),22 and that the
coupling products should preferably satisfy the Lipinski rule of
5 for druglikeness, building blocks meeting any of the following
criteria were discarded: (a) >5 rotatable bonds; (b) number of
heavy atoms (= non-hydrogen) smaller than 3 or larger than
35; (c) >2 chiral centers. Each virtual reaction was also encoded
to discard any building block that contained undesired chemical
functionalities that would require a protecting group or lead to
cross-reactivity problems. For instance, for the Buchwald−
Hartwig coupling, the amine building blocks containing a halide
(which would ultimately lead to self-condensation) were not
kept for the virtual reactions.
A total of ∼70,000 virtual compounds were generated:
32,000 carboxylic amides (A), 19,000 anilines (B), and 19,000
C−C coupled ligands (C). Five independent docking
campaigns were carried out with libraries A, B, and C using
the CBP bromodomain structures 3P1C, 4TQN, and 4NYX
(see section 1.3 in the Supporting Information). Multiple
crystal structures were used because of the ﬂexibility of the
Arg1173 side chain and the rigid-protein protocol employed for
docking by the open-source software rDock.83 The acetyl
benzene was initially oriented in the binding site to mimic the
KAc residue as observed in the crystal structure and then
underwent ﬂexible docking. The poses obtained by docking
were subsequently minimized using the CHARMM program84
and the CHARMM36/CGenFF force ﬁeld85,86 with evaluation
of desolvation eﬀects in the continuum dielectric approxima-
tion.87 Receiver operating characteristic (ROC) curves using
known positive controls70,71 were plotted as to ensure the
ability of the force ﬁeld and implicit solvent approximation
(ﬁnite-diﬀerence Poisson) to prioritize active ligands.
Synthesis of de Novo Ligand Binders: Potency,
Selectivity, and Binding Mode Validation. Overall, 53
top-ranking compounds were synthesized (Scheme 1A−C) and
a competition binding assay (BROMOscan)88 was used to
measure dissociation constants (for exhaustive data on all
synthesized ligands, see section 2 in the Supporting
Information). Using amide coupling for fragment assembly
enabled us to identify arylsulfonamides, -acetamides, and
-thiazoles with diverse substitution patterns (5−8) as suitable
motifs to replace the original benzoate “tail group”. These de
novo synthesized ligands displayed comparable or even
improved levels of potency and selectivity compared to those
previously observed for 1. Compound 5 showed not only a 4-
fold improvement in potency (Kd = 200 nM) but also a
remarkably high selectivity (>250-fold) against BRD4(1).
Furthermore, the “amide-coupling” campaign resulted in 33
synthesized molecules, four of which display submicromolar
aﬃnity (compounds 5−8, Scheme 1A), 17 are low micromolar
binders (1.2−6.5 μM), and 10 have Kd values between 10 μM
and 45 μM (see Figure S1). Compounds stemming from both
Buchwald−Hartwig amination (9, 10) and Suzuki cross-
coupling (11−15) consistently showed improved aﬃnities
and good selectivity while oﬀering additional motifs (cyclic and
linear alkylsulfonamides, diester, tetrazoles) to the portfolio of
“tail groups” for CBP ligands (Scheme 1B,C).
Interestingly, ﬁve out of 10 molecules synthesized by Suzuki
cross-couplings are nanomolar binders with Kd values ranging
from 85 to 840 nM (Scheme 1C, compounds 11−15), thus
conﬁrming the ability of AutoCouple to identify good binders.
The comparison between the three series of compounds (A,
B, C) conﬁrms that the amide linker does not contribute
signiﬁcantly to binding aﬃnity, which is consistent with
previous molecular dynamics simulations that showed rotations
of the amide group on the 100 ns time scale.70,89 In addition,
the analysis of the growing vectors of the three coupling
strategies reveals interesting trends. As shown by the green
arrows (growing vectors) in Scheme 1, a geometric similarity
between the amide and the C−C coupled products (A, C) can
be found, in line with the consistently higher potency observed
for the compounds obtained via these two reactions compared
to those introducing the amine linker (B).
The preparation of an analogue of compound 1 bearing a
triazole as KAc mimic (Table S2) turned out to be more
selective for BRD4(1) over CBP, suggesting that the selectivity
Figure 3. (A) Structural alignment of the crystal structure of the CBP bromodomain (cyan) in complex with ligand 16 (green) (PDB code 5NLK)
and the pose of ligand 7 (yellow) as predicted by docking into the CBP structure 4NYX (Arg1173 side chain in yellow). (B) Overlay of the complex
of compound 16 (green) with the CBP bromodomain (cyan) and the structure of BRD4(1) (4PCI) shows that the selectivity is due to bumping of
the phenyl into the Trp81 side chain (red) of the so-called WPF triad of BRD4(1).
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can possibly arise from the KAc mimic moiety.90 AutoCouple
was therefore further validated through a virtual-coupling
campaign to design BRD4(1) inhibitors (detailed information
is available in section 3 in the Supporting Information).
Hybridization Strategies. Aiming to further improve the
aﬃnity of these compounds, we decided to combine the best
performing motifs in the amide-coupling campaign (acetamide
5, dimethoxybenzene 6, and furan 7) into compounds 16−18.
This hybridization approach resulted in additional low
nanomolar CBP ligands (Scheme 1D). Remarkably, compound
16 shows an aﬃnity for the CBP bromodomain higher by a
factor of more than 10,000 with respect to the aﬃnity for the
BRD4(1) bromodomain while still exhibiting an excellent
ligand eﬃciency for the target of 0.31 and 0.32 kcal mol−1 per
non-hydrogen atom (according to BROMOscan and Al-
phaScreen, respectively) in line with recommendations for
maintaining druglike properties throughout the optimization
process.91,92
The crystal structure of CBP in complex with ligand 16
(PDB code 5NLK) could be obtained, conﬁrming that the
binding mode predicted by AutoCouple is correct (Figure 3A):
the furan ring of compound 16 is at favorable van der Waals
distance to the Pro1106 side chain as predicted by the docked
pose of the parent compound 7. The overlap of the crystal
structure of the CBP/ligand 16 complex with the BRD4(1)
structure shows steric conﬂicts with the Trp81 side chain
(Figure 3B), which explains its high selectivity.59,60 Compound
16 was further proﬁled via a BROMOscan against a panel of
bromodomains covering all subfamilies (Figure 4E). While the
strong binding to CREBBP and EP300 could again be
conﬁrmed, only moderate aﬃnity for the bromodomains of
CECR2 (the bromodomain of the cat eye syndrome critical
region protein 2) and TAF1(2) (the second bromodomain of
human transcription initiation factor TFIID subunit 2) was
observed.93
Target Engagement in Cells and Preliminary Bio-
logical Evaluation. The target engagement of some of these
ligands and thus their cell permeability were evaluated by
means of a ﬂuorescence recovery after photobleaching (FRAP)
assay.94 In human osteosarcoma U2OS cells, compounds 6, 7,
13, 16, and 17 at a concentration of 1 μM showed signiﬁcant
displacement of the GFP-fused CBP bromodomain from
chromatin. In particular, compound 16, which displayed the
highest aﬃnity for the CBP bromodomain in the biochemical
assay (Kd = 35 nM), showed also the strongest eﬀect in the
FRAP assay (Figure 4A,B). The compounds’ purity was
evaluated by peak integration of the UV/visible HPLC
chromatograms for compounds 6 (99%), 7 (94%), 13 (99%),
16 (97%), and 17 (92%) (see section 11 in the SI).
Compound 16 was further tested in cellular proliferation
assays. Three cell lines known to be sensitive to CBP
bromodomain inhibition, i.e., LP1 (multiple myeloma),
Kasumi, and HL-60 (acute myeloblastic leukemia),59,95 were
selected as well as nontransformed primary ﬁbroblast MRC5.96
The MRC5 cells are used as control as they are noncancer cells
and with limited lifespan caused by replicative senescence.97
The resazurin assay was employed with compound incubation
for 72 h (LP1, Kasumi, and MRC5; Figure 4C) or 144 h (LP1,
Kasumi, and HL-60; Figure S9).98 Remarkably, compound 16
selectively inhibited the proliferation of the three cancer cell
lines, but was not toxic in MRC5 cells (GI50 > 20 μM) (Figure
4C, Figures S8 and S9). Since CBP and EP300 regulate the
transcription of the lymphocyte-speciﬁc transcription factor
IRF4 and the IRF4 target gene c-MYC in myeloma cells,59,60
we investigated the transcription of IRF4 and c-MYC in the
LP1 cell line using RT-qPCR (reverse transcription quantitative
Figure 4. (A,B) FRAP assay for compounds 6, 7, 13, 16, and 17; U2OS cells were transfected with plasmids encoding GFP-fused to wild-type (WT)
or mutant (N1168F) multimerized CBP bromodomain, with or without 2.5 μM suberoylanilide hydroxamic acid (SAHA, a deacetylase inhibitor)
and indicated compounds at a concentration of 1 μM. (A) Fluorescent recovery curves after photobleaching (normalized to the intensity before
bleaching). (B) Half-times of the ﬂuorescence recovery (t1/2) (n ≥ 7 cells per group, error bars: standard error of the mean). The recovery t1/2 of the
compound-treated cells was compared to that of DMSO-treated cells (bar on the left) within the same experiment setup using Mann−Whitney test.
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (C) Concentration of compound 16 that results in 50% growth inhibition (GI50). LP1 and Kasumi
are human tumor cell lines while the nontransformed ﬁbroblast MRC5 is a negative control. GI50 values were determined by a resazurin assay after
72 h compound incubation. (D) Dose-dependent inhibition of IRF4 and c-Myc mRNA transcription (RT-qPCR) by compound 16 in LP1 cells after
6 h of treatment. (C, D) Values represent the mean of at least three biological replicates ± SD. The curves are ﬁts by a four-parameter logistic
function. (E) Selectivity proﬁle of compound 16 in a panel of bromodomains representing all subfamilies of human bromodomains. The Kd values
were determined by a competition binding assay.88 (F, G) FRAP assay for compound 16 in U2OS cells transfected with a plasmid encoding GFP-
BRD4. Cells were treated with compound 16 (1 μM) or a BRD4 ligand JQ1 (0.1 μM). (F) Fluorescent recovery curves after photobleaching
(normalized to the intensity before bleaching). (G) t1/2 in the FRAP assay of F (n ≥ 7 cells per group, error bars: standard error of the mean, Mann−
Whitney test; ***, P < 0.001; n.s., not signiﬁcant).
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polymerase chain reaction). The dose−response curves showed
that the mRNA levels of IRF4 and c-MYC were reduced after
incubation for 6 h with compound 16 (Figure 4D). Since the
inhibition of BRD4 bromodomains also has a strong eﬀect on c-
MYC expression,99 one could argue that the c-MYC inhibition
by compound 16 arises from a weak binding to the BRD4
protein. To address this issue, we evaluated the BRD4
engagement in cells by FRAP. Compound 16 at 1 μM showed
no eﬀect on the ﬂuorescence recovery time (Figure 4F,G), thus
conﬁrming the potential of compound 16 as a useful tool to
unravel the speciﬁc role of CBP bromodomain in disease.
■ CONCLUSIONS
A de novo design approach based on virtual chemical reactions
starting from commercially available building blocks (Auto-
Couple) has been developed and successfully applied to the
identiﬁcation of potent and selective bromodomain ligands.
This novel approach makes full use of the three-dimensional
structure of the protein target and calculates the binding energy
by molecular mechanics (transferable force ﬁeld including
electrostatic solvation by the Poisson equation) without any
ﬁtting parameter. Thus, AutoCouple is a fragment-growing
program that generates synthetically accessible molecules with
an accurate and eﬃcient prediction of their binding energy. Our
in silico guided medicinal chemistry optimization represents a
very eﬃcient strategy to expand the chemical diversity while
swiftly acquiring knowledge on previously unexplored areas of
chemical space for the target of choice.
AutoCouple has been benchmarked on the CBP bromodo-
main taking an existing hit as starting point for a ligand
optimization campaign. While only potency and synthetic
accessibility were encoded in the design working principles of
AutoCouple, highly potent and selective ligands with improved
solubility and cell permeability have been identiﬁed, thus
underpinning the importance of chemical diversity in tackling
properties that are hard to predict with existing softwares. Hit
expansion by AutoCouple resulted in compound 16, a cell-
permeable ligand of the CBP bromodomain with low-
nanomolar potency and high selectivity against BRD4(1).
This probe represents a useful chemical tool to unravel the
individual role of CBP in several types of diseases including
cancer, inﬂammation, and hematological malignancies among
others. Further biological evaluation of these compounds and
application of AutoCouple to other protein targets are currently
ongoing in our laboratories.
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Gerhardt, S.; Schüle, R.; Jung, M.; Einsle, O.; Günther, S. 4-Acyl
Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading.
Angew. Chem., Int. Ed. 2013, 52, 14055−14059.
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1. Computational methods 
1.1 Python scripts for AutoCouple 
The scripts presented herein were written using the Python programming language1 calling the following 
Object Oriented Libraries: Numpy,2 RDkit.3  
All molecular files were stored under the structure data file (sdf) format.4 
Building-blocks library preparation 
Building-blocks' libraries from various chemical providers, namely Acros Organics, AK Scientific, Alfa 
Aesar, ApolloChem, FluoroChem, Sigma-Aldrich, SpiroChem were retrieved under the computer-
readable sdf-format with appended information about the molecule's Chemical Abstract Service (CAS) 
registration number (widely used by chemists), catalog number, prices and amounts.  
Script Procedure:  
To avoid redundancies, any building-block with the same CAS (hence same chemical formula) were 
merged. By mean of substructure-search, all the building-blocks containing the structures reported as 
toxic functional groups,5 and heavy-metal containing molecules were detected and filtered-out. 
Considering that chemical couplings imply an increase of the molecular complexity (exception taken 
for cleavage reactions), and that the coupling products should preferably satisfy the Lipinski rule of 5 
for druglikeliness,6 building-blocks meeting the following criteria were discarded: (a) number of 
rotatable bonds larger than 5, since most non-cyclisation reactions create one to two additional rotatable 
bonds;7 (b) number of heavy atoms (= non-hydrogen) smaller than 3 or larger than 35; (c) chiral centers 
larger than 2 (depending on the nature of the reagents and the reaction itself, additional chiral centers 
can be created upon coupling).  
In this way, a collection of building-blocks containing ~270’000 unique molecules stored under the sdf-
format was generated. 
Reactants filters  
Literature reviews estimated around ~20 reagent classes.7-8 Those classes were redefined and merged 
giving 12 categories of building-blocks : (a) alcohols; (b) I- and II-amines (including anilines); (c) alkyl 
halides; (d) aryl/vinyl halides; (e) boronic acids/esters; (f) carboxylic acids/esters, nitriles, acylchlorides; 
(g) epoxides; (h) isocyanates; (i) aldehydes, ketones; (j) phophorus ylids, (k) sulfonyl chlorides, (l) 
terminal alkenes.  
Script Procedure: 
An RDkit-based Python script using substructure search parsed the building-blocks library and sorted 
out the molecules onto separate reactant libraries. Molecules containing several functions of the same 
type were saved in a different library than for the mono-functionalized ones (to avoid 
protection/deprotection steps). Ultimately, the reactant libraries contained the following information 
about the compounds: (a) reactivity (amine, carboxylic acid, halide, etc.) (b) position of the reactive 
centers (c) functional groups inducing side-reactions (see Reactions Pool, such data helps to foresee the 
reagent's adequacy for a single-step synthesis) (d) CAS number. Once the library was established, it was 
used multiple times and enriched on demand. 
Reactions pool 
The present collection comprises three reactions:8-9 (a) Amide condensation : I- or II-amines/anilines 
addition onto carboxylic acids; (b) Suzuki coupling of boronic acids with aryl halides; (c) Buchwald-
Hartwig coupling of I- or II-amines/anilines with aryl halides. Libraries or software making use of 
similar reaction collections were recently developed for in-silico drug design.7-8,10 
Script Procedure: 
The python script for virtual coupling parsed the sdf files of the two reaction partners retrieving 
information on the possible presence of undesired functionalities (if a competing functional group was 
present, the script would discard the building block). Subsequently it generated a new sdf file of the 
coupling product. Relying on the robustness of the used reaction and on the fact that compounds were 
generated in one step from the building-blocks, no assessment of the synthetic accessibility score11-12 
was needed for the product.  
The python scripts used in AutoCouple were released on GitHub in the following repository: 
https://github.com/Caflisch-Group/AutoCouple_Python-based.  
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1.2 Conformers and protonation states  
The software suite ChemAxon (Marvins Beans)13 and the chemical toolbox OpenBabel14 were used for 
preparation of the ligand libraries before docking. The command line program cxcalc within Marvins 
Beans performed various calculations such as lowest conformer generation (leconformer), generation of 
multiple conformers (conformers), major microspecies at given pH (majormicrospecies), microspecies 
list with distributions at given pH (microspeciesdistribution). OpenBabel was used for conversion 
between different chemical data formats.  
1.3 Flexible ligand docking and binding energy evaluation 
Target Preparation 
The 3D coordinates of CBP, that were used for docking, originated from the crystallographic structures 
of the CBP bromodomain in complex with three different ligands, viz., 3P1C, CBP bromodomain in 
complex with the endogenous acetylated lysine ligand; 4TQN, CBP bromodomain in complex with our 
previously reported acetylbenzene ligand 1;15-16 4NYX, CBP bromodomain in complex with a 
dihydroquinoxalinone ligand.17 Only one structure of BRD4(1) was used for docking, from the complex 
with benzodiazepin-2-one (4PCI).18 To do so, the target coordinates were extracted from the crystal 
structure. Protons and missing side-chains were added to the coordinates using the module AutoPSF of 
VMD based on the topology from CHARMM param36 force field for protein. The hereby prepared 
crystal structure in complex with the ligand and either 5, 6 or 7 structural water molecules was used for 
optimization of the positions of the hydrogen atoms by steepest descent and conjugate gradient methods 
implemented in the CHARMM program (version 38b1).19  
Flexible ligand docking with tethered head group 
The subsequently extracted bromodomain's coordinates as well as the optimized structural water 
molecules were used for flexible docking with the open-source software rDock.20 During flexible ligand 
docking, the head groups were tethered in the binding site (command sdtether) to mimic the KAc 
residue. 
Pose minimization 
Atom typing, assignment of parameters and charges for the ligand were performed with the CHARMM 
General Force Field (CGenFF) program using the CHARMM param36 force field topology.21,22 The 
minimization of the ligand's poses within the binding site was performed successively by steepest 
descent and conjugate gradient methods implemented in the CHARMM program (version 38b1).19 All 
target's atoms were fixed during optimization.  
Binding energy evaluation 
The binding energy is the sum of protein/ligand van der Waals and electrostatic contribution. The 
electrostatic energy is the sum of bromodomain desolvation, ligand desolvation, and intermolecular 
interaction screened by the solvent which is treated implicitly by the finite-difference Poisson-
Boltzmann method using the PBEQ module in CHARMM.23 The dielectric constant of the solute was 
set to 4.0 and for the solvent to 78.5.   
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2. Molecules suggested by AutoCouple for CBP 
- Amide linker (Amide coupling): 
 
 
Figure S1. CBP inhibitors with an amide linker that originate from the virtual chemical reaction 
campaign by AutoCouple. The molecules are ordered from lowest to highest Kd for binding on 
CBP bromodomain. The Kd was determined in a competition binding assay (see section 6 for 
further details) onto CBP bromodomain (blue) or BRD4(1) bromodomain (red). Selectivity (S1) 
for CBP bromodomain over BRD4(1) bromodomain determined by the ratio of Kd values. 
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- Amine linker (Buchwald-Hartwig coupling) 
 
 
Figure S2. same as Figure S1 - synthesized CBP inhibitors containing an amine linker.  
 
- No linker (Suzuki cross-coupling) 
 
 
Figure S3. same as Figure S1 - synthesized CBP inhibitors without a linker (Suzuki coupling). 
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3. Molecules suggested by SEED and AutoCouple for BRD4(1) 
3.1 Selective ligands of BRD4(1) identified by SEED 
3.1.1 Fragment docking (SEED) 
To further validate AutoCouple, we decided to focus on alternative KAc mimic fragments that, in 
contrast with the acetyl benzene moiety 61, would exhibit higher affinity for BRD4(1) than for CBP. 
Preceding the present work, alternative “head-group” fragments (Table S1) had been identified by the 
fragment-docking program SEED (version 3.3.6):24-25  A library of 419 heteroaromatics22 was docked 
to the crystal structure of the CBP bromodomain (PDB code 3P1C) and the BRD4(1) bromodomain 
(PDB code 3MXF). The SEED docking of 419 fragments required about 15 minutes of a single core of 
a Xeon® Processor E3-1245 at 3.5 GHz. The CHARMM3621 and CGenFF force fields22 were used for 
the protein and fragments, respectively. The electrostatic energy is the sum of bromodomain desolvation, 
fragment desolvation, and intermolecular interaction screened by the solvent which is treated implicitly 
by the generalized Born approximation. 
 
Table S1. Fragments with favorable binding energy as predicted by SEED.  
Fragment 
CBP 
 
 BRD4(1)  
van der 
Waals 
electrostatic total 
 
van der Waals electrostatic total 
61 
 
-14.0 -2.3 -16.3 
 
-14.6 0.5 -14.0 
62 
 
-18.5 -1.4 -19.9 
 
-17.5 -0.8 -18.3 
63 
 
-17.5 -1.9 -19.4 
 
-16.6 2.1 -14.5 
64 
 
-15.3 -4.6 -19.9 
 
-17.7 1.1 -16.5 
  
3.1.2 Molecules suggested by SEED for BRD4(1) 
Compounds 65-67 (Table S2) are analogs of compound 1 bearing a benzoic acid moiety as tail group 
and are connected via an amide linker to those SEED-identified hit fragments as KAc mimic (head 
group, see Table S1). Although these three compounds had high affinity for CBP (blue column in Table 
S2), compound 65 turned out to be slightly more potent towards BRD4(1) (Kd of 6.9 µM) than CBP 
(Kd of 17 µM), suggesting that the selectivity can possibly arise from the KAc mimic moiety. The 
benzotriazole moiety of compound 65 thus appeared as an alternative KAc mimic head group for 
targeting preferentially BRD4(1). We therefore set out to generate novel ligands via AutoCouple that 
would bear the benzotriazole moiety 65 as a KAc mimic. 
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Table S2. Affinity of compounds 1, 65-67 for the CBP and BRD4(1) bromodomains.  
 
Cmpd R1 R2 
LE 
CBP 
Kd (μM)
[a] 
S1
[b] S2
[b] 
ΔTm(°C)
[c] 
CBP BRD4(1) CBP BRD4(1) 
1 
  
CO2H 0.35 0.77 > 50 > 65 < 0.02 3.8 0.4 
65 
 
CO2H 0.30 17 6.9 0.4 2.5 2.0 2.8 
66 
  
CO2H 0.37 4.1 33 8.0 0.1 1.9 0.9 
67 
  
CO2H 0.35 1.1 41 37 0.03 4.0 1.4 
[a] Kd values were determined by a competition binding assay26 in duplicates for CBP (blue) and 
BRD4(1) (red). [b] Selectivity (S1) for CBP bromodomain over BRD4(1) bromodomain and selectivity 
(S2) for BRD4(1) bromodomain over CBP bromodomain as determined by the ratio of Kd values 
obtained via the competition binding assay.26 [c] Median value of the shift in the melting temperature 
(number of measurements > 12). The thermal shift assay was carried out with a 2 µM concentration of 
the bromodomain and 100 µM compound concentration (see section 5: Thermal shift measurements). 
  
3.2 Molecules suggested by AutoCouple for BRD4(1) 
Following the same strategy as described for CBP in the main text, virtual libraries were generated in 
silico by coupling of the benzotriazole moiety with commercially-available reactants. Two campaigns 
involving amide condensation and Suzuki cross-coupling reactions on the benzotriazole head groups 68 
(see Figure S5) and 69 (see Figure S6) provided 32’000 amides and 19’000 C−C coupled compounds, 
respectively. A crystal structure of BRD4(1) in complex with a low micromolar benzodiazepine-2-one 
ligand previously resolved in our groups was used as the target18 for flexible ligand docking. During the 
latter, the benzotriazole was tethered in the binding site (command sdtether) to mimic the KAc residue 
as observed in SEED pose (for BRD4(1), see Figure S4).  
A total of 20 compounds were prioritized and synthesized (10 for the amide condensation and 10 for the 
Suzuki coupling). Nine of these compounds (70-74 with amide linkers and 80-83 via direct C-C 
coupling) presented a Kd lower than 10 µM with promising LE values (up to 0.37 kcal mol-1 per non-
hydrogen atom for compound 81; see Figure S6). Furthermore, the selectivity towards BRD4(1) was 
improved from 2.5 fold for compound 65 up to 11 and 12 fold for pyridine 71 and sulfonamide 70, 
respectively. Interestingly, compound 70 is 26 times more potent than the original fragment 68. As in 
the previous campaign, AutoCouple offered significant structural diversity with a broad range of 
functional groups, including sulfonamides (70, 74, 83), pyridines (71, 80), and diverse five membered 
ring heterocycles (72, 73, 82) among others, thus demonstrating the ability of this in silico tool to identify 
alternative motifs streamlining hit-optimization efforts. 
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Figure S4: SEED pose of the Benzotriazole fragment (green) in BRD4(1) – During the docking of 
ligands generated by virtual couplings, the benzotriazole head groups were tethered to reproduce the 
pose within the binding site (sdtether command). 
- Amide linker (Amide coupling) 
 
 
Figure S5. BRD4(1) inhibitors with an amide linker that originate from the virtual chemical 
reaction campaign by AutoCouple. The molecules are ordered from lowest to highest Kd for 
binding on BRD4(1) bromodomain. The Kd was determined in a competition binding assay (see 
section 6 for further details) onto CBP bromodomain (blue) or BRD4(1) bromodomain (red). 
Selectivity (S2) for BRD4(1) bromodomain over CBP bromodomain determined by the ratio of 
Kd values. 
 
  
Asn140 
Tyr97 
Benzotriazole 
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- No linker (Suzuki cross-coupling) 
 
 
Figure S6. same as Figure S5 - synthesized BRD4(1) inhibitors without a linker (Suzuki cross-
couplings). 
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4. Bromodomain expression and purification  
Proteins were purified as described previously.27 Briefly, Poly-Histidine-tagged (His-tag) 
bromodomains were expressed in Escherichia coli BL21(DE3) cells upon induction with isopropyl thio-
beta-D-galactoside (IPTG, final concentration 0.1 mM) for 16 h at 18 °C.  Bacteria were lysed and (when 
required) the resulting extract was treated to remove DNA, and 0.15% polyethylenimine (PEI) was 
added. The His-tagged proteins were purified on HisTrap columns (GE Healthcare) and eluted using a 
step gradient of imidazole. The His-tags were removed by overnight incubation with His-tagged tobacco 
etch virus (TEV) protease purified in-house (if required by the purification protocol, in the meantime 
the sample was exchanged via dialysis). A size-exclusion chromatography step (HiLoad 16/600 
Superdex75 column) and a Ni-affinity chromatography step were subsequently performed to finally 
purify the cleaved bromodomains.  Samples were then concentrated, flash frozen and stored at –80 °C.  
5. Thermal shift measurements   
Thermal shift measurements were performed using a 2 µM and 100 µM concentration for the 
bromodomains and ligands, respectively, as precedently described.28 The reported values (ΔTm) were 
calculated as the difference between the transition midpoints of an individual sample and the average of 
the reference wells (containing the protein and the DMSO only) in the same plate. DMSO concentration 
was kept at 0.2% (v/v). 
6. BROMOscan assays26 
The binding constant (Kd) determinations by means of BROMOscan technology were carried out at 
DiscoverX. An E. coli strain derived from BL21 was used as the host to grow T7 phage strains displaying 
the bromodomains. E. coli, grown to log-phase, were infected with T7 phage (from a frozen stock, being 
the multiplicity of infection 0.4) and incubated while shaking at 32 °C for 90-150 minutes until lysis. In 
order to remove cell debris, lysates were centrifuged at 5,000 x g and filtered (0.2 μm). Affinity resins 
were obtained by treating streptavidin-coated magnetic beads with biotinylated acetylated peptide 
ligands for 30 minutes at 25°C. Those beads were then blocked with excess of biotin and washed with 
blocking buffer (SeaBlock (Pierce), 1 % bovine serum albumin (BSA), 0.05 % Tween 20, 1 mM 
dithiothreitol (DTT)) to remove the unbound ligand and reduce non-specific phage binding.  
During the experiment, the bromodomain, ligand-bound affinity beads and test compounds were 
combined in a buffer composed of 17% SeaBlock, 33% phosphate-buffered solution (PBS), 0.04% 
Tween 20, 0.02% BSA, 0.004% sodium azide and 7.4 mM DTT. Test compounds were prepared as 50 
mM in pure DMSO and diluted to 5 mM with monoethylene gycol, MEG (100× concentrated in respect 
to the top screening concentration 50 µM). During the assay the DMSO and MEG final concentrations 
were 0.1% and 0.9%, respectively. The assays were carried out in polystyrene 96-well plates in a final 
volume of 0.135 mL.  The assay plates were incubated at 25 °C with shaking for 1 hour and the affinity 
beads were washed with a buffer composed of 0.05% Tween 20 in PBS. The beads were then re-
suspended in the elution buffer (1x PBS, 0.05% Tween 20, 2 μM non-biotinylated affinity ligand) and 
incubated at 25°C with shaking for 30 minutes. The bromodomain concentration in the elutes was 
measured by qPCR.  Kd values were calculated with a standard dose-response curve using the Hill 
equation and curves were fitted using a non-linear least square fit with the Levenberg-Marquardt 
algorithm. 
 
7. Alpha Screen assays29 
IC50 determinations by means of Amplified Luminescent Proximity Homogeneous Assay (Alpha) 
Screen technology were carried out at Reaction Biology. Compounds were tested in 10-dose IC50 mode 
with 2 or 3-fold serial dilution starting at varying concentrations. The competitive ligand was H4/4Ac: 
Histone H4 peptide (1-21) K5/8/12/16Ac-Biotin. The detection was performed by the AlphaScreen 
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Binding assay in Envision (Ex/Em=680/520-620 nm). Data include raw data (signal-Background, 
Background was measured without BRD but all other components.), % binding (relative to DMSO 
controls), and curve fits. An IC50 value higher than the starting compound concentration was estimated 
based on the best curve fitting available.   
Compound 16 
Bromodomain IC50 (µM) 
CBP 0.019 
BRD4(1) >200 
Selectivity >10526 
Table S3. Half maximal inhibitory concentration (IC50) as determined by Alpha Screen assays for 
compound 16 with BRD4(1) and the bromodomain of CBP. The selectivity is calculated as the ratio of 
the IC50 values. 
 
8. Target engagement in cells and preliminary biological evaluation 
 
8.1 FRAP assays30 
In order to determine if our inhibitors engage CBP bromodomain within a cellular setting, we conducted 
a fluorescence recovery after photo-bleaching (FRAP) assay for the most potent and chemically diverse 
inhibitors. Compounds 6, 7, 13, 16 and 17 were able to displace the CBP bromodomain from chromatin 
at concentration of 1 µM (Figure S8 and Scheme 1D in the main text). The half times (t1/2) required to 
recover the fluorescence in a photobleach area of U2OS cells expressing GFP-tagged multimerized (3X) 
CBP bromodomains were measured (Figure 4A, 4B in the main text and Figure S7). The presence of 
our inhibitors reduced the recovery t1/2 compared to cells without compound treatment, in the presence 
of 2.5 µM of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Moreover, in 
the case of compound 16, the t1/2 value resembles that of the N1168F mutant, indicating that our 
compound interacts with the KAc binding site of the CBP bromdomain efficiently, displacing it from 
chromatin (Figure 4A, 4B in the main text and Figure S7). 
Plasmids: 
The GFP-BRD4 plasmid was a gift from Kyle Miller (Addgene plasmid # 65378).55  
CBP Plasmid cloning 
The CBP multimerised bromodomain construct was made as previously reported.30 Plasmids containing 
the fragments shown below were purchased from GenScript and their PCR products were cloned with 
Gateway BP Clonase II enzyme mix (MultiSite Gateway System, ThermoFisher) into either pDONR221 
P4r-P3r, pDONR221 P3-P2 or pDONR221 P1-P4 to create entry clones. 
 
pENTR221 P4r-P3r 
CBP aa868-1341 
 
GGGGACAACTTTTCTATACAAAGTTGCTCTCCAGCACACGACACCACCTGGGATGACTCCTCCC
CAGCCAGCAGCTCCCACTCAGCCATCAACTCCTGTGTCGTCTTCCGGGCAGACTCCCACCCCGA
CTCCTGGCTCAGTGCCCAGTGCTACCCAAACCCAGAGCACCCCTACAGTCCAGGCAGCAGCCC
AGGCCCAGGTGACCCCGCAGCCTCAAACCCCAGTTCAGCCCCCGTCTGTGGCTACCCCTCAGTC
ATCGCAGCAACAGCCGACGCCTGTGCACGCCCAGCCTCCTGGCACACCGCTTTCCCAGGCAGC
AGCCAGCATTGATAACAGAGTCCCTACCCCCTCCTCGGTGGCCAGCGCAGAAACCAATTCCCA
GCAGCCAGGACCTGACGTACCTGTGCTGGAAATGAAGACGGAGACCCAAGCAGAGGACACTG
AGCCCGATCCTGGTGAATCCAAAGGGGAGCCCAGGTCTGAGATGATGGAGGAGGATTTGCAAG
GAGCTTCCCAAGTTAAAGAAGAAACAGACATAGCAGAGCAGAAATCAGAACCAATGGAAGTG
GATGAAAAGAAACCTGAAGTGAAAGTAGAAGTTAAAGAGGAAGAAGAGAGTAGCAGTAACG
GCACAGCCTCTCAGTCAACATCTCCTTCGCAGCCGCGCAAAAAAATCTTTAAACCAGAGGAGT
TACGCCAGGCCCTCATGCCAACCCTAGAAGCACTGTATCGACAGGACCCAGAGTCATTACCTTT
CCGGCAGCCTGTAGATCCCCAGCTCCTCGGAATTCCAGACTATTTTGACATCGTAAAGAATCCC
ATGGACCTCTCCACCATCAAGCGGAAGCTGGACACAGGGCAATACCAAGAGCCCTGGCAGTAC
GTGGACGACGTCTGGCTCATGTTCAACAATGCCTGGCTCTATAATCGCAAGACATCCCGAGTCT
ATAAGTTTTGCAGTAAGCTTGCAGAGGTCTTTGAGCAGGAAATTGACCCTGTCATGCAGTCCCT
TGGATATTGCTGTGGACGCAAGTATGAGTTTTCCCCACAGACTTTGTGCTGCTATGGGAAGCAG
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CTGTGTACCATTCCTCGCGATGCTGCCTACTACAGCTATCAGAATAGGTATCATTTCTGTGAGA
AGTGTTTCACAGAGATCCAGGGCGAGAATGTGACCCTGGGTGACGACCCTTCACAGCCCCAGA
CGACAATTTCAAAGGATCAGTTTGAAAAGAAGAAAAATGATACCTTAGACCCCGAACCTTTCG
TTGATTGCAAGGAGTGTGGCCGGAAGATGCATCAGATTTGCGTTCTGCACTATGACATCATTTG
GCCTTCAGGTTTTGTGTGCGACAACTGCTTGAAGAAAACTGGCAGACCTCGAAAAGAAAACAA
ATTCAGTGCTAAGAGGCTGCAGACCACAAGACTGGGAAACCACTTGGAAGACCGAACAACTTT
GTATAATAAAGTTGTCCCC 
pENTR221 P3-P2 
CBP aa868-1341 
GGGGACAACTTTGTATAATAAAGTTGCTCTCCAGCACACGACACCACCTGGGATGACTCCTCCC
CAGCCAGCAGCTCCCACTCAGCCATCAACTCCTGTGTCGTCTTCCGGGCAGACTCCCACCCCGA
CTCCTGGCTCAGTGCCCAGTGCTACCCAAACCCAGAGCACCCCTACAGTCCAGGCAGCAGCCC
AGGCCCAGGTGACCCCGCAGCCTCAAACCCCAGTTCAGCCCCCGTCTGTGGCTACCCCTCAGTC
ATCGCAGCAACAGCCGACGCCTGTGCACGCCCAGCCTCCTGGCACACCGCTTTCCCAGGCAGC
AGCCAGCATTGATAACAGAGTCCCTACCCCCTCCTCGGTGGCCAGCGCAGAAACCAATTCCCA
GCAGCCAGGACCTGACGTACCTGTGCTGGAAATGAAGACGGAGACCCAAGCAGAGGACACTG
AGCCCGATCCTGGTGAATCCAAAGGGGAGCCCAGGTCTGAGATGATGGAGGAGGATTTGCAAG
GAGCTTCCCAAGTTAAAGAAGAAACAGACATAGCAGAGCAGAAATCAGAACCAATGGAAGTG
GATGAAAAGAAACCTGAAGTGAAAGTAGAAGTTAAAGAGGAAGAAGAGAGTAGCAGTAACG
GCACAGCCTCTCAGTCAACATCTCCTTCGCAGCCGCGCAAAAAAATCTTTAAACCAGAGGAGT
TACGCCAGGCCCTCATGCCAACCCTAGAAGCACTGTATCGACAGGACCCAGAGTCATTACCTTT
CCGGCAGCCTGTAGATCCCCAGCTCCTCGGAATTCCAGACTATTTTGACATCGTAAAGAATCCC
ATGGACCTCTCCACCATCAAGCGGAAGCTGGACACAGGGCAATACCAAGAGCCCTGGCAGTAC
GTGGACGACGTCTGGCTCATGTTCAACAATGCCTGGCTCTATAATCGCAAGACATCCCGAGTCT
ATAAGTTTTGCAGTAAGCTTGCAGAGGTCTTTGAGCAGGAAATTGACCCTGTCATGCAGTCCCT
TGGATATTGCTGTGGACGCAAGTATGAGTTTTCCCCACAGACTTTGTGCTGCTATGGGAAGCAG
CTGTGTACCATTCCTCGCGATGCTGCCTACTACAGCTATCAGAATAGGTATCATTTCTGTGAGA
AGTGTTTCACAGAGATCCAGGGCGAGAATGTGACCCTGGGTGACGACCCTTCACAGCCCCAGA
CGACAATTTCAAAGGATCAGTTTGAAAAGAAGAAAAATGATACCTTAGACCCCGAACCTTTCG
TTGATTGCAAGGAGTGTGGCCGGAAGATGCATCAGATTTGCGTTCTGCACTATGACATCATTTG
GCCTTCAGGTTTTGTGTGCGACAACTGCTTGAAGAAAACTGGCAGACCTCGAAAAGAAAACAA
ATTCAGTGCTAAGAGGCTGCAGACCACAAGACTGGGAAACCACTTGGAAGACCGATAGTACCC
AGCTTTCTTGTACAAAGTGGTCCCC 
pENTR221 P1-P4 
NLS/CBP aa868-1341 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGCCCAAGAAGAAGAGGAAAGTCTCTCTCCA
GCACACGACACCACCTGGGATGACTCCTCCCCAGCCAGCAGCTCCCACTCAGCCATCAACTCCT
GTGTCGTCTTCCGGGCAGACTCCCACCCCGACTCCTGGCTCAGTGCCCAGTGCTACCCAAACCC
AGAGCACCCCTACAGTCCAGGCAGCAGCCCAGGCCCAGGTGACCCCGCAGCCTCAAACCCCAG
TTCAGCCCCCGTCTGTGGCTACCCCTCAGTCATCGCAGCAACAGCCGACGCCTGTGCACGCCCA
GCCTCCTGGCACACCGCTTTCCCAGGCAGCAGCCAGCATTGATAACAGAGTCCCTACCCCCTCC
TCGGTGGCCAGCGCAGAAACCAATTCCCAGCAGCCAGGACCTGACGTACCTGTGCTGGAAATG
AAGACGGAGACCCAAGCAGAGGACACTGAGCCCGATCCTGGTGAATCCAAAGGGGAGCCCAG
GTCTGAGATGATGGAGGAGGATTTGCAAGGAGCTTCCCAAGTTAAAGAAGAAACAGACATAG
CAGAGCAGAAATCAGAACCAATGGAAGTGGATGAAAAGAAACCTGAAGTGAAAGTAGAAGTT
AAAGAGGAAGAAGAGAGTAGCAGTAACGGCACAGCCTCTCAGTCAACATCTCCTTCGCAGCCG
CGCAAAAAAATCTTTAAACCAGAGGAGTTACGCCAGGCCCTCATGCCAACCCTAGAAGCACTG
TATCGACAGGACCCAGAGTCATTACCTTTCCGGCAGCCTGTAGATCCCCAGCTCCTCGGAATTC
CAGACTATTTTGACATCGTAAAGAATCCCATGGACCTCTCCACCATCAAGCGGAAGCTGGACA
CAGGGCAATACCAAGAGCCCTGGCAGTACGTGGACGACGTCTGGCTCATGTTCAACAATGCCT
GGCTCTATAATCGCAAGACATCCCGAGTCTATAAGTTTTGCAGTAAGCTTGCAGAGGTCTTTGA
GCAGGAAATTGACCCTGTCATGCAGTCCCTTGGATATTGCTGTGGACGCAAGTATGAGTTTTCC
CCACAGACTTTGTGCTGCTATGGGAAGCAGCTGTGTACCATTCCTCGCGATGCTGCCTACTACA
GCTATCAGAATAGGTATCATTTCTGTGAGAAGTGTTTCACAGAGATCCAGGGCGAGAATGTGA
CCCTGGGTGACGACCCTTCACAGCCCCAGACGACAATTTCAAAGGATCAGTTTGAAAAGAAGA
AAAATGATACCTTAGACCCCGAACCTTTCGTTGATTGCAAGGAGTGTGGCCGGAAGATGCATC
AGATTTGCGTTCTGCACTATGACATCATTTGGCCTTCAGGTTTTGTGTGCGACAACTGCTTGAA
GAAAACTGGCAGACCTCGAAAAGAAAACAAATTCAGTGCTAAGAGGCTGCAGACCACAAGAC
TGGGAAACCACTTGGAAGACCGACACCCAACTTTTCTATACAAAGTTGTCCCC 
 
The three entry clones were then combined by LR cloning (MultiSite Gateway System, ThermoFisher)  
into the pcDNA6.2/N-EmGFP-DEST vector creating an expression clone for three tandem repeats of 
the CBP bromodomain fused to an N-terminal GFP.  
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The N1168F CBP bromodomain mutant plasmid was generated using the QuikChange Lightning Multi 
Site-Directed Mutagenesis Kit (Agilent Technologies) starting from the non-mutagenic plasmid.  The 
mutagenic primer was designed in the Agilent Technologies’ website:  
5’- GGATGTCTTGCGAAAATAGAGCCAGGCATTGTTGAACATG-3’ 
 
Cell culture 
U2OS cells are kind gift from Dr. Sander Botter (Balgrist University Hospital, Zurich, Switzerland). 
Cells were grown at 37°C with 5% CO2 in a humidified incubator in Dulbecco’s modified medium 
(DMEM) (GibcoTM, ThermoFischer Scientific). The medium contained 10% FCS, 100U/ml penicillin 
and 100mg/ml streptomycin. 
 
FRAP assay 
FRAP studies were performed according to a published protocol,30 with slight modifications.  In brief, 
U2OS cells in a 8-well chamber (ibidi) were transfected (Lipofectamine 2000, ThermoFisher) with the 
GFP-CBP-bromodomain plasmid (WT), GFP-CBP mutant plasmid (N1168F) or GFP-BRD4 plasmid. 
Six hours after transfection, culture medium was replaced with or without 2.5 μM SAHA (only for CBP 
plasmids), and the inhibitors (1 μM for CBP compounds and 0.1 μM for JQ1) were added 23 hours after 
transfection. Cells were then imaged 24 hours after transfection.   
 
The FRAP experiments were conducted with a Leica SP5 confocal microscope (Leica microsystems 
GmbH, Wetzla, Germany) equipped with a HCX PL APO 40× Objective (NA 1.25) (Leica) and a 
controlled chamber set at 37°C and 5% CO2. Bleaching and GFP fluorescence imaging were carried out 
with an argon laser (488 nm) and a detector set to detect fluorescence between 500 and 550 nm. Cells 
with nuclei just below saturation within the gain range of 650 to 850 were bleached.  A square region 
(16 µm2) of a GFP-positive nucleus was selected, and, after five prescans, the region was bleached. A 
time-lapse series was then taken to record GFP recovery. During the time-lapse series, images were 
acquired with a frame size of 256 pixels × 256 pixels with line-stepping of 2, bidirectional scanning and 
a zoom factor of 6, which allowed for a time interval time of 0.1-0.2 seconds. The laser power was set 
to 100% for photobleaching and attenuated to 2% for acquisition. 
 
Data analysis 
The fluorescence signal was measured with FIJI and normalized according to a published method.30 All 
experiments were transferred to Prism (GraphPad) and fit on an exponential FRAP curve (one-way 
association). Different groups were compared by determining the half time (t½) of the fluorescence 
recovery to reach a plateau level. 
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Figure S7. Fluorescence recovery after photo-bleaching (FRAP) demonstrating the displacement of 
CBP bromodomain from chromatin. U2OS cells were transfected with plasmids encoding GFP fused to 
wild-type (WT) or mutant (N1168F) multimerised CBP bromodomain, with or without 2.5 μM 
suberoylanilide hydroxamic acid (SAHA) and indicated compounds (1 μM).  A) Representative images 
of the nuclei of cells treated with DMSO or compound 16, with the presence of SAHA. The bleached 
area (16 μm2) is indicated by a square. B) Half-times of fluorescence recovery (t½) in the FRAP assays. 
Bars represent the mean t½ calculated from individual recovery curves of at least 7 cells per group, and 
error bars represent the standard error of the mean. (statistics: Man-Whitney, always compared to 
SAHA-treated cells within the same experiment setup (significance: **P< 0.01, ***P<0.001 and ****P 
< 0.0001.) 
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8.2 Proliferation assays and Reverse Transcription Quantitative Polymerase Chain 
Reaction (RT-qPCR) 
Cell proliferation assays 
Cellular proliferation was assessed by Resazurin assay. Cells were plated at 104 cells/well of a 96-well 
plate for 24 h prior to incubation for three or six days with two-fold compound dilutions from 50µM or 
DMSO 1% control. Resazurin at 86µM (#R12204, ThermoFisher) was added and the metabolic activity 
was measured after six hours incubation at excitation of 560nM and detecting emission at 590nM. 
Procedures referred to Conery et al.31 
 
Figure S8. Proliferation assay of compound 16 in cells: LP1, Kasumi and non-transformed fibroblast 
MRC5, resazurin assay, 72 h incubation. Curves represent non-linear fit by a four-parameter logistic 
function; data points are mean values of at least three independent experiments; error bars: S.D. Hill 
coefficients for LP1 = -1.2, Kasumi = -2.5, MRC5 = -3.0. 
 
 
Figure S9. Same as Figure S8 with 144 h incubation and an additional cell line, the leukemia cell line 
HL-60. Hill coefficients for LP1 = -2.7, Kasumi = -4.1, HL-60 = -6.2. 
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Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) 
LP1 cells were incubated with compounds or DMSO control at 0.1% for six hours. RNA was isolated 
with an RNeasy kit (#74104, Qiagen) or by consistent quality with TRIzol reagent (#15596026, 
ThermoFisher) following manufacturer’s instructions. RNA was converted to cDNA by Applied 
Biosystems’ reverse transcriptase (#4368814, ThermoFisher). qPCR was operated in a Roche 
LightCycler®480 and performed by fluorescence detection of SYBRgreen® (#4368577, ThermoFisher) 
cycled from 1µg converted cDNA. Transcript specific primers are: IRF4: 5’-
GCCAAGATTCCAGGTGACTC 3’-CTGGCTAGCAGAGGTTCTACG; cMYC: 5’-
TACAACACCCGAGCAAGGAC 3’-GAGGCTGCTGGTTTTCCACT; and control transcript 
GAPDH: 5’-AGCCACATCGCTCAGACAC 3’-GCCCAATACGACCAAATCC. 
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12. Protein purification, crystallization and structural determination  
CBP bromodomain was expressed and purified by following the protocol described previously.27  
Protein was concentrated to 20 mg/ml in the buffer of 20 mM HEPES, pH 7.4, 500 mM NaCl, 5% 
glycerol and 0.5 mM TCEP for crystallization. The co-crystal of 16 bound to CBP bromodomain was 
grown by sitting-drop vapor diffusion at 277 K in 0.1 M Morpheus® Buffer System 3, pH 8.5, 37.50% 
v/v MPD_P1K_P3350 and 0.09 M NPS at a1:1 (v/v) ratio of protein/ligand to reservoir buffer. Crystals 
were cryoprotected by crystallization buffer supplemented with 20% ethylene glycol prior to freezing 
in liquid nitrogen. Diffraction data were collected at the X06SA beamline at the Swiss Light Source, 
Paul Scherrer Institut, Villigen, Switzerland. Data was integrated with XDS49 and scaled with 
AIMLESS.50 Structure was solved by molecular replacement with Phaser51 using PDB 3DWY as a 
search model. Model building and refinement was performed with Coot52 and Phenix,53 respectively. 
Programs used for crystallographic data processing and analysis were supported by the SBGrid 
Consortium54. The statistics of data process and refinement are summarized in Table S3.  
Table S4. X-ray data collection and refinement statistics for co-crystal structure of the CBP 
bromodomain with compound 16. 
Data Collection 
PDB ID 5NLK 
Space group P212121 
Cell dimensions  
  a, b, c (Å) 37.38, 40.81, 87.38 
  α, β, γ (°) 90.00, 90.00, 90.00 
Resolution (Å) 40.81 - 1.80 
Unique observationsa 12880(745) 
Completenessa  99.3(99.8) 
Redundancya  12.6(13.5) 
Rmergea  0.164(0.689) 
I/σIa  9.9(2.6) 
CC 1/2a 0.99(0.94) 
Refinement 
Rwork/Rfreea  
0.176(0.227) 
/0.216(0.333) 
R.m.s. deviations of 
bond lengths (Å) 
0.005 
R.m.s. deviations of 
bond angles (°) 
0.989 
Average B-factor (Å2)  
  Protein 35.23 
  Ligand 32.10 
  Wwater 42.50 
Ramachandran  
  Favored (%) 99.12 
  Allowed (%) 0.88 
  Disallowed (%) 0 
a Highest resolution shell is shown in parentheses.  
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Figure S10. 2mFo – DFc electron density maps of ligand 16, structural water molecules and key 
residues of the CBP bromodomain;  PDB code : 5NLK 
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ABSTRACT: Small-molecule hits for the bromodomains of CREBBP and BAZ2B
have been identiﬁed by scaﬀold hopping followed by docking of a set of ∼200
compounds containing the acetyl indole scaﬀold. Chemical synthesis of nearly 30
derivatives has resulted in ligands of representatives of three subfamilies of human
bromodomains with favorable ligand eﬃciency. The X-ray crystal structures of three
diﬀerent bromodomains (CREBBP, BAZ2B, and BRPF1b) in complex with acetyl
indole derivatives reveal the inﬂuence of the gatekeeper residue on the orientation of
small-molecule ligands in the acetyl lysine binding site.
■ INTRODUCTION
Acetylation of lysine residues is an important post-translational
modiﬁcation of histone proteins that contributes to the
regulation of chromatin structure and transcription.1,2 Bromo-
domains are protein modules with four-helix bundle topology
that speciﬁcally recognize (“read”) acetylated lysine residues, as
well as butyryllysine and crotonyllysine,3 and are considered
protein targets of interest for the development of chemical
probes and clinical tools for the treatment of cancer,
inﬂammation, and other diseases.4−8
The BET (bromodomain and extra terminal) subfamily
(BRD2/3/4/T) has been widely addressed, and as a
consequence, several potent and selective inhibitors have
been developed, some of which are currently undergoing
clinical trials for the treatment of NUT midline carcinoma
(NMC), solid tumors, leukemia, lymphoma, hematological
malignancies, atherosclerosis, and type II diabetes.7,9,10 In
contrast, the speciﬁc function and potential pharmacological
relevance of other bromodomains, including CREB binding
protein (CREBBP), E1A binding protein p300 (EP300),
BRD7/9, and bromodomain adjacent to zinc ﬁnger domain
(BAZ2B), are much less understood, and thus, small-molecule
inhibitors will be valuable tools for unraveling their biological
roles.
The bromodomains of EP300 and CREBBP, which belong to
the same subfamily and share 96% sequence identity,11 play
important roles in DNA replication and repair, cell growth and
cell cycle regulation, and genomic stability.12,13 As an example,
EP300 and CREBBP are able to acetylate p53 on its K382
residue through the histone acetyl transferase (HAT) domain
upon extracellular stress or DNA damage, and they are also
known to speciﬁcally bind to acetylated p53 via their
bromodomain module.14 As a consequence, changes in the
p53-dependent activation of target genes result in cell cycle
arrest, senescence, or apoptosis.15−17 On one hand, chromo-
some translocations resulting in gene fusions containing
CREBBP or EP300 have been linked to leukemias and
lymphomas.18,19 On the other hand, CREBBP and EP300 are
mutated in solid tumors and B-cell lymphoma, suggesting they
possess a tumor-suppressing role.13,20 Thus, because both
oncogene or tumor suppressor roles have been reported for
CREBBP and EP300,18,21 the development of chemical probes
will be instrumental for the analysis of their biological
function(s).
The bromodomains of BRD7 and BRD9 belong to the same
subfamily and share 72% sequence identity.22 Both BRD7 and
BRD9 are part of the SWI/SNF (SWItch/Sucrose Non-
Fermentable) chromatin remodelling complex, which plays a
key role in the regulation of gene expression.23−25 Recent
reports have linked BRD9 to oncology, including non-small cell
lung26 and cervical cancer.27 Its paralogue, BRD7, is frequently
downregulated in cancer28−30 and is able to regulate the tumor
suppressor protein p53.31−33 The bromodomain of BRPF1b
(bromodomain-PHD ﬁnger protein 1b) belongs to the same
subfamily as BRD7 and BRD9. Despite the function of the
BRPF1b bromodomain not being yet fully understood, the
availability of BRPF1b ligands might help in the elucidation of
its role.34−36
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BAZ2B is another bromodomain-containing protein whose
role in physiology and disease is not clear. Biophysical
screening of a library of 1300 fragments resulted in the
identiﬁcation of 10 small molecules that bind in the micromolar
range to BAZ2B.37 Recently, the ﬁrst submicromolar selective
CREBBP,11,38,39 BAZ2B,40,41 and BRD7/922,42,43 inhibitors
have been reported.
Here we present the result of a combined scaﬀold hopping
and docking approach that has permitted the discovery of acetyl
indoles as ligands of the bromodomains of CREBBP, BAZ2B,
BRPF1b, and/or BRD9, which belong to three diﬀerent
subfamilies that lie outside of the BET bromodomain subfamily.
A comparative analysis of four crystal structures of
bromodomain/acetyl indole complexes shows the importance
of the so-called gatekeeper residue with respect to the binding
mode of the ligand.
■ RESULTS AND DISCUSSION
In Silico Screening by Scaﬀold Hopping and Docking.
In the past few years, our groups have successfully identiﬁed
several low micromolar to nanomolar kinase44−47 and
bromodomain39,48,49 inhibitors by high-throughput virtual
screening campaigns. In this work, we decided to dock a
small subset of compounds containing a moiety identiﬁed by
scaﬀold hopping (see Experimental Section). First, the ZINC
all-now library was decomposed into approximately 600000
fragments retaining key functional groups. These fragments
were queried by the indolizine fragment A, which is present in
the potent BAZ2B ligand GSK2801 (1a)41 and more recently
has been identiﬁed in BRD7 and BRD9 ligands.22 (Capital
letters are used to label generic chemical blueprints. 1a−i
correspond to commercially available compounds. 1−50
represent the synthetic intermediates and self-made products.)
The acetyl indole B was identiﬁed as the top-ranking fragment
with an activity-oriented ﬁngerprint similarity of 0.975 with
respect to A. The high degree of similarity is due to almost
identical geometry and connecting vectors in fragments A and
B (Figure 1).
In a second step, we retrieved ∼200 commercially available
compounds containing fragment B. As in our previous
fragment-based virtual screening approach,46,48,49 the retrieved
compounds were docked into crystal structures of the targets,
namely, the bromodomains of CREBBP [Protein Data Bank
(PDB) entry 4A9K] and BAZ2B (PDB entry 3Q2F). An in-
house-developed program for automatic docking was
used.48,50−52 The docking poses were subsequently rescored
by a transferable scoring function (see Experimental
Section).45,50−54 Finally, 14 molecules were selected for
experimental validation by means of a competition binding
assay.55,56 At a concentration of 50 μM, seven compounds
showed signiﬁcant competition [i.e., a percentage of residual
binding of CREBBP to the acetylated histone peptide of <70%
with respect to the DMSO control (Figure 2)], which
corresponds to a hit rate of 50% for the in silico screening
approach based on scaﬀold hopping and docking. The most
active compound, 1b, exhibits an equilibrium dissociation
constant (Kd) of 20 μM for CREBBP. Using the same threshold
of 70% as for CREBBP, the hit rate for BAZ2B was 29%
(Figure 2). Interestingly, at a concentration of 50 μM, only
compound 1g shows a signiﬁcantly higher aﬃnity for BAZ2B
than for CREBBP.
Binding Mode of Compound 1b: Validation by X-ray
Protein Crystallography. The opposite selectivity toward
CREBBP and BAZ2B observed for compounds 1b and 1g
(Figure 2) prompted us to study their binding mode. While we
could not determine the structure with compound 1g, the
crystal structure of CREBBP in complex with compound 1b
was determined at 2.0 Å resolution (Figure 3, green, PDB entry
4TS8), which revealed an overall binding mode essentially
identical to the docked pose of compound 1b (Figure 3, blue).
The binding of compound 1b in CREBBP is characterized by a
lipophilic sandwich of its bicyclic core between residues
Phe1111, Val1174, and Ala1164 on one side and Val1115,
Leu1120, and Ile1122 on the other side of the binding pocket.
The carbonyl oxygen of the acetyl indole acts as the acetylated
lysine mimic and is engaged in hydrogen bonding interactions
with the side chains of the conserved Asn1168 (BC loop) and
Tyr1125 (ZA loop), where the latter is bridged by a water
molecule. Another four water molecules present at the bottom
of the pocket are conserved. In addition, there is a water
molecule bridging the dihydro-pyrazole ring and the
guanidinium group of Arg1173 (Figure 3).
Assessing the Aﬃnity Diﬀerence between Indolizine
and Indole Ligands. Compound 1a is reported to be a potent
ligand for the BAZ2B bromodomain with a Kd of 136 nM.
41 To
study the inﬂuence on the binding aﬃnity of the position of the
nitrogen atom in our hit compound 1b, we decided to
synthesize the indole analogue of indolizine 1a. Commercially
available 1H-indol-5-ol (1) was transformed into compound 3
via alkylation of the phenol moiety with 1-iodopropane,
followed by introduction of an N-benzenesulfonyl group and
bromination at C3 in the presence of molecular bromine
(Scheme 1). Bromo indole 3 was then coupled to [2-
(methylsulfonyl)phenyl]boronic acid, aﬀording compound 4
in moderate yield. Removal of the sulfonyl group under basic
conditions preceded the incorporation of the acetyl group to
give the indole analogue of compound 1a (5).
Interestingly, a 24-fold reduction in binding aﬃnity toward
BAZ2B was observed for acetyl indole 5 with respect to 1a
[IC50 values of 8.55 and 0.36 μM, respectively, determined by
AlphaScreen (see the Supporting Information)], which
indicates that the position of the nitrogen atom in the
double-ring system is crucial.
Synthesis.We decided to focus our derivatization campaign
on compounds 1b and 1g as ligands. Compound 1b was
selected because of its ligand eﬃciency for CREBBP (0.34 kcal/
mol per heavy atom) and the availability of the crystal structure
(Figure 3), while compound 1g was chosen because of its
selectivity toward BAZ2B (Figure 2).
Figure 1. GSK2801 (1a), a nanomolar chemical probe for BAZ2A and
BAZ2B bromodomains.22,41 Core fragment hopping by activity-
oriented ﬁngerprint using fragment A as the query molecule. A and
B respresent generic chemical blueprints.
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Synthesis of Compound 1b and Its Derivatives. The
synthesis of CREBBP hit 1b is shown in Scheme 2. The
carboxylic acid of commercially available 2-(1H-indol-3-yl)-
acetic acid (6) was transformed into the corresponding methyl
ester. Acetylation of the N atom aﬀorded indole 7.
Deprotonation of 7 in the presence of in situ-generated lithium
diisopropylamide (LDA) followed by reaction with acetic
anhydride or 4-methoxyphenylacetic anhydride delivered
intermediate 8 or 9, respectively. Cyclization in the presence
of hydrazine hydrate aﬀorded hit compound 1b and derivative
10 in moderate yields (Scheme 2).
Hit compound 1b was then reacted with a variety of acid and
sulfonyl chlorides, aﬀording disubstituted (11−18) as well as
monosubstituted dihydro-pyrazole derivatives (19−22) as
indicated in Scheme 3. Two more derivatives were prepared:
upon condensation of 1,2-dibromoethane with compound 1b
in the presence of K2CO3, derivative 23 was obtained. The
reaction of 1b with p-methoxybenzyl bromide in the presence
of NaH aﬀorded O-alkylated product 24 (Scheme 3).
Figure 2. Binding aﬃnity and two-dimensional structures of acetyl indole derivatives 1b−i identiﬁed by core fragment hopping and docking. The
values are a percentage of residual binding of the CREBBP or BAZ2B bromodomain to an acetylated histone peptide at a compound concentration
of 50 μM with respect to the DMSO control. Thus, lower percentages indicate higher aﬃnities of the compound. Values in brackets are equilibrium
dissociation constants (Kd) determined by two independent dose−response measurements of 11 doses each. Compounds 1c, 1d, and 1i were
measured as a racemic mixture. All values were determined by the BROMOscan competition binding assay.55,56
Figure 3. Crystal structure (green) and docked pose (blue) of the
CREBBP bromodomain (gray) in complex with compound 1b (PDB
entry 4TS8). The conserved Tyr1125 and Asn1168 residues, together
with Arg1173 (a characteristic residue for the CREBBP bromodo-
main),11,38,39,49 are shown as sticks. Hydrogen bonds are shown as
yellow dashed lines, and the crystallographic water molecules are
represented by red spheres.
Scheme 1a
aReagents and reaction conditions: (a) (i) 1-iodopropane, K2CO3,
acetone, reﬂux, 72 h, 84%; (ii) benzenesulfonyl chloride, TBAB, 50%
NaOH, H2O, toluene, 0−25 °C, 69 h, 97%; (b) Br2, DMF, 25 °C, 7 h,
47%; (c) [2-(methylsulfonyl)phenyl]boronic acid, 1 M NaHCO3,
Pd(PPh3)4, DME, 25−85 °C, 15 min, 33%; (d) (i) 2 M NaOH,
MeOH, 85 °C, 5 h, 69%; (ii) AcCl, NaOH, TBAHS, DCM, 25 °C, 13
h, 63%. Abbreviations: TBAB, tetra-n-butylammonium bromide;
DMF, dimethylformamide; DME, 1,2-dimethoxyethane; TBAHS,
tetrabutylammonium hydrogen sulfate.
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Finally, we decided to incorporate the propoxy group at
position 5 of the indole, for which a similar protocol was
applied to 1H-indol-5-ol (1), delivering the ﬁnal products 27
and 28 (Scheme 4).
Synthesis of Derivatives of Compound 1g. The common
intermediate for the synthesis of derivatives of ligand 1g was
obtained from the commercially available non-natural amino
acid 29 in four steps with a 20% overall yield (Scheme 5).
Condensation of intermediate 32 with diverse commercially
available anilines aﬀorded acetyl indole intermediates 33−38,
which were then acylated in the presence of diverse acid
chlorides, aﬀording compounds 39−46. Four additional
derivatives were prepared by cleaving the methoxy substituent
in the presence of BBr3 to produce phenol derivatives 47−50
(Scheme 5).
Biophysical Characterization. Compound 1b and Its
Derivatives. Compound 1b was screened against a panel of 10
diﬀerent bromodomains using a thermal shift assay (Table 1
and Table S2 in the Supporting Information). This initial
screening revealed BRD9 bromodomain as a potential oﬀ target
for compound 1b with a shift in the melting temperature of 1.3
°C, which translated into a KD of 5.3 μM, as measured by a
competition binding assay,55,56 and a ligand eﬃciency (LE)
value of 0.38 kcal/mol per heavy atom. This result is in line
with the recent work of Brennan and co-workers, who
Scheme 2a
aReagents and reaction conditions: (a) (i) MeOH, H2SO4, 25 °C, 1 h, 94%; (ii) Ac2O, DMAP, Et3N, THF, 25 °C, 17 h, 90%; (b) (
iPr)2NH, n-BuLi,
THF, −75 °C, 1 h, then, acetic anhydride or 4-methoxyphenylacetic anhydride, −78 °C, 2−4 h; (c) hydrazine hydrate, camphoric acid, EtOH,
toluene, 93 °C, 30 min−1 h, 29−51% over two steps. Abbreviation: DMAP, 4-dimethylaminopyridine.
Scheme 3a
aReagents and reaction conditions: (a) R-Cl, Et3N, DCM, 0−25 °C, 5−12 h, 24−89%; (b) 1,2-dibromoethane, K2CO3, DMF, 80 °C, 7 h, 41%; (c)
PMB-Br, NaH, TBAI, DMF, 0−25 °C, 1.5 h, 23%. Abbreviations: PMB, 4-methoxybenzyl ether; TBAI, tetrabutylammonium iodide.
Scheme 4a
aReagents and reaction conditions: (a) (i) 1-iodopropane, K2CO3,
acetone, reﬂux, 72 h, 84%; (ii) (COCl)2, Et2O, 0 °C, then NaOMe in
MeOH, −78 °C, 3 h; (iii) Pd/C, NaH2PO2, dioxane, H2O, 25 °C, 12
h, 88% over two steps; (b) Ac2O, DMAP, Et3N, THF, 25 °C, 12 h,
42%; (c) (i) (iPr)2NH, n-BuLi, THF, −78 °C, 1 h, then, acetic
anhydride, −78 °C, 4 h; (ii) hydrazine hydrate, camphoric acid, EtOH,
toluene, reﬂux, 4 h, 18%; (d) 4-methoxybenzoyl chloride, Et3N, DCM,
0−25 °C, 12 h, 19%.
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developed BRD7 and BRD9 nanomolar potent indolizine
derivatives starting from the BAZ2B inhibitor 1a.22 Impor-
tantly, no activity of compound 1b was observed for the tested
BET family members, BRD4(1) and BRD4(2) (see the
Supporting Information).
Because of the involvement of the acetyl group of compound
1b in hydrogen bonds with the conserved Asn1168 and
Tyr1125 residues of CREBBP (Figure 3), we decided to
maintain this moiety and introduce the main modiﬁcations at
the dihydro-pyrazole ring to gain aﬃnity for CREBBP.
On the outset, we decided to modulate the interactions of
the solvent-exposed NH groups of the dihydro-pyrazole ring.
To do so, mono- and disubstituted amide and sulfonamides
that could establish new interactions with the surrounding
amino acid residues, including the characteristic Leu1109 and
Arg1173 residues in the CREBBP bromodomain and His42 and
Phe44 in BRD9, were incorporated [compounds 11−22 (Table
1)]. The presence of methyl-substituted sulfonamides in
compound 11 provided a KD of 6.6 μM in CREBBP, which
is a 3-fold binding aﬃnity improvement with respect to the hit
compound 1b and corresponds to a LE value of 0.26 kcal/mol
per heavy atom.
In an eﬀort to form π-stacking interactions with Arg1173 in
CREBBP,11,38 and residues Phe43 and Phe44 in BRD9,
aromatic substituents, some of them electron-rich, were
incorporated (compounds 14−18, 20, and 21). Compound
14 yielded the most active ligand toward BRD9 with a KD of 3.5
μM. Interestingly, the presence of a p-methoxybenzoate
substituent in compound 20 resulted in a 2-fold improvement
of binding aﬃnity with a thermal shift of 3.3 °C in CREBBP
and a KD of 9.3 μM. At the same time, compound 20 retained
the activity toward BRD9 with a thermal shift of 5.1 °C and a
KD of 6.3 μM. The presence of a morpholine ring at the same
position (derivative 22) could only slightly improve the binding
aﬃnity for CREBBP with a KD of 12 μM.
A dihydro-pyrazolo-oxazole ring was installed (compound
23), which allowed us to revert the hydrogen bond donor
capacity of the dihydro-pyrazole ring bearing two NH groups to
a hydrogen bond acceptor-fused ring. Remarkably, compound
23 showed a KD of 6.2 μM in CREBBP and retained the LE of
the initial hit (0.34 kcal/mol per heavy atom), which makes it
an attractive lead for further optimization. On the other hand,
compound 24 exhibited a drop in the thermal shift, probably
due to steric clashes of the p-methoxybenzyl group.
We then aimed to establish new interactions with the
hydrophobic residues located on top of the binding site,
Ile1122 and Leu1120 in CREBBP and Ala54 and Ile53 in
BRD9, by substitution of the indole moiety at position 5 with a
propoxy group (Table 1, compounds 27 and 28), a
modiﬁcation that has proven to be successful in our previous
work and in compound 1a.39,41 Unfortunately, the presence of
the propoxy substituent retained an activity of ∼10 μM.
Importantly, with the exception of compounds 14 and 23, all
derivatives displayed ΔTm values of <0.6 °C for BRD4(1), one
of the most promiscuous bromodomains.11,38,57
Compound 1g and Its Derivatives. Intrigued by the
selectivity diﬀerence observed in the hit compound 1g toward
BAZ2B (Figure 2), we decided to examine its binding mode
more closely. As we could not obtain crystals of the complex of
compound 1g with BAZ2B, several analogues were synthesized
(Table 2), aiming not only to obtain a crystal structure of the
complex but also to improve the binding aﬃnity for BAZ2B.
The chloroacetamide moiety was replaced by metabolically
more stable amides in all derivatives to avoid covalent binding
to the protein.
Scheme 5a
aReagents and reaction conditions: (a) (i) chloroacetic acid, K2CO3, H2O, 90 °C, 16 h; (ii) Ac2O, 25 °C, 30 min, then 37% HCl for 12 h, 33% over
two steps; (b) Ac2O, Et3N, reﬂux, 30 min, 89%; (c) Na2SO3, reﬂux, 2 h, 83%; (d) method I: aniline, AcOH, reﬂux, 1−8 h, 26−56%; method II:
aniline, pTSA, toluene, reﬂux, 2.5−4 h, 50−52%; (e) for MeCOCl, toluene, reﬂux, 12 h, 36−78%; if R4 = aryl, R4COCl, toluene, Et3N, DMAP, 100
°C, 1 h, 13−21%; (f) BBr3, DCM, 0−25 °C, 1−12 h, 47−84%. Abbreviation: pTSA, p-toluenesulfonic acid.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01757
J. Med. Chem. 2016, 59, 3087−3097
3091
The aﬃnity of the synthesized derivatives 39−50 for BAZ2B
was assessed by an AlphaScreen competition binding assay at a
compound concentration of 50 μM. Compound 47, bearing an
o-methyl and m-hydroxy substituent at the benzene ring,
showed a 54% reduction in the magnitude of the signal relative
to the negative control DMSO in the AlphaScreen binding
assay, which translated into a KD of 23 μM and a LE value of
0.27 kcal/mol per heavy atom. Upon substitution of the acetyl
substituent at R4 with a m-CF3-benzoate group, an IC50 value of
27 μM in the AlphaScreen assay and a KD of 39 μM
(BROMOscan) were measured for compound 50.
Crystal structures of the most potent derivatives, 47 and 50,
in complex with BAZ2B were determined at 1.71 and 1.78 Å
resolution, respectively. Compounds 47 and 50 (Figure 4A,B)
have essentially identical binding modes in BAZ2B. As in the
binding mode of hit 1b in CREBBP (Figure 3), the N-acetyl
substituent of the indole moiety of compounds 47 and 50 is
engaged in hydrogen bonds with the side chain of the
conserved Tyr1901 and Asn1944, where the hydrogen bond
with Tyr1901 is bridged by a water molecule. An additional
hydrogen bond is formed between the carbonyl group of the
acetamide and the backbone NH of Asn1894 in the ZA loop.
Table 1. Evaluation of Compounds 10−24, 27, and 28 Derived from 1b
aMedian value of the shift in the melting temperature. The total number of measurements for each compound and bromodomain was between 7 and
24. Ligand and protein concentrations were 100 and 2 μM, respectively. Standard errors of the mean are given in parentheses. The similar thermal
shift values measured with the CREBBP bromodomain and its paralogue, EP300, are consistent with the fact that identical residues are present in the
acetyllysine binding site of both proteins. bKd values were determined by a competition binding assay
55,56 in duplicate. Dose−response data and
ﬁtting curves can be found in the Supporting Information. Dashes indicate data not acquired.
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The o-methyl substituent of the phenol ring provides suﬃcient
steric hindrance to block the conformation of compounds 47
and 50 with their hydroxyphenyl ring pointing toward
Trp1887, which is the ﬁrst residue of the WPF segment in
BAZ2B. The additional triﬂuoromethylbenzoate of compound
50 points toward the solvent (Figure 4B), which explains the
similar aﬃnity for BAZ2B of compounds 47 and 50 (Table 2).
As mentioned above, the bromodomains of BRD9 and
BRPF1/3 belong to the same subfamily. Aiming to obtain
further structural information, we took advantage of the
availability in our laboratory of crystals of the apo state of the
bromodomain of BRPF1b that were soaked in a solution of
compound 1b. In this way, we determined the crystal structure
of the complex of compound 1b with BRPF1b at a resolution of
1.35 Å (PDB entry 5D7X). Interestingly, the size of the so-
called gatekeeper residue, small (Val1174 in CREBBP) and
large (Phe714 in BRPF1b), has a noticeable inﬂuence on the
orientation of the indole moiety (Figure 4C). Furthermore, the
presence of the bulkier Phe714 residue in the BRPF1b
bromodomain has a strong eﬀect on the orientation of the
dihydro-pyrazole ring that is rotated by ∼180° in BRPF1b with
respect to the complex with CREBBP. Despite these structural
diﬀerences, compound 1b has a very similar aﬃnity for the
bromodomains of CREBBP and BRPF1b with Kd values of 20
and 15 μM, respectively (see the Supporting Information).
The superposition of the X-ray structures of compound 1b in
CREBBP and BRPF1b with compound 47 in BAZ2B provides
additional evidence of the inﬂuence of the gatekeeper residue
for ligand binding (Figure 4, D). Interestingly, the 6-membered
ring of the indole moiety of compound 47 is located between
the indole of compound 1b in BRPF1b and CREBBP because
the gatekeeper residue in BAZ2B (Ile1950) is smaller than the
one in BRPF1b (Phe714) and larger than that in CREBBP
(Val1174). It is important to note that in these three crystal
structures (viz., the 1b/CREBBP, 1b/BRPF1b, and 47/BAZ2B
complexes) there are no crystal contacts in the binding site that
could aﬀect the orientation of the acetyl indole scaﬀold.
Moreover, the structure of BAZ2B is essentially identical in the
complex with compounds 47 and 50, and the same is observed
for the structures of CREBBP in the complex with compound
1b and a previously reported acetyl benzene ligand (PDB entry
4TQN) that diﬀer only by a small rigid-body displacement of
the ZA loop. It is also interesting to compare with the
orientation of the scaﬀold of the BAZ2B inhibitor 1a. The same
progressive tilting of the indole emerges from the structural
superposition of the complex of BAZ2B and the nanomolar
inhibitor 1a (PDB entry 4RVR)41 with the crystal structures of
the hit compound 1b in CREBBP and BRPF1b (Figure 4E).
Overall, these structural data suggest that acetyl indole mimics
the acetylated lysine side chain in its rather unselective binding
to bromodomains. In addition, the precise orientation of the
indole double-ring system and the substituent at its position 3
are inﬂuenced by the size of the gatekeeper residue that is
diﬀerent in diﬀerent bromodomains.
■ CONCLUSIONS
We have discovered in silico a series of small-molecule
antagonists of the bromodomains of CREBBP and BAZ2B by
docking ∼200 compounds containing an acetyl indole moiety,
which we had identiﬁed by scaﬀold hopping from a potent
BAZ2B ligand. Considering that only 14 compounds were
tested in vitro (by a competition binding assay), the hit rates of
the in silico screening based on scaﬀold hopping and docking
are 50 and 29% for CREBBP and BAZ2B, respectively. One of
the original hits (compound 1b) has equilibrium dissociation
constants of 20, 15, and 5.3 μM for CREBBP, BRPF1b, and
BRD9, respectively. With a relatively small derivatization
campaign (i.e., ∼30 derivatives), we were able to improve the
aﬃnity for CREBBP and BAZ2B and maintain the ligand
eﬃciency (0.34 kcal/mol per heavy atom for both hit 1b and
derivative 23 in CREBBP) or even slightly improve it (from
<0.26 kcal/mol for hit 1g to 0.27 kcal/mol per heavy atom for
compound 47 in BAZ2B). The crystal structures of three acetyl
indole derivatives in complex with three diﬀerent bromodo-
mains conﬁrm the binding mode predicted by docking with the
acetyl oxygen of the ligand involved as a hydrogen bond
acceptor in two hydrogen bonds with the conserved Asn side
chain in the BC loop and a structural water that acts as bridge
to the conserved Tyr of the ZA loop. Moreover, the X-ray
structures show that the size of the gatekeeper side chain
(Val1174, Ile1950, and Phe714 in the bromodomains of
CREBBP, BAZ2B, and BRPF1b, respectively) inﬂuences the
orientation of the indole moiety. This structural information
can be used to further improve the selectivity for a single
bromodomain target or a small subset of bromodomains
sharing the same gatekeeper residue.
Table 2. Evaluation of Compounds 39−50 Derived from 1g
aKd values were determined by a competition binding assay
55,56 in
duplicate. Dose−response data and ﬁtting curves are in the Supporting
Information. bPercentage of the measured signal (i.e., percentage
binding of acetylated histone peptide to BAZ2B) relative to the
negative control at a compound concentration of 50 μM. Lower values
indicate stronger binding of the compounds. The AlphaScreen
competition binding assay was performed at Reaction Biology. Dashes
indicate data not acquired.
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■ EXPERIMENTAL SECTION
Scaﬀold Hopping. We have used an activity-oriented ﬁngerprint
that consists of (1) chemical features such as hybridization states and
diﬀerent types of hydrogen bonding donors and acceptors, (2) the
two-dimensional topology index as a way to reﬂect the spatial
arrangement of such features, and (3) three-dimensional shape
descriptors (Figure S1 of the Supporting Information). A similarity
coeﬃcient is computed between two ﬁngerprints ranging from 0 to 1,
with 1 being the highest degree of similarity, where the two molecules
are not necessarily identical. As such, scaﬀold hopping resembles
pharmacophore mapping but distinguishes itself by using a molecular
ﬁngerprint.
Docking and Scoring. The genetic algorithm-based program for
ﬂexible ligand docking has been described in previous applica-
tions.50−52 Approximately 20 docking poses for each compound were
ﬁrst minimized by the CHARMM program58 and subsequently ranked
by a transferable scoring function.45,50−54
Assays. Thermal shift measurements were taken as previously
described.39,49 Thermal shift assays detect, by a ﬂuorescent dye, the
increase in the thermal stability of a protein in the presence of a
ligand.59 BROMOscan technology is a competition experiment that
uses an immobilized ligand and a DNA-tagged bromodomain
protein.55,56 Compounds that bind to the bromodomain of interest
will prevent binding of the bromodomain to the immobilized ligand.
The amount of bromodomain captured on the solid support is then
quantiﬁed by qPCR, and dissociation constants are calculated.
Figure 4. Crystal structures show the inﬂuence of the gatekeeper on the binding mode of the ligand. (A) Crystal structures of the BAZ2B
bromodomain in complex with compound 47 (PDB entry 5E73). (B) Same as panel A for the complex with compound 50 (PDB entry 5E74). (C)
Crystal structure of the complex of compound 1b (yellow) and the BRPF1b bromodomain (blue) (PDB entry 5D7X) structurally superposed to the
crystal structure with CREBBP (compound 1b colored green and CREBBP side chains colored gray). (D) Superposition of the crystal structures of
compound 47 (brown) in BAZ2B (pink) and compound 1b (green and yellow), in CREBBP (gray) and BRPF1b (blue). The side chain of the
gatekeeper is shown as cylinders with labels for the residue number. (E) Same as panel D for the BAZ2B inhibitor 1a (brown) (PDB entry 4RVR).
In all panels, hydrogen bonds are shown as yellow dashed lines and the crystallographic water molecules are represented by spheres.
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AlphaScreen assays consist of a donor bead that is able to transfer
singlet oxygen to an acceptor bead that is in the proximity, and as a
result, the acceptor bead emits a luminescent/ﬂuorescent signal. In the
presence of a bromodomain ligand, the donor/acceptor complex is
disrupted, leading to a loss of singlet oxygen transfer and loss of the
ﬂuorescent signal. Further details about the assays can be found in the
Supporting Information.
X-ray Crystallography. The His-tagged human bromodomains of
CREBBP (residues 1081−1097), BRPF1b (residues 626−740), and
BAZ2B (residues 1858−1972) were expressed in Escherichia coli. The
puriﬁcation procedures are reported in the Supporting Information.
The inhibitors were soaked into apo crystals of the bromodomains of
BRPF1b and BAZ2B, while the structure of the complex of compound
1b and CREBBP was obtained by cocrystallization as described in the
Supporting Information. Data collection and reﬁnement statistics are
listed in Table S1.
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1. Computational methods 
 
Figure S1. Scheme of the activity-oriented fingerprint (AoF), which consists of three sections: 
chemical features, 2D topology indices, and 3D shape descriptors. See below for detailed explanation. 
 
Section A: Chemical features 
 1: number of heavy atoms divided by 2; 
 2: number of element phosphor 
 3: number of elements halogen (F + Cl + Br + I) 
 4: degrees of unsaturation 
 5: number of chemical rings 
 6: number of C.1 
 7: number of (N.ar + N.2)  
 8: number of (N.pl3 + N.am) 
 9: number of N.1 
10: number of N.4 
11: number of (O.3+S.3) 
12: number of (O.2+S.2) 
13: number of O.co2 
14: number of S.o 
15: number of S.o2 
16: number of rotatable bonds. 
*Atom types follow the definition of SYBYL atom types. 
 
Section B: 2D topology 
1: Randic first topology index divided by number of bonds scaled by a factor of 10 
2: Randic second topology index divided by number of bonds scaled by a factor of 10 
 
Section C: 3D shape 
12 moments described in reference 1. 
 
Similarity Index 
In each section, a similarity index was computed between two molecules A and B by the 
following equation,1 
)1(
||
1
1
1
n
BiAi
simi n
i




  
The overall similarity index is the arithmetic mean of those from the three sections. 
Chemical features
2D topology
3D shape
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Figure S2. Distribution of similarity index between a query fragment and a 0.6 million fragments 
library. The 2D structure of the query molecule is shown in red.  
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Figure S3. Distribution of similarity index between a query fragment and a 0.6 million fragments 
library. The 2D structure of the query molecule is shown in red. 
 
2. Synthetic methods 
All reactions, unless otherwise stated, were carried out under a nitrogen atmosphere using standard 
Schlenk-techniques. All reagents were used as received unless otherwise noted. Solvents were 
purchased in the best quality available, degassed by purging thoroughly with nitrogen and dried over 
activated molecular sieves of appropriate size. Alternatively, they were purged with argon and passed 
through alumina columns in a solvent purification system (Innovative Technology). Reactions were 
monitored by thin layer chromatography (TLC) using Merck TLC silica gel 60 F254. Flash column 
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Chapter 7  
 
 
X-ray crystal structures and binding mode analysis of BRPF1 
bromodomain complexed with ligand-efficient virtual screening hits 
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In chapter 2, we showed that several diverse chemotypes targeting BRPF1 were discovered by 
high-through virtual screening and validated by X-ray crystallography. Subsequent hit 
optimization work led to the discovery of two series of low micromolar selective BRPF1 
inhibitors, which was described in chapter 3. Here, we present another virtual screening 
campaign carried out for a different fragment library which resulted in two novel ligand-
efficient fragments targeting BRPF1 bromodomain.  
 The rigid-ligand docking campaign was performed with SEED [1,2]. A fragment-like 
library of 60000 compounds was assembled from a large panel of commercial vendors and 
academic collaborators. The crystal structure of BRPF1 in complex with a pan-bromodomain 
inhibitor Bromosporine (PDB code 5C7N) was used for docking. The conserved asparagine 
(Asn708) and conserved water molecules in the Kac pocket were defined as the binding site. 
The partial charges and van der Waals parameters for the atoms in the receptor and the small 
molecules were taken from the CHARMM36 all-atom force field [3,4] and the CHARMM 
general force field (CGenFF) [5], respectively. The SEED binding energy consists of van der 
Waals energy, and electrostatics energy which is evaluated in the continuum dielectric 
approximation. The values of the dielectric constant were set to be 2.0 and 78.5 for the volume 
occupied by solute and solvent, respectively.  
 The docked poses of fragments were ranked by a consensus scoring method to prioritize 
the total binding energy, the electrostatic contribution to the ligand binding and van der Waals 
interactions divided by the number of non-hydrogen atoms of ligand. The latter term favors 
small molecules with few non-hydrogen atoms. Three top-ranked fragments were selected after 
inspection of the novelty for further biochemical assays. All three fragments showed more than 
50% inhibition activity at 500 μM concentration in the single dose BROMOscan assay. Next, 
DSPBP1004 and DSPBP1010 were analyzed by dose-response BROMOscan and AlphaScreen 
assays. DSPBP1004 displayed highly favorable ligand efficiencies of 0.53 and 0.48 in the 
BROMOscan assay (KD = 24 uM) and AlphaScreen assay (IC50 = 60.2 μM), respectively 
(Table 1). Compound DSP1010 appeared to be slightly less potent as BRPF1 inhibitor, showing 
a KD value of 74 μM in the BROMOscan assay (ligand efficiency is 0.33), while the IC50 value 
was not determined in the AlphaScreen assay. 
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Table 1. 2D chemical structure of screening hits for BRPF1and their biochemical assay data. 
 
Cpd 
 
2D structure 
 
HACa 
 BROMOscan 
 %Ctrlb 
BROMOscan 
KD (μM) 
LEc 
AlphaScreen 
IC50 (μM) 
LEc   
 
DSPBP1004 
 
 
 
12 
 
 
17  
 15 
@500 μM 
24 
[0.53] 
60.2 
[0.48] 
 
 
DSPBP1010 
 
 17 
@330 μM 
74 
[0.33] 
 
> 157 
[< 0.31] 
DSPBP1002 
 
 
15 
 46 
@500 μM 
 
- - 
 aHeavy atom count. bThe single-dose value is the percentage of remaining binding of the 
competitor molecule with respect to DMSO solution at the compound concentration shown 
in μM; thus lower values indicate stronger binding of the compounds. cLigand efficiency is 
calculated as LE = (1.4/HA) × pKD. 
 
 In our previous fragment-based virtual screening campaigns for bromodomains BRPF1 [6] 
and CREBBP [7], the predicted docking pose of screening hits were validated by X-
crystallography. Similarly, in this study, co-crystallization of the BRPF1 with ligand was 
performed to experimentally determine the binding mode. 
The BRPF1 bromodomain was expressed and purified as an N-terminal GST fusion protein 
in E.coli as described previously [6]. It was co-crystallized with inhibitors by vapor diffusion 
in hanging drops at 277 K. Co-crystals of BRPF1 with compound DSPBP1004 and DSPBP1010 
were grown by mixing protein sample at 23 mg/ml concentration with an equal volume of 
reservoir buffer of 0.1 M Bis-tris propane, pH 6.5, 0.15 M Sodium nitrate, 20% PEG3350.  
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Crystal datasets were collected at beamline X06SA of Swiss Light Source. Data reduction 
was performed with XDS [8] and scaled with Aimless [9]. Structures were solved by molecular 
replacement with Molrep [10] in CCP4 suite [11] using apo BRPF1 structure 4LC2 as staring 
model, further refined with PHENIX [12] and were manually built with COOT [13] for several 
rounds. The co-crystal of BRPF1/DSPBP1004 and BRPF1/DSPBP1010 were solved at 
resolutions of 1.65 and 1.70 angstrom, respectively. The data collection and refinement statistics 
are summarized in table 2.  
 
Table 2. X-ray data collection and refinement statistics for complex structures of the BRPF1 
bromodomain and two fragments identified by docking with SEED. 
 
 
PDB ID 5OWB 5OWE 
Compound DSPBP1004 DSPBP1010 
Data Collection   
space group P3221 P3221 
Cell dimensions a, b, c (Å) 60.43, 60.43, 63.47 60.53, 60.53, 63.68 
Cell dimensions α, β, γ (°) 90.00,90.00, 120.00 90.00, 90.00, 120.00 
resolution (Å) 40.38 - 1.65 27.33 - 1.70 
unique observations*  16528(815) 15062 (794) 
completeness* 99.8 (99.3) 98.9 (98.2) 
redundancy* 19.3(17.0) 19.8 (20.9) 
Rmerge* 0.068 (0.641) 0.050 (0.540) 
CC (1/2) 0.999 (0.924) 0.998 (0.956) 
I/σI* 26.7 (4.3) 31.1 (5.2) 
Refinement   
Rwork/Rfree* 0.174(0.240)/0.204(0.264) 0.190(0.229)/0.213(0.272) 
r.m.s deviations bond (Å) 0.007 0.007 
r.m.s deviations angles (°) 0.831 0.666 
Ramanchandran Favored  99.09 98.20 
Ramanchandran Allowed 0.91 1.80 
Ramanchandran Disallowed 0.00 0.00 
* Statistics for the highest resolution shell is shown in parentheses. 
  
As seen from the co-crystal structure of BRPF1/DSPBP1004, the fragment locate at the 
Kac binding site sandwiched by van der Waals contacts with ZA-loop residues Val657, Pro658 
and Val662 on one side of the pocket and Ile652, Phe653 and Phe714 on the opposite side 
(Figure 1A). The methyl group on the benzene locates deeply in the Kac site, forming van der 
Waals interactions with surrounding residues Ile652, Phe653 and Phe714. Extensive hydrogen 
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bonds formation upon fragment binding was also observed. The carbonyl group on the 
benzofuran core is involved in the hydrogen bond with the NH group of the conserved 
asparagine Asn708 as well as a water-bridged hydrogen bond to the Tyr665. The hydroxyl group 
on the benzene and the oxygen atom on the furan ring contact conserved and re-organized water 
molecules in the Kac site as hydrogen bond donor and receptor, respectively. Interestingly, a 
relatively weaker CH···O hydrogen bond interaction is observed between the backbone 
carbonyl group of Ile652 and a carbon atom on the benzene ring.  The docked pose of 
DSPBP1004 shows that key hydrogen bond interactions with the Asn708 and the conserved 
water molecule bridging to Tyr665 are present by involving the carbonyl group on the furan 
ring as same as the crystal structure.  
Compound DSPBP1010 is located at the hydrophobic Kac pocket in the co-crystal 
structure with BRPF1 in a similar way as DSPBP1004 (Figure 1B). The carbonyl group of the 
pyran ring hydrogen bonds to the Asn708 and Tyr665 via a conserved water molecule. In 
addition, the oxygen atom on the paran forms a hydrogen bond with Asn708 in a distance of 
3.6 angstrom. The CH···O hydrogen bonding is observed between the carbonyl group of Ile652 
and one of the carbon atoms of the benzene ring. The docked pose shows a flipped conformation 
of fragment as compared to the crystallographic pose, while the key hydrogen bond between 
carbonyl group on the pyran and the conserved water molecule is still maintained.  
Despite the main hydrogen bond is predicted correctly, the docked pose of the two 
fragments shows different orientation as compared to the crystallographic pose, this might be 
due to the reorientation and rearrangement of water molecules in the Kac pocket. Another 
reason might be related with the protein receptor used for docking. It is also possible that both 
poses are populated with different weights in solution conditions. As previously reported, the 
loop regions of BRPF1 always undergo conformational changes upon binding of different 
ligands [6]. To investigate the discrepancy between the poses predicted by docking and in the 
the crystal structure, we suggest a molecular dynamics (MD) analysis of the binding mode. 
Multiple MD runs should be started from each of the docked pose and binding mode in the 
crystal structure to assess kinetic stability. 
In this study, a fragment-based virtual screening by SEED followed by X-ray 
crystallography validation was carried out which led to the identification of two ligand-efficient 
BRPF1 inhibitors. To the best of our knowledge, these two fragments represent two novel 
chemotypes that have not reported as bromodomain inhibitors. The structural information of 
fragment binding revealed by X-ray crystallography analysis is helpful for further developing 
these fragment hits into potent BRPF1 inhibitors. 
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Figure 1. Comparison of the crystallographic pose (yellow) and docking pose (green) of DSPBP1004 
(A) and DSPBP1010 (B). The conserved water molecules and other water molecules involved in ligand 
binding are shown as pink and red spheres, respectively, while hydrogen bonds are shown by dashed 
lines. The 2Fo – Fc electron density maps are shown in blue mesh at a contour level of 1.0 sigma. Note 
that in the predicted pose the fragments make the same hydrogen bonds with the conserved Asn708 and 
the water bridging to the conserved Tyr665 as in the crystal structure. The docked and crystal poses are 
related by a rotation of 180 degrees around axis that spans two oxygen atoms. 
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Chapter 8 
 
Conclusions 
 
This thesis focuses on the application of fragment-based drug discovery approach in the 
identification of inhibitors targeting human bromodomain proteins with an emphasis of the use 
of X-ray crystallography in fragment-based drug design. Usually bromodomains can be 
recombinantly expressed and purified as stable single-domain constructs so that biophysical 
tools, such as NMR spectroscopy, X-ray crystallography and differential scanning fluorimetry 
(DSF) are suitable for the analysis of protein-ligand interactions for bromodomains.   
 In practice, the FBDD in our group commonly starts with fragment-based high throughput 
docking, which can efficiently filter out putative hits from a large library of rigid framents by 
binding energy ranking. Top-ranked fragments are then assayed for affinity biophysically and/or 
biochemically. In this thesis, we present in silico fragment screening studies for BRPF1 
(Chapters 2 and 7) and CREBBP (Chapter 4) bromodomains. These docking campaigns 
successfully generated highly ligand-efficient fragment hits, and importantly, some screening 
hits provided chemical expansion vectors for optimization by medicinal chemistry. In these 
cases, the success ratio, i.e., ratio of binders versus purchased fragments are greater than 10%, 
according to the X-ray crystallography validation, which is significantly higher than the success 
rate (< 1%) of conventional high throughput screening. 
 This theis presents two stories of hit optimization by different ways. In the BRPF1 project 
(Chapter 3), using an integrative approach based on in silico docking, compoud searching by 
cheminformatics techniques and experimental validation, two series of low micromolar 
inhibitors that derive from initial fragment hits were discovered. The main idea of this approach 
is to use structural information of fragment binding to explore the commercial available 
chemical collections. One of the identified compounds exhibits 2-µM affinity for the BRPF1 
bromodomain and more than 100-fold selectivity for BRPF1 over other tested bromodomains. 
These newly identified chemotypes provided interesting starting points for further development 
of BRPF1 chemical probes. It’s worth mentioning that due to the high sequence similarity of 
bromodomain proteins, highly selective chemical probes are required to effectively prevent off-
target effects. In a hit optimization effort for CREBBP (Chapter 5), in silico chemical coupling 
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alongside organic synthesis enabled the identification of a series of low nanomolar selective 
CREBBP inhibitors. In this study, fragment-based docking and structure-guided chemical 
synthesis were jointly used as an efficient way for hit expansion. Similar to the aforesaid work 
on BRPF1, the CREBBP hit-optimization campaign took full advantage of structural 
information obtained from high quality protein-ligand crystal structures. In Chapter 6, hit 
optimization was carried out by scaffold hopping followed by ligand docking, which led to the 
identification of acetyl indoles that target the bromodomains of CREBBP, BAZ2B and BRPF1. 
Analysis of crystal structures of these bromodomains with the same ligand revealed the 
importance of the so-called gatekeeper residue with respect to the binding of ligands, which 
provided useful information for development of selective bromodomain inhibitors. 
 Taken togethor, FBDD approach was applied in different ways for bromodomain drug 
development in our group. X-ray protein crystallography played a central role in these work, as 
high resolution complex crystal structures can clearly illustrate detailed protein-ligand 
interactions which is pivotal for hit optimization in FBDD. The combination of in silico and in 
vitro (mainly X-ray crystallography) methods described here could be employed for other drug 
discovery projects for epigenetic modules and even challenging therapeutic protein targets.  
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